{"PMC7297420": [["Financial support and sponsorshipNil.Conflicts of interestThere are no conflicts of interest.", [["Financial support", "TREATMENT", 0, 17], ["sponsorshipNil", "TREATMENT", 22, 36], ["no", "UNCERTAINTY", 68, 70], ["conflicts", "OBSERVATION", 71, 80]]]], "27ae3f39b9760d891f7c8f2fd3d1b6d5e038f232": [["a b s t r a c tA real-time PCR (qPCR) assay targeting on invA and pagC genes was developed and validated for the detection and quantification of Salmonella enterica strains (Bai et al., 2018) [1] .", [["invA", "GENE_OR_GENE_PRODUCT", 57, 61], ["pagC", "GENE_OR_GENE_PRODUCT", 66, 70], ["Salmonella enterica", "ORGANISM", 145, 164], ["invA and pagC genes", "DNA", 57, 76], ["Salmonella enterica", "SPECIES", 145, 164], ["Salmonella enterica", "SPECIES", 145, 164], ["a b s", "TEST", 0, 5], ["a c tA real", "TEST", 10, 21], ["PCR", "TEST", 27, 30], ["qPCR", "TEST", 32, 36], ["invA and pagC genes", "TEST", 57, 76], ["the detection", "TEST", 109, 122], ["Salmonella enterica strains", "PROBLEM", 145, 172]]], ["A host gene, normally an endogenous housekeeping gene (Beer-Davidson et al., 2018; Poon et al., 2004) [2, 3] , or an irrelevant exogenous gene (Cheng et al., 2015; Sedlak et al., 2014) [4, 5] has been widely used as an internal control to monitor nucleic acid extraction efficiencies and potential PCR inhibitions in PCR-based detection assays.", [["nucleic acid", "CHEMICAL", 247, 259], ["[2, 3", "GENE_OR_GENE_PRODUCT", 102, 107], ["nucleic acid", "SIMPLE_CHEMICAL", 247, 259], ["host gene", "DNA", 2, 11], ["endogenous housekeeping gene", "DNA", 25, 53], ["exogenous gene", "DNA", 128, 142], ["an internal control", "TREATMENT", 216, 235], ["nucleic acid extraction efficiencies", "TREATMENT", 247, 283], ["potential PCR inhibitions", "PROBLEM", 288, 313], ["PCR", "TEST", 317, 320], ["based detection assays", "TEST", 321, 343]]], ["An endogenous internal control designed based on the 18S rRNA gene was used in the above-mentioned qPCR assay.", [["18S", "GENE_OR_GENE_PRODUCT", 53, 56], ["rRNA", "CELLULAR_COMPONENT", 57, 61], ["18S rRNA gene", "DNA", 53, 66], ["An endogenous internal control", "TREATMENT", 0, 30], ["the 18S rRNA gene", "TREATMENT", 49, 66], ["endogenous", "OBSERVATION_MODIFIER", 3, 13], ["internal control", "OBSERVATION", 14, 30]]], ["This 18S rRNA internal control amplifies the target gene in multiple species including bovine, swine, ovine, caprine and cervine.", [["cervine", "ANATOMY", 121, 128], ["18S", "GENE_OR_GENE_PRODUCT", 5, 8], ["rRNA", "CELLULAR_COMPONENT", 9, 13], ["bovine", "ORGANISM", 87, 93], ["swine", "ORGANISM", 95, 100], ["ovine", "ORGANISM", 102, 107], ["caprine", "ORGANISM", 109, 116], ["cervine", "CANCER", 121, 128], ["target gene", "DNA", 45, 56], ["bovine", "SPECIES", 87, 93], ["swine", "SPECIES", 95, 100], ["ovine", "SPECIES", 102, 107], ["caprine", "SPECIES", 109, 116], ["bovine", "SPECIES", 87, 93], ["swine", "SPECIES", 95, 100], ["ovine", "SPECIES", 102, 107], ["caprine", "SPECIES", 109, 116], ["This 18S rRNA internal control", "TREATMENT", 0, 30], ["bovine, swine", "TREATMENT", 87, 100], ["multiple", "OBSERVATION_MODIFIER", 60, 68], ["species", "OBSERVATION", 69, 76]]], ["Data was generated by the duplex qPCR assay on 138 enriched cattle lymph node samples without the internal control, and compared with data on the same samples tested by the triplex qPCR assay that has Similar threshold cycle (Ct) data were generated with and without the use of the 18S rRNA gene as internal control.a b s t r a c tAlthough an internal control is strongly recommended for real-time PCR assays in diagnostic settings, it may be optional to use for certain research projects like the one reported here.DataReal-time PCR (qPCR) test data on 138 culture-enriched cattle lymph node samples for Salmonella enterica detections is shown in Table 1 .", [["lymph node samples", "ANATOMY", 67, 85], ["samples", "ANATOMY", 151, 158], ["lymph node samples", "ANATOMY", 582, 600], ["cattle", "ORGANISM", 60, 66], ["lymph node samples", "MULTI-TISSUE_STRUCTURE", 67, 85], ["18S", "GENE_OR_GENE_PRODUCT", 282, 285], ["rRNA", "CELLULAR_COMPONENT", 286, 290], ["cattle", "ORGANISM", 575, 581], ["lymph node", "MULTI-TISSUE_STRUCTURE", 582, 592], ["samples", "MULTI-TISSUE_STRUCTURE", 593, 600], ["Salmonella enterica", "ORGANISM", 605, 624], ["18S rRNA gene", "DNA", 282, 295], ["cattle", "SPECIES", 60, 66], ["cattle", "SPECIES", 575, 581], ["Salmonella enterica", "SPECIES", 605, 624], ["cattle", "SPECIES", 60, 66], ["cattle", "SPECIES", 575, 581], ["Salmonella enterica", "SPECIES", 605, 624], ["the duplex qPCR assay", "TEST", 22, 43], ["the triplex qPCR assay", "TEST", 169, 191], ["Ct) data", "TEST", 226, 234], ["the 18S rRNA gene", "TREATMENT", 278, 295], ["internal control", "TREATMENT", 299, 315], ["an internal control", "TREATMENT", 340, 359], ["DataReal", "TEST", 516, 524], ["time PCR", "TEST", 525, 533], ["test data", "TEST", 541, 550], ["culture", "TEST", 558, 565], ["cattle lymph node samples", "TEST", 575, 600], ["Salmonella enterica detections", "TEST", 605, 635], ["lymph node", "OBSERVATION", 67, 77], ["lymph node", "OBSERVATION", 582, 592]]], ["Data were generated by: 1) A duplex qPCR assay using invA and pagC genes; and 2) A triplex qPCR assay using invA, pagC, and 18S rRNA gene as an internal control.", [["invA", "GENE_OR_GENE_PRODUCT", 53, 57], ["pagC", "GENE_OR_GENE_PRODUCT", 62, 66], ["invA", "GENE_OR_GENE_PRODUCT", 108, 112], ["pagC", "GENE_OR_GENE_PRODUCT", 114, 118], ["18S rRNA", "GENE_OR_GENE_PRODUCT", 124, 132], ["invA and pagC genes", "DNA", 53, 72], ["invA, pagC, and 18S rRNA gene", "DNA", 108, 137], ["A duplex qPCR assay", "TEST", 27, 46], ["invA and pagC genes", "TREATMENT", 53, 72], ["A triplex qPCR assay", "TEST", 81, 101], ["invA", "TREATMENT", 108, 112], ["pagC", "TREATMENT", 114, 118], ["18S rRNA gene", "TREATMENT", 124, 137], ["an internal control", "TREATMENT", 141, 160]]], ["The Ct differences between the duplex and triplex qPCR assays are also presented in the last two columns in Table 1 .Experimental design, materials and methodsA total of 647 subiliac lymph nodes were collected from cattle procured from Texas, Oklahoma, Kansas, and South Dakota [6] and transported in cold storage to the Kansas State University for processing within 24 h.", [["subiliac lymph nodes", "ANATOMY", 174, 194], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 183, 194], ["cattle", "ORGANISM", 215, 221], ["cattle", "SPECIES", 215, 221], ["cattle", "SPECIES", 215, 221], ["The Ct differences", "TEST", 0, 18], ["the duplex and triplex qPCR assays", "TEST", 27, 61], ["Experimental design, materials", "PROBLEM", 117, 147], ["subiliac lymph nodes", "TREATMENT", 174, 194], ["lymph nodes", "OBSERVATION", 183, 194]]], ["Each lymph node was manually trimmed to remove fat and fascia tissues.", [["lymph node", "ANATOMY", 5, 15], ["fat", "ANATOMY", 47, 50], ["fascia tissues", "ANATOMY", 55, 69], ["lymph node", "MULTI-TISSUE_STRUCTURE", 5, 15], ["fat", "TISSUE", 47, 50], ["fascia tissues", "TISSUE", 55, 69], ["Each lymph node", "PROBLEM", 0, 15], ["lymph node", "OBSERVATION", 5, 15], ["fat", "ANATOMY", 47, 50], ["fascia tissues", "ANATOMY", 55, 69]]], ["Trimmed lymph nodes were surface sterilized by a 5 sec submersion in boiling water, placed in a sterile bag, then manually pulverized with a rubber mallet.", [["lymph nodes", "ANATOMY", 8, 19], ["surface", "ANATOMY", 25, 32], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 8, 19], ["Trimmed lymph nodes", "TREATMENT", 0, 19], ["a 5 sec submersion in boiling water", "TREATMENT", 47, 82], ["a sterile bag", "TREATMENT", 94, 107], ["a rubber mallet", "TREATMENT", 139, 154], ["lymph nodes", "OBSERVATION", 8, 19], ["surface", "OBSERVATION_MODIFIER", 25, 32], ["rubber mallet", "OBSERVATION", 141, 154]]], ["Eighty milliliters of TSB was added to each bag and sterilized lymph nodes were then homogenized for 30 s in a Stomacher 80 Biomaster (Thomas Scientific, Swedesboro, NJ) prior to culture-enrichment.", [["lymph nodes", "ANATOMY", 63, 74], ["TSB", "SIMPLE_CHEMICAL", 22, 25], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 63, 74], ["Eighty milliliters of TSB", "TREATMENT", 0, 25], ["each bag", "TREATMENT", 39, 47], ["sterilized lymph nodes", "TREATMENT", 52, 74], ["culture", "TEST", 179, 186], ["lymph nodes", "OBSERVATION", 63, 74]]], ["The enrichment procedure has been described [6, 7] .", [["The enrichment procedure", "TREATMENT", 0, 24], ["enrichment", "OBSERVATION", 4, 14]]], ["Briefly, the homogenate was incubated at 25\u00b0C for 2 h then at 42\u00b0C for 12 h.", [["homogenate", "ANATOMY", 13, 23]]], ["One Table 1 Real-time PCR threshold cycle (Ct) data on 138 Salmonella-positive cattle lymph node samples with and without the 18S rRNA internal control.Experimental design, materials and methodsSample ID Three-gene qPCR data Two-gene qPCR data Ct difference (three-gene Ct minus two-gene Ct) milliliter of enriched homogenate was then subjected to immunomagnetic separation using 20 \u00b5l anti-Salmonella beads.", [["lymph node samples", "ANATOMY", 86, 104], ["homogenate", "ANATOMY", 315, 325], ["cattle", "ORGANISM", 79, 85], ["lymph node", "MULTI-TISSUE_STRUCTURE", 86, 96], ["samples", "CANCER", 97, 104], ["homogenate", "ORGANISM_SUBSTANCE", 315, 325], ["cattle", "SPECIES", 79, 85], ["cattle", "SPECIES", 79, 85], ["PCR threshold cycle", "TEST", 22, 41], ["Ct) data", "TEST", 43, 51], ["Salmonella", "TEST", 59, 69], ["positive cattle lymph node samples", "PROBLEM", 70, 104], ["Experimental design, materials", "PROBLEM", 152, 182], ["methods", "TREATMENT", 187, 194], ["qPCR data", "TEST", 215, 224], ["Ct difference", "TEST", 244, 257], ["immunomagnetic separation", "TREATMENT", 348, 373], ["20 \u00b5l anti-Salmonella beads", "TREATMENT", 380, 407], ["lymph node", "OBSERVATION", 86, 96]]], ["One hundred microliters of PBS was added to the final immunomagnetic separation step.", [["PBS", "SIMPLE_CHEMICAL", 27, 30], ["PBS", "TREATMENT", 27, 30], ["the final immunomagnetic separation step", "TREATMENT", 44, 84], ["immunomagnetic separation", "OBSERVATION", 54, 79]]], ["The bead suspension was then transferred into 3 mL RV broth and incubated at 42\u00b0C for 18-20 h.", [["The bead suspension", "TREATMENT", 0, 19], ["bead suspension", "OBSERVATION", 4, 19]]], ["One hundred microliters of enriched homogenate was streaked onto HE agar plates and incubated at 37\u00b0C for 24 h.", [["homogenate", "ANATOMY", 36, 46], ["homogenate", "ORGANISM_SUBSTANCE", 36, 46], ["HE agar plates", "TREATMENT", 65, 79]]], ["Six dark-colored colonies with morphology consistent with Salmonella were re-streaked onto BAPs and incubated at 37\u00b0C for 18-20 h.", [["colonies", "ANATOMY", 17, 25], ["BAPs", "ANATOMY", 91, 95], ["dark-colored colonies", "CELL_LINE", 4, 25], ["Salmonella", "SPECIES", 58, 68], ["Six dark-colored colonies", "PROBLEM", 0, 25], ["Salmonella", "PROBLEM", 58, 68], ["colored colonies", "OBSERVATION", 9, 25], ["consistent with", "UNCERTAINTY", 42, 57], ["Salmonella", "OBSERVATION", 58, 68]]], ["The resulting cultures was used for DNA extraction by boiling 1 ml of culture for 10 min and centrifuging at 9300 g for 5 min; the supernatant was used as template for the qPCR reactions with the duplex qPCR assay using both invA and pagC genes as molecular targets.", [["cultures", "ANATOMY", 14, 22], ["supernatant", "ANATOMY", 131, 142], ["DNA", "CELLULAR_COMPONENT", 36, 39], ["invA", "GENE_OR_GENE_PRODUCT", 225, 229], ["pagC", "GENE_OR_GENE_PRODUCT", 234, 238], ["invA and pagC genes", "DNA", 225, 244], ["The resulting cultures", "TEST", 0, 22], ["DNA extraction", "TREATMENT", 36, 50], ["culture", "TEST", 70, 77], ["the qPCR reactions", "TEST", 168, 186], ["the duplex qPCR assay", "TEST", 192, 213]]], ["Endogenous housekeeping genes [2, 3] , or irrelevant exogenous gene [4, 5] have been widely used as internal controls to monitor nucleic acid extraction efficiencies and potential PCR inhibitions in PCR-based detection assays.", [["nucleic acid", "CHEMICAL", 129, 141], ["housekeeping genes [2, 3", "GENE_OR_GENE_PRODUCT", 11, 35], ["nucleic acid", "SIMPLE_CHEMICAL", 129, 141], ["housekeeping genes", "DNA", 11, 29], ["exogenous gene", "DNA", 53, 67], ["nucleic acid extraction efficiencies", "TREATMENT", 129, 165], ["potential PCR inhibitions", "PROBLEM", 170, 195], ["PCR", "TEST", 199, 202], ["based detection assays", "TEST", 203, 225]]], ["We have selected an endogenous housekeepig gene, 18S rRNA gene, as internal control in this study.", [["housekeepig", "GENE_OR_GENE_PRODUCT", 31, 42], ["18S rRNA", "GENE_OR_GENE_PRODUCT", 49, 57], ["endogenous housekeepig gene", "DNA", 20, 47], ["18S rRNA gene", "DNA", 49, 62], ["an endogenous housekeepig gene", "TREATMENT", 17, 47], ["18S rRNA gene", "TREATMENT", 49, 62], ["this study", "TEST", 87, 97]]], ["Randomly selected 138 duplex qPCR-positive samples were proceed with the triplex qPCR assay using the same molecular targets, and with an 18S rRNA gene as internal control [1] .", [["samples", "ANATOMY", 43, 50], ["18S rRNA gene", "DNA", 138, 151], ["duplex qPCR", "TEST", 22, 33], ["the triplex qPCR assay", "TEST", 69, 91], ["an 18S rRNA gene", "TREATMENT", 135, 151]]], ["Comparison data using the duplex and triplex assays is presented in Table 1 .Transparency document.", [["Comparison data", "TEST", 0, 15], ["the duplex and triplex assays", "TEST", 22, 51]]]], "69162411f7e4e71f5660650ec20e437c6d6d2a5a": [["la determinaci\u00f3n de IL-6 que result\u00f3 mayor de 40 pg/ml, por lo que se decidi\u00f3 iniciar tratamiento con tocilizumab.", [["tocilizumab", "SIMPLE_CHEMICAL", 102, 113], ["iniciar tratamiento con tocilizumab", "TREATMENT", 78, 113]]], ["Ante este resultado y debido a la persistencia de reactantes inflamatorios elevados, se instaur\u00f3 tratamiento con anakinra.", [["anakinra", "CHEMICAL", 113, 121], ["se instaur\u00f3 tratamiento con anakinra", "TREATMENT", 85, 121]]]], "f5363f1f956d35871b67c13454f7656cc10078ef": [["TextWe read with great interest the paper by Mendoza, which suggests the use of anti-IL-17 therapy in coronavirus disease 2019 (COVID-19) patients 1 .", [["anti-IL-17", "CHEMICAL", 80, 90], ["coronavirus disease", "DISEASE", 102, 121], ["anti-IL-17", "GENE_OR_GENE_PRODUCT", 80, 90], ["coronavirus", "ORGANISM", 102, 113], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["anti-IL-17 therapy", "TREATMENT", 80, 98], ["coronavirus disease", "PROBLEM", 102, 121]]], ["While agreeing on the potential role of anti-IL-17 drugs in controlling the excessive production of inflammatory cytokines, we would like to emphasize another possible relevant benefit that could derive from using these treatments in such patients.TextAs observed in the paper by Mendoza, IL-17 is thought to play a key role in the immune dysregulation observed in COVID-19 and in other severe coronavirus-mediated respiratory syndromes, therefore its inhibition has been suggested to determine a better outcome in these patients.", [["respiratory", "ANATOMY", 415, 426], ["COVID-19", "CHEMICAL", 365, 373], ["coronavirus", "DISEASE", 394, 405], ["respiratory syndromes", "DISEASE", 415, 436], ["anti-IL-17", "GENE_OR_GENE_PRODUCT", 40, 50], ["patients", "ORGANISM", 239, 247], ["TextAs", "GENE_OR_GENE_PRODUCT", 248, 254], ["IL-17", "GENE_OR_GENE_PRODUCT", 289, 294], ["COVID-19", "CELL", 365, 373], ["coronavirus", "ORGANISM", 394, 405], ["patients", "ORGANISM", 521, 529], ["inflammatory cytokines", "PROTEIN", 100, 122], ["TextAs", "PROTEIN", 248, 254], ["patients", "SPECIES", 239, 247], ["patients", "SPECIES", 521, 529], ["COVID-19", "SPECIES", 365, 373], ["anti-IL-17 drugs", "TREATMENT", 40, 56], ["inflammatory cytokines", "PROBLEM", 100, 122], ["these treatments", "TREATMENT", 214, 230], ["TextAs", "TREATMENT", 248, 254], ["the immune dysregulation", "PROBLEM", 328, 352], ["COVID", "TEST", 365, 370], ["other severe coronavirus", "PROBLEM", 381, 405], ["mediated respiratory syndromes", "PROBLEM", 406, 436], ["inflammatory cytokines", "OBSERVATION", 100, 122], ["severe", "OBSERVATION_MODIFIER", 387, 393], ["coronavirus", "OBSERVATION", 394, 405], ["respiratory syndromes", "OBSERVATION", 415, 436]]], ["1 Basing on these assumptions, the use of the IL-17 inhibitor ixekizumab is currently being investigated for the acute phase of COVID-19.", [["ixekizumab", "CHEMICAL", 62, 72], ["ixekizumab", "CHEMICAL", 62, 72], ["COVID-19", "CHEMICAL", 128, 136], ["IL-17", "GENE_OR_GENE_PRODUCT", 46, 51], ["ixekizumab", "SIMPLE_CHEMICAL", 62, 72], ["the IL-17 inhibitor ixekizumab", "TREATMENT", 42, 72], ["COVID", "TEST", 128, 133]]], ["3 However, COVID-19, besides being associated with acute respiratory distress syndrome (ARDS), can also determine long-term sequelae.", [["respiratory", "ANATOMY", 57, 68], ["acute respiratory distress syndrome", "DISEASE", 51, 86], ["ARDS", "DISEASE", 88, 92], ["COVID", "TEST", 11, 16], ["acute respiratory distress syndrome", "PROBLEM", 51, 86], ["ARDS", "PROBLEM", 88, 92], ["long-term sequelae", "PROBLEM", 114, 132], ["associated with", "UNCERTAINTY", 35, 50], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["respiratory distress", "OBSERVATION", 57, 77], ["long-term sequelae", "OBSERVATION_MODIFIER", 114, 132]]], ["These will likely represent a considerable therapeutic challenge in the upcoming months, chronic lung fibrosis arguably being the most important 2 .TextIL-17 is a cytokine with pleiotropic effects which might enhance the progression towards pulmonary fibrosis in COVID-19 patients.TextIL-17 has been shown to exert direct pro-fibrotic effects on fibroblasts isolated from mouse and human lung through the activation of NF-kB, promoting production of TGF-\u03b2 and expression of \u03b1smooth muscle actin and eventually leading to collagen deposition 5 .", [["lung", "ANATOMY", 97, 101], ["pulmonary", "ANATOMY", 241, 250], ["fibroblasts", "ANATOMY", 346, 357], ["lung", "ANATOMY", 388, 392], ["\u03b1smooth muscle", "ANATOMY", 474, 488], ["fibrosis", "DISEASE", 102, 110], ["pulmonary fibrosis", "DISEASE", 241, 259], ["TextIL-17", "CHEMICAL", 281, 290], ["TextIL-17", "CHEMICAL", 281, 290], ["lung", "ORGAN", 97, 101], ["TextIL-17", "GENE_OR_GENE_PRODUCT", 148, 157], ["pulmonary", "ORGAN", 241, 250], ["patients", "ORGANISM", 272, 280], ["TextIL-17", "GENE_OR_GENE_PRODUCT", 281, 290], ["fibroblasts", "CELL", 346, 357], ["mouse", "ORGANISM", 372, 377], ["human", "ORGANISM", 382, 387], ["lung", "ORGAN", 388, 392], ["NF-kB", "GENE_OR_GENE_PRODUCT", 419, 424], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 450, 455], ["\u03b1smooth muscle actin", "GENE_OR_GENE_PRODUCT", 474, 494], ["collagen", "GENE_OR_GENE_PRODUCT", 521, 529], ["TextIL-17", "PROTEIN", 148, 157], ["cytokine", "PROTEIN", 163, 171], ["TextIL-17", "PROTEIN", 281, 290], ["fibroblasts", "CELL_TYPE", 346, 357], ["NF-kB", "PROTEIN", 419, 424], ["TGF-\u03b2", "PROTEIN", 450, 455], ["\u03b1smooth muscle actin", "PROTEIN", 474, 494], ["collagen", "PROTEIN", 521, 529], ["patients", "SPECIES", 272, 280], ["mouse", "SPECIES", 372, 377], ["human", "SPECIES", 382, 387], ["mouse", "SPECIES", 372, 377], ["human", "SPECIES", 382, 387], ["chronic lung fibrosis", "PROBLEM", 89, 110], ["TextIL", "TEST", 148, 154], ["a cytokine with pleiotropic effects", "PROBLEM", 161, 196], ["pulmonary fibrosis", "PROBLEM", 241, 259], ["TextIL", "TEST", 281, 287], ["direct pro-fibrotic effects", "PROBLEM", 315, 342], ["TGF", "TEST", 450, 453], ["\u03b1smooth muscle actin", "PROBLEM", 474, 494], ["collagen deposition 5", "PROBLEM", 521, 542], ["will likely represent", "UNCERTAINTY", 6, 27], ["considerable", "OBSERVATION_MODIFIER", 30, 42], ["therapeutic", "OBSERVATION_MODIFIER", 43, 54], ["chronic", "OBSERVATION_MODIFIER", 89, 96], ["lung", "ANATOMY", 97, 101], ["fibrosis", "OBSERVATION", 102, 110], ["progression", "OBSERVATION_MODIFIER", 221, 232], ["pulmonary", "ANATOMY", 241, 250], ["fibrosis", "OBSERVATION", 251, 259], ["pro-fibrotic", "OBSERVATION", 322, 334], ["lung", "ANATOMY", 388, 392], ["\u03b1smooth muscle", "ANATOMY", 474, 488], ["collagen deposition", "OBSERVATION", 521, 540]]], ["Moreover, by acting on both epithelial cells and fibroblasts, IL-17 promotes epithelial to mesenchymal transition, as well as myofibroblast differentiation and extracellular matrix production, resulting in pulmonary fibrosis 4 .TextIntriguingly, permanent pulmonary damage appears to be more severe in ARDS patients who have been mechanically ventilated 5 .", [["epithelial cells", "ANATOMY", 28, 44], ["fibroblasts", "ANATOMY", 49, 60], ["epithelial", "ANATOMY", 77, 87], ["mesenchymal", "ANATOMY", 91, 102], ["myofibroblast", "ANATOMY", 126, 139], ["extracellular matrix", "ANATOMY", 160, 180], ["pulmonary", "ANATOMY", 206, 215], ["pulmonary", "ANATOMY", 256, 265], ["fibrosis", "DISEASE", 216, 224], ["pulmonary damage", "DISEASE", 256, 272], ["ARDS", "DISEASE", 302, 306], ["epithelial cells", "CELL", 28, 44], ["fibroblasts", "CELL", 49, 60], ["IL-17", "GENE_OR_GENE_PRODUCT", 62, 67], ["epithelial", "CELL", 77, 87], ["mesenchymal", "CELL", 91, 102], ["myofibroblast", "CELL", 126, 139], ["extracellular matrix", "CELLULAR_COMPONENT", 160, 180], ["pulmonary", "ORGAN", 206, 215], ["pulmonary", "ORGAN", 256, 265], ["patients", "ORGANISM", 307, 315], ["epithelial cells", "CELL_TYPE", 28, 44], ["fibroblasts", "CELL_TYPE", 49, 60], ["IL-17", "PROTEIN", 62, 67], ["patients", "SPECIES", 307, 315], ["IL", "TEST", 62, 64], ["epithelial to mesenchymal transition", "PROBLEM", 77, 113], ["extracellular matrix production", "PROBLEM", 160, 191], ["pulmonary fibrosis", "PROBLEM", 206, 224], ["permanent pulmonary damage", "PROBLEM", 246, 272], ["mechanically ventilated", "PROBLEM", 330, 353], ["epithelial cells", "ANATOMY", 28, 44], ["mesenchymal transition", "OBSERVATION", 91, 113], ["myofibroblast differentiation", "OBSERVATION", 126, 155], ["extracellular matrix production", "OBSERVATION", 160, 191], ["pulmonary", "ANATOMY", 206, 215], ["fibrosis", "OBSERVATION", 216, 224], ["pulmonary", "ANATOMY", 256, 265], ["damage", "OBSERVATION", 266, 272], ["appears to be", "UNCERTAINTY", 273, 286], ["more severe", "OBSERVATION_MODIFIER", 287, 298], ["ARDS", "OBSERVATION", 302, 306], ["mechanically", "OBSERVATION_MODIFIER", 330, 342], ["ventilated", "OBSERVATION", 343, 353]]], ["Pulmonary fibrosis in SARS patients may be the result of the high inflammatory burden related not only to the anti-viral immune response, but also to ventilatorinduced lung injury (VILI).TextNeutrophilic inflammation in response to higher levels of IL-8 is a pivotal step in the pathogenesis of VILI 5 and higher concentrations of IL-6 and TNF\u03b1 have been reported in the lungs of patients with VILI 6 .", [["Pulmonary", "ANATOMY", 0, 9], ["lung", "ANATOMY", 168, 172], ["lungs", "ANATOMY", 371, 376], ["Pulmonary fibrosis", "DISEASE", 0, 18], ["SARS", "DISEASE", 22, 26], ["lung injury", "DISEASE", 168, 179], ["VILI", "DISEASE", 181, 185], ["inflammation", "DISEASE", 204, 216], ["VILI", "DISEASE", 394, 398], ["Pulmonary", "ORGAN", 0, 9], ["patients", "ORGANISM", 27, 35], ["lung", "ORGAN", 168, 172], ["IL-8", "GENE_OR_GENE_PRODUCT", 249, 253], ["IL-6", "GENE_OR_GENE_PRODUCT", 331, 335], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 340, 344], ["lungs", "ORGAN", 371, 376], ["patients", "ORGANISM", 380, 388], ["IL-8", "PROTEIN", 249, 253], ["IL-6", "PROTEIN", 331, 335], ["TNF\u03b1", "PROTEIN", 340, 344], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 380, 388], ["Pulmonary fibrosis", "PROBLEM", 0, 18], ["SARS", "PROBLEM", 22, 26], ["the high inflammatory burden", "PROBLEM", 57, 85], ["ventilatorinduced lung injury", "PROBLEM", 150, 179], ["TextNeutrophilic inflammation", "PROBLEM", 187, 216], ["IL", "TEST", 249, 251], ["VILI", "TEST", 295, 299], ["IL", "TEST", 331, 333], ["TNF", "PROBLEM", 340, 343], ["VILI", "TEST", 394, 398], ["fibrosis", "OBSERVATION", 10, 18], ["high", "OBSERVATION_MODIFIER", 61, 65], ["inflammatory", "OBSERVATION", 66, 78], ["lung", "ANATOMY", 168, 172], ["injury", "OBSERVATION", 173, 179], ["inflammation", "OBSERVATION", 204, 216], ["lungs", "ANATOMY", 371, 376]]], ["Although IL-17 levels have not been evaluated in specific studies, IL-17 represents a crucial molecule in IL-8-mediated neutrophil recruitment and its interplay with IL-6 and TNF\u03b1 has been largely demonstrated 1 .TextMoreover, IL-17 has been suggested to be involved in the endothelial dysfunction and thrombophilia that has been observed in COVID-19 7 .", [["neutrophil", "ANATOMY", 120, 130], ["endothelial", "ANATOMY", 274, 285], ["endothelial dysfunction", "DISEASE", 274, 297], ["thrombophilia", "DISEASE", 302, 315], ["IL-17", "GENE_OR_GENE_PRODUCT", 9, 14], ["IL-17", "GENE_OR_GENE_PRODUCT", 67, 72], ["IL-8", "GENE_OR_GENE_PRODUCT", 106, 110], ["neutrophil", "CELL", 120, 130], ["IL-6", "GENE_OR_GENE_PRODUCT", 166, 170], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 175, 179], ["IL-17", "GENE_OR_GENE_PRODUCT", 227, 232], ["endothelial", "CELL", 274, 285], ["IL", "PROTEIN", 9, 11], ["IL-17", "PROTEIN", 67, 72], ["IL-8", "PROTEIN", 106, 110], ["IL-6", "PROTEIN", 166, 170], ["TNF\u03b1", "PROTEIN", 175, 179], ["IL-17", "PROTEIN", 227, 232], ["IL", "TEST", 9, 11], ["IL", "TEST", 67, 69], ["IL", "TEST", 106, 108], ["neutrophil recruitment", "TREATMENT", 120, 142], ["IL", "TEST", 166, 168], ["IL", "TEST", 227, 229], ["the endothelial dysfunction", "PROBLEM", 270, 297], ["thrombophilia", "PROBLEM", 302, 315], ["COVID", "TEST", 342, 347], ["neutrophil recruitment", "OBSERVATION", 120, 142], ["endothelial", "ANATOMY", 274, 285], ["dysfunction", "OBSERVATION", 286, 297], ["thrombophilia", "OBSERVATION", 302, 315]]], ["In fact, studies performed on both human patients and murine models have shown that IL-17 correlates with vascular dysfunction and induces platelet aggregation, facilitating arterial thrombosis 7 .", [["vascular", "ANATOMY", 106, 114], ["platelet", "ANATOMY", 139, 147], ["arterial", "ANATOMY", 174, 182], ["vascular dysfunction", "DISEASE", 106, 126], ["platelet aggregation", "DISEASE", 139, 159], ["arterial thrombosis", "DISEASE", 174, 193], ["human", "ORGANISM", 35, 40], ["patients", "ORGANISM", 41, 49], ["murine", "ORGANISM", 54, 60], ["IL-17", "GENE_OR_GENE_PRODUCT", 84, 89], ["vascular", "MULTI-TISSUE_STRUCTURE", 106, 114], ["platelet", "CELL", 139, 147], ["arterial", "MULTI-TISSUE_STRUCTURE", 174, 182], ["IL-17", "PROTEIN", 84, 89], ["human", "SPECIES", 35, 40], ["patients", "SPECIES", 41, 49], ["murine", "SPECIES", 54, 60], ["human", "SPECIES", 35, 40], ["studies", "TEST", 9, 16], ["murine models", "TEST", 54, 67], ["IL", "TEST", 84, 86], ["vascular dysfunction", "PROBLEM", 106, 126], ["platelet aggregation", "PROBLEM", 139, 159], ["facilitating arterial thrombosis", "PROBLEM", 161, 193], ["vascular", "ANATOMY", 106, 114], ["dysfunction", "OBSERVATION", 115, 126], ["platelet aggregation", "OBSERVATION", 139, 159], ["arterial", "ANATOMY", 174, 182], ["thrombosis", "OBSERVATION", 183, 193]]], ["Furthermore, IL-17 activates endothelial cells, stimulating the production of tissue factor and modulating thrombomodulin expression 7 .", [["endothelial cells", "ANATOMY", 29, 46], ["IL-17", "GENE_OR_GENE_PRODUCT", 13, 18], ["endothelial cells", "CELL", 29, 46], ["tissue factor", "GENE_OR_GENE_PRODUCT", 78, 91], ["thrombomodulin", "GENE_OR_GENE_PRODUCT", 107, 121], ["IL-17", "PROTEIN", 13, 18], ["endothelial cells", "CELL_TYPE", 29, 46], ["tissue factor", "PROTEIN", 78, 91], ["thrombomodulin", "PROTEIN", 107, 121], ["IL", "TEST", 13, 15], ["endothelial cells", "TREATMENT", 29, 46], ["tissue factor", "PROBLEM", 78, 91], ["modulating thrombomodulin expression", "TREATMENT", 96, 132], ["endothelial cells", "OBSERVATION", 29, 46], ["thrombomodulin expression", "OBSERVATION", 107, 132]]], ["In turn, the activation of coagulation might enhance the fibrotic process.", [["the fibrotic process", "PROBLEM", 53, 73], ["fibrotic", "OBSERVATION", 57, 65]]], ["In fact, in the bronchoalveolar lavage of interstitial lung disease patients, tissue factor has been shown to be more active than in healthy controls 8 .", [["bronchoalveolar lavage", "ANATOMY", 16, 38], ["interstitial lung", "ANATOMY", 42, 59], ["tissue", "ANATOMY", 78, 84], ["interstitial lung disease", "DISEASE", 42, 67], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 16, 38], ["interstitial lung", "CANCER", 42, 59], ["patients", "ORGANISM", 68, 76], ["tissue", "TISSUE", 78, 84], ["tissue factor", "PROTEIN", 78, 91], ["patients", "SPECIES", 68, 76], ["the bronchoalveolar lavage", "TEST", 12, 38], ["interstitial lung disease", "PROBLEM", 42, 67], ["tissue factor", "PROBLEM", 78, 91], ["bronchoalveolar lavage", "OBSERVATION", 16, 38], ["interstitial", "ANATOMY_MODIFIER", 42, 54], ["lung", "ANATOMY", 55, 59], ["disease", "OBSERVATION", 60, 67], ["more", "OBSERVATION_MODIFIER", 113, 117], ["active", "OBSERVATION_MODIFIER", 118, 124]]], ["The pro-coagulative cascade following the activation of tissue factor has been pathogenetically linked to the establishment of pulmonary fibrosis 8 .", [["tissue", "ANATOMY", 56, 62], ["pulmonary", "ANATOMY", 127, 136], ["pulmonary fibrosis", "DISEASE", 127, 145], ["tissue factor", "GENE_OR_GENE_PRODUCT", 56, 69], ["pulmonary", "ORGAN", 127, 136], ["tissue factor", "PROTEIN", 56, 69], ["The pro-coagulative cascade", "TREATMENT", 0, 27], ["pulmonary fibrosis", "PROBLEM", 127, 145], ["pulmonary", "ANATOMY", 127, 136], ["fibrosis", "OBSERVATION", 137, 145]]], ["Notably, factor Xa and thrombin seem to activate protease-associated receptors which induce myofibroblast differentiation in lung fibroblasts.", [["myofibroblast", "ANATOMY", 92, 105], ["lung fibroblasts", "ANATOMY", 125, 141], ["factor Xa", "GENE_OR_GENE_PRODUCT", 9, 18], ["thrombin", "GENE_OR_GENE_PRODUCT", 23, 31], ["myofibroblast", "CELL", 92, 105], ["lung fibroblasts", "CELL", 125, 141], ["factor Xa", "PROTEIN", 9, 18], ["thrombin", "PROTEIN", 23, 31], ["protease-associated receptors", "PROTEIN", 49, 78], ["lung fibroblasts", "CELL_TYPE", 125, 141], ["factor Xa", "PROBLEM", 9, 18], ["thrombin", "TREATMENT", 23, 31], ["associated receptors", "PROBLEM", 58, 78], ["myofibroblast differentiation in lung fibroblasts", "PROBLEM", 92, 141], ["myofibroblast differentiation", "OBSERVATION", 92, 121], ["lung", "ANATOMY", 125, 129], ["fibroblasts", "OBSERVATION", 130, 141]]], ["Moreover, anticoagulant therapies have been shown to ameliorate lung fibrosis in both murine models and human patients.", [["lung", "ANATOMY", 64, 68], ["fibrosis", "DISEASE", 69, 77], ["lung", "ORGAN", 64, 68], ["murine", "ORGANISM", 86, 92], ["human", "ORGANISM", 104, 109], ["patients", "ORGANISM", 110, 118], ["murine", "SPECIES", 86, 92], ["human", "SPECIES", 104, 109], ["patients", "SPECIES", 110, 118], ["human", "SPECIES", 104, 109], ["anticoagulant therapies", "TREATMENT", 10, 33], ["lung fibrosis", "PROBLEM", 64, 77], ["lung", "ANATOMY", 64, 68], ["fibrosis", "OBSERVATION", 69, 77]]], ["8 Therefore, it is conceivable that IL-17 inhibition could also contribute to fibrosis prevention in COVID-19 by interfering with the coagulative pathways.TextCurrently, IL-17 inhibitors like secukinumab and IL-17 receptor inhibitors like brodalumab are used for the treatment of psoriasis 9 .", [["fibrosis", "DISEASE", 78, 86], ["COVID-19", "CHEMICAL", 101, 109], ["secukinumab", "CHEMICAL", 192, 203], ["brodalumab", "CHEMICAL", 239, 249], ["psoriasis", "DISEASE", 280, 289], ["COVID-19", "CHEMICAL", 101, 109], ["secukinumab", "CHEMICAL", 192, 203], ["brodalumab", "CHEMICAL", 239, 249], ["IL-17", "GENE_OR_GENE_PRODUCT", 36, 41], ["COVID-19", "CELL", 101, 109], ["IL-17", "GENE_OR_GENE_PRODUCT", 170, 175], ["secukinumab", "SIMPLE_CHEMICAL", 192, 203], ["IL-17 receptor inhibitors", "SIMPLE_CHEMICAL", 208, 233], ["brodalumab", "SIMPLE_CHEMICAL", 239, 249], ["IL-17 inhibition", "TREATMENT", 36, 52], ["fibrosis prevention", "PROBLEM", 78, 97], ["COVID", "TEST", 101, 106], ["TextCurrently", "TREATMENT", 155, 168], ["IL-17 inhibitors", "TREATMENT", 170, 186], ["secukinumab and IL", "TREATMENT", 192, 210], ["receptor inhibitors", "TREATMENT", 214, 233], ["brodalumab", "TREATMENT", 239, 249], ["psoriasis", "PROBLEM", 280, 289], ["fibrosis", "OBSERVATION", 78, 86], ["psoriasis", "OBSERVATION", 280, 289]]], ["In psoriatic patients, secukinumab has been demonstrated to decrease serum levels of Krebs von der Lungen-6 (KL6), a marker of lung fibrosis.", [["serum", "ANATOMY", 69, 74], ["lung", "ANATOMY", 127, 131], ["psoriatic", "DISEASE", 3, 12], ["secukinumab", "CHEMICAL", 23, 34], ["lung fibrosis", "DISEASE", 127, 140], ["secukinumab", "CHEMICAL", 23, 34], ["patients", "ORGANISM", 13, 21], ["secukinumab", "SIMPLE_CHEMICAL", 23, 34], ["serum", "ORGANISM_SUBSTANCE", 69, 74], ["Krebs von der Lungen-6", "GENE_OR_GENE_PRODUCT", 85, 107], ["KL6", "GENE_OR_GENE_PRODUCT", 109, 112], ["lung", "ORGAN", 127, 131], ["patients", "SPECIES", 13, 21], ["secukinumab", "TREATMENT", 23, 34], ["serum levels", "TEST", 69, 81], ["Krebs von der Lungen", "TEST", 85, 105], ["lung fibrosis", "PROBLEM", 127, 140], ["psoriatic", "OBSERVATION_MODIFIER", 3, 12], ["lung", "ANATOMY", 127, 131], ["fibrosis", "OBSERVATION", 132, 140]]], ["10 Furthermore, in a case series of psoriatic patient with concomitant interstitial pneumonia, the inhibition of the IL-23/IL-17 pathway by ustekinumab, secukinumab or brodalumab correlated with a stabilization or an amelioration of lung fibrosis 9 .TextIn conclusion, IL-17 appears to be involved in several processes which might be relevant in the pathogenesis of COVID-19-induced pulmonary fibrosis.", [["interstitial", "ANATOMY", 71, 83], ["lung", "ANATOMY", 233, 237], ["pulmonary", "ANATOMY", 383, 392], ["psoriatic", "DISEASE", 36, 45], ["interstitial pneumonia", "DISEASE", 71, 93], ["ustekinumab", "CHEMICAL", 140, 151], ["secukinumab", "CHEMICAL", 153, 164], ["brodalumab", "CHEMICAL", 168, 178], ["fibrosis", "DISEASE", 238, 246], ["COVID-19", "CHEMICAL", 366, 374], ["pulmonary fibrosis", "DISEASE", 383, 401], ["secukinumab", "CHEMICAL", 153, 164], ["brodalumab", "CHEMICAL", 168, 178], ["COVID-19", "CHEMICAL", 366, 374], ["patient", "ORGANISM", 46, 53], ["IL-23", "GENE_OR_GENE_PRODUCT", 117, 122], ["IL-17", "GENE_OR_GENE_PRODUCT", 123, 128], ["ustekinumab", "SIMPLE_CHEMICAL", 140, 151], ["secukinumab", "SIMPLE_CHEMICAL", 153, 164], ["brodalumab", "SIMPLE_CHEMICAL", 168, 178], ["lung", "ORGAN", 233, 237], ["IL-17", "GENE_OR_GENE_PRODUCT", 269, 274], ["COVID-19", "CELL", 366, 374], ["pulmonary", "ORGAN", 383, 392], ["IL-17", "PROTEIN", 269, 274], ["patient", "SPECIES", 46, 53], ["concomitant interstitial pneumonia", "PROBLEM", 59, 93], ["the IL", "TREATMENT", 113, 119], ["secukinumab", "TREATMENT", 153, 164], ["a stabilization", "TREATMENT", 195, 210], ["lung fibrosis", "PROBLEM", 233, 246], ["COVID", "TEST", 366, 371], ["pulmonary fibrosis", "PROBLEM", 383, 401], ["psoriatic", "OBSERVATION", 36, 45], ["interstitial", "ANATOMY_MODIFIER", 71, 83], ["pneumonia", "OBSERVATION", 84, 93], ["lung", "ANATOMY", 233, 237], ["fibrosis", "OBSERVATION", 238, 246], ["pulmonary", "ANATOMY", 383, 392], ["fibrosis", "OBSERVATION", 393, 401]]], ["Notably, IL-17 could act both directly, by activating fibroblasts, and indirectly, enhancing virus-mediated and ventilator-mediated inflammatory processes.", [["fibroblasts", "ANATOMY", 54, 65], ["IL-17", "GENE_OR_GENE_PRODUCT", 9, 14], ["fibroblasts", "CELL", 54, 65], ["IL-17", "PROTEIN", 9, 14], ["fibroblasts", "CELL_TYPE", 54, 65], ["enhancing virus-mediated and ventilator-mediated inflammatory processes", "PROBLEM", 83, 154], ["inflammatory", "OBSERVATION", 132, 144]]], ["Furthermore, IL-17 could stimulate fibrogenesis through the activation of pro-coagulative pathways.", [["IL-17", "GENE_OR_GENE_PRODUCT", 13, 18], ["IL-17", "PROTEIN", 13, 18], ["IL", "TREATMENT", 13, 15], ["fibrogenesis", "PROBLEM", 35, 47], ["fibrogenesis", "OBSERVATION", 35, 47]]], ["Therefore, we suggest that IL-17 inhibitors may be helpful not only for the acute phase of COVID-19, but also for the prevention of its long-term fibrotic sequelae.", [["COVID-19", "CHEMICAL", 91, 99], ["COVID-19", "CHEMICAL", 91, 99], ["IL-17", "GENE_OR_GENE_PRODUCT", 27, 32], ["IL-17 inhibitors", "TREATMENT", 27, 43], ["COVID", "TEST", 91, 96], ["its long-term fibrotic sequelae", "PROBLEM", 132, 163], ["long-term", "OBSERVATION_MODIFIER", 136, 145], ["fibrotic", "OBSERVATION_MODIFIER", 146, 154], ["sequelae", "OBSERVATION", 155, 163]]]], "PMC7229465": [["IntroductionHIV is a significant health issue in China (Lo, 2018).", [["significant", "OBSERVATION_MODIFIER", 21, 32]]], ["According to the China CDC, the total number of people living with HIV/AIDS (PLWHA) was 849,602 as of September 2018 (China CDC, 2018).", [["HIV/AIDS", "DISEASE", 67, 75], ["people", "ORGANISM", 48, 54], ["people", "SPECIES", 48, 54]]], ["Current reports of the HIV epidemic in Shanghai, China estimate that approximately 29,463 people were infected with HIV at the end of November 2018 (Shanghai Municipal Health Commission, 2018).", [["HIV", "DISEASE", 116, 119], ["people", "ORGANISM", 90, 96], ["people", "SPECIES", 90, 96], ["HIV", "SPECIES", 116, 119], ["HIV", "SPECIES", 23, 26], ["HIV", "SPECIES", 116, 119], ["the HIV epidemic", "PROBLEM", 19, 35], ["HIV", "PROBLEM", 116, 119]]], ["HIV-related expenses are costly from both an economic and human suffering standpoint (Liu et al., 2018).BackgroundA symptom is defined as an objective perception of a physical, psychological, or social condition that may indicate a condition of disease (Hegyvary, 1991).", [["human", "ORGANISM", 58, 63], ["HIV", "SPECIES", 0, 3], ["human", "SPECIES", 58, 63], ["HIV", "SPECIES", 0, 3], ["human", "SPECIES", 58, 63], ["BackgroundA symptom", "PROBLEM", 104, 123], ["disease", "PROBLEM", 245, 252]]], ["For PLWHA, antiretroviral therapy (ART) has changed HIV to a chronic and manageable disease (Martinez et al., 2012).", [["HIV", "SPECIES", 52, 55], ["HIV", "SPECIES", 52, 55], ["PLWHA", "TREATMENT", 4, 9], ["antiretroviral therapy (ART", "TREATMENT", 11, 38], ["a chronic and manageable disease", "PROBLEM", 59, 91], ["antiretroviral therapy", "OBSERVATION", 11, 33], ["chronic", "OBSERVATION_MODIFIER", 61, 68]]], ["However, compared to other chronic illnesses (e.g., diabetes or hypertension), PLWHA are still a vulnerable group who experience multiple physiological and psychological symptoms resulting from the disease itself, from side effects of ART, and from other medications related to comorbidities (Lalanne et al., 2015; Roman & Chou, 2011).BackgroundStudies found that many PLWHA (30%) presented with high symptom burden, with seven or more symptoms at the same time being common (Wilson et al., 2016).", [["chronic illnesses", "DISEASE", 27, 44], ["diabetes", "DISEASE", 52, 60], ["hypertension", "DISEASE", 64, 76], ["other chronic illnesses", "PROBLEM", 21, 44], ["diabetes", "PROBLEM", 52, 60], ["hypertension", "PROBLEM", 64, 76], ["multiple physiological and psychological symptoms", "PROBLEM", 129, 178], ["the disease itself", "PROBLEM", 194, 212], ["ART", "TREATMENT", 235, 238], ["other medications", "TREATMENT", 249, 266], ["comorbidities", "PROBLEM", 278, 291], ["high symptom burden", "PROBLEM", 396, 415], ["more symptoms", "PROBLEM", 431, 444], ["chronic", "OBSERVATION_MODIFIER", 27, 34], ["illnesses", "OBSERVATION", 35, 44], ["hypertension", "OBSERVATION", 64, 76], ["disease", "OBSERVATION", 198, 205], ["many", "OBSERVATION_MODIFIER", 364, 368], ["PLWHA", "OBSERVATION", 369, 374]]], ["Fatigue, fever, headache, nausea/vomiting, diarrhea, weight loss, pruritus/itching, chills, rash, sweat, dyspnea, cough, muscle pain/joint pain, numbness/pain in feet, and poor sleep were among the most prevalent and distressing physical symptoms for PLWHA (McGowan et al., 2014; Peltzer, 2013; Wakeham et al., 2010; Wilson et al., 2016).", [["muscle", "ANATOMY", 121, 127], ["joint", "ANATOMY", 133, 138], ["feet", "ANATOMY", 162, 166], ["Fatigue", "DISEASE", 0, 7], ["fever", "DISEASE", 9, 14], ["headache", "DISEASE", 16, 24], ["nausea/vomiting", "DISEASE", 26, 41], ["diarrhea", "DISEASE", 43, 51], ["weight loss", "DISEASE", 53, 64], ["pruritus", "DISEASE", 66, 74], ["itching", "DISEASE", 75, 82], ["chills", "DISEASE", 84, 90], ["rash", "DISEASE", 92, 96], ["dyspnea", "DISEASE", 105, 112], ["cough", "DISEASE", 114, 119], ["muscle pain", "DISEASE", 121, 132], ["pain", "DISEASE", 139, 143], ["numbness", "DISEASE", 145, 153], ["pain", "DISEASE", 154, 158], ["sweat", "ORGANISM_SUBDIVISION", 98, 103], ["muscle", "ORGANISM_SUBDIVISION", 121, 127], ["joint", "ORGANISM_SUBDIVISION", 133, 138], ["Fatigue", "PROBLEM", 0, 7], ["fever", "PROBLEM", 9, 14], ["headache", "PROBLEM", 16, 24], ["nausea", "PROBLEM", 26, 32], ["vomiting", "PROBLEM", 33, 41], ["diarrhea", "PROBLEM", 43, 51], ["weight loss", "PROBLEM", 53, 64], ["pruritus", "PROBLEM", 66, 74], ["itching", "PROBLEM", 75, 82], ["chills", "PROBLEM", 84, 90], ["rash", "PROBLEM", 92, 96], ["sweat", "PROBLEM", 98, 103], ["dyspnea", "PROBLEM", 105, 112], ["cough", "PROBLEM", 114, 119], ["muscle pain", "PROBLEM", 121, 132], ["joint pain", "PROBLEM", 133, 143], ["numbness", "PROBLEM", 145, 153], ["pain in feet", "PROBLEM", 154, 166], ["poor sleep", "PROBLEM", 172, 182], ["distressing physical symptoms", "PROBLEM", 217, 246], ["sweat", "ANATOMY", 98, 103], ["cough", "OBSERVATION", 114, 119], ["muscle", "ANATOMY", 121, 127], ["joint", "ANATOMY", 133, 138], ["numbness", "OBSERVATION", 145, 153], ["feet", "ANATOMY", 162, 166]]], ["In addition, PLWHA also deal with burden related to psychosocial problems.", [["psychosocial problems", "PROBLEM", 52, 73]]], ["Studies have shown that sleep disturbances and fatigue were one of the major unpleasant symptoms among Chinese PLWHA (Chen et al., 2013; Zhu et al., 2019).", [["sleep disturbances", "DISEASE", 24, 42], ["fatigue", "DISEASE", 47, 54], ["Studies", "TEST", 0, 7], ["sleep disturbances", "PROBLEM", 24, 42], ["fatigue", "PROBLEM", 47, 54], ["the major unpleasant symptoms", "PROBLEM", 67, 96], ["sleep disturbances", "OBSERVATION", 24, 42]]], ["Further, Chinese PLWHA often face mental health crises after receiving their HIV diagnosis (Chen et al., 2011).BackgroundFear, anxiety, sadness, and depression are common problems among PLWHA, and some of these symptoms are more prominent in the later stages of illness (Chu & Selwyn, 2011).", [["anxiety", "DISEASE", 127, 134], ["sadness", "DISEASE", 136, 143], ["depression", "DISEASE", 149, 159], ["illness", "DISEASE", 262, 269], ["HIV", "SPECIES", 77, 80], ["anxiety", "PROBLEM", 127, 134], ["sadness", "PROBLEM", 136, 143], ["depression", "PROBLEM", 149, 159], ["common problems", "PROBLEM", 164, 179], ["these symptoms", "PROBLEM", 205, 219], ["more prominent", "OBSERVATION_MODIFIER", 224, 238]]], ["Not surprisingly, the prevalence of depression was 46.5% among HIV-positive men who have sex with men (MSM) in Shanghai, China (Pan et al., 2017).", [["depression", "DISEASE", 36, 46], ["HIV-positive", "DISEASE", 63, 75], ["HIV", "ORGANISM", 63, 66], ["men", "ORGANISM", 76, 79], ["men", "ORGANISM", 98, 101], ["HIV", "SPECIES", 63, 66], ["men", "SPECIES", 76, 79], ["men", "SPECIES", 98, 101], ["HIV", "SPECIES", 63, 66], ["depression", "PROBLEM", 36, 46]]], ["Worrying about their health condition was one of the major symptoms PLWHA associated with depression, followed by feeling unhopeful about the future (Liu et al., 2018).BackgroundUntreated symptoms are likely to impact activities of daily living and can lead to poor quality of life and nonadherence to HIV regimens (Baran et al., 2014; Gay et al., 2011).", [["depression", "DISEASE", 90, 100], ["HIV", "ORGANISM", 302, 305], ["HIV", "SPECIES", 302, 305], ["the major symptoms", "PROBLEM", 49, 67], ["depression", "PROBLEM", 90, 100], ["BackgroundUntreated symptoms", "PROBLEM", 168, 196], ["HIV regimens", "TREATMENT", 302, 314]]], ["Therefore, effective symptom management is essential for HIV-positive individuals to maintain their quality of life (Holzemer, 2002; Tsai, Hsiung, & Holzemer, 2002).", [["HIV", "ORGANISM", 57, 60], ["individuals", "ORGANISM", 70, 81], ["HIV", "SPECIES", 57, 60], ["effective symptom management", "TREATMENT", 11, 39], ["HIV", "PROBLEM", 57, 60], ["positive individuals", "PROBLEM", 61, 81]]], ["A recent meta-analysis identified that self-management of pain and symptoms (such as fatigue, headache, etc.) in PLWHA is still under development (Nkhoma et al., 2018), which implies that PLWHA have a high need for effective self-management interventions.BackgroundMany symptom management interventions offered by healthcare providers (HCPs) might not be the need of PLWHA (Simpson et al., 2013).", [["pain", "DISEASE", 58, 62], ["fatigue", "DISEASE", 85, 92], ["headache", "DISEASE", 94, 102], ["A recent meta-analysis", "TEST", 0, 22], ["pain", "PROBLEM", 58, 62], ["symptoms", "PROBLEM", 67, 75], ["fatigue", "PROBLEM", 85, 92], ["headache", "PROBLEM", 94, 102], ["effective self-management interventions", "TREATMENT", 215, 254]]], ["Thus, HCPs can solve the unpleasant symptoms on site after interviewed with PLWHA.BackgroundUnmet needs are defined as the differences between those services judged necessary and those services actually being received (Carr & Wolfe, 1976).", [["the unpleasant symptoms on site", "PROBLEM", 21, 52]]], ["Unmet need for symptom management is defined as the descriptions given by patients who have unmet needs in the current management of symptoms (Hwang et al., 2004).", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["symptom management", "TREATMENT", 15, 33], ["symptoms", "PROBLEM", 133, 141]]], ["Measurement of patient-reported unmet needs for symptom management will reflecting the deficits in HIV care (Snyder et al., 2010; Walling et al., 2016).", [["patient", "ORGANISM", 15, 22], ["patient", "SPECIES", 15, 22], ["HIV", "SPECIES", 99, 102], ["symptom management", "TREATMENT", 48, 66], ["the deficits", "PROBLEM", 83, 95]]], ["Thus, the level of unmet needs reported is an important indicator of whether inconsistences exist between patients' needs and HCP\u2019 perceptions of the level of care they are providing.BackgroundThe morbidities and distress resulting from HIV-related symptoms can lead to unmet needs across a range of domains.", [["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["HIV", "SPECIES", 237, 240], ["HIV", "SPECIES", 237, 240], ["The morbidities", "PROBLEM", 193, 208], ["distress", "PROBLEM", 213, 221], ["HIV", "PROBLEM", 237, 240], ["related symptoms", "PROBLEM", 241, 257], ["morbidities", "OBSERVATION", 197, 208]]], ["Current studies focus on the need for symptom management in the HIV-positive population; however, they do not specifically discuss the unmet symptom management needs of PLWHA (Chen et al., 2013; Fu, 2014; Shadloo et al., 2018).", [["HIV", "SPECIES", 64, 67], ["Current studies", "TEST", 0, 15], ["symptom management", "TREATMENT", 38, 56], ["symptom management", "TREATMENT", 141, 159]]], ["Studies have focused on descriptions of unmet symptom management needs in cancer (Walling et al., 2016) and end-of-life care (Khandelwal et al., 2017).", [["cancer", "ANATOMY", 74, 80], ["cancer", "DISEASE", 74, 80], ["cancer", "CANCER", 74, 80], ["unmet symptom management", "TREATMENT", 40, 64]]], ["One study found that psychiatric disorders were found in 50.2% for PLWHA in Iran and only 22% had received minimally adequate treatment (Shadloo et al., 2018).", [["psychiatric disorders", "DISEASE", 21, 42], ["One study", "TEST", 0, 9], ["psychiatric disorders", "PROBLEM", 21, 42], ["minimally adequate treatment", "TREATMENT", 107, 135]]], ["In China, one study has shown that the major needs of symptom management were rash, shortness of breath, and blurred vision (Fu, 2014).", [["rash", "DISEASE", 78, 82], ["shortness of breath", "DISEASE", 84, 103], ["blurred vision", "DISEASE", 109, 123], ["one study", "TEST", 10, 19], ["symptom management", "TREATMENT", 54, 72], ["rash", "PROBLEM", 78, 82], ["shortness of breath", "PROBLEM", 84, 103], ["blurred vision", "PROBLEM", 109, 123]]], ["Chen, Shiu, et al. (2013) have also reported that Chinese HIV-positive individuals experienced digestive discomfort, skin rashes, numbness, memory loss, nightmares, and dizziness, along with depressive mood.BackgroundAn understanding of the prevalence and presence of symptoms is important to guide and design an effective symptom management in PLWHA.", [["digestive", "ANATOMY", 95, 104], ["skin", "ANATOMY", 117, 121], ["HIV-positive", "DISEASE", 58, 70], ["digestive discomfort", "DISEASE", 95, 115], ["skin rashes", "DISEASE", 117, 128], ["numbness", "DISEASE", 130, 138], ["memory loss", "DISEASE", 140, 151], ["nightmares", "DISEASE", 153, 163], ["dizziness", "DISEASE", 169, 178], ["depressive mood", "DISEASE", 191, 206], ["Chinese HIV", "ORGANISM", 50, 61], ["individuals", "ORGANISM", 71, 82], ["digestive", "ORGAN", 95, 104], ["skin", "ORGAN", 117, 121], ["HIV", "SPECIES", 58, 61], ["Chinese", "SPECIES", 50, 57], ["HIV", "SPECIES", 58, 61], ["digestive discomfort", "PROBLEM", 95, 115], ["skin rashes", "PROBLEM", 117, 128], ["numbness", "PROBLEM", 130, 138], ["memory loss", "PROBLEM", 140, 151], ["nightmares", "PROBLEM", 153, 163], ["dizziness", "PROBLEM", 169, 178], ["depressive mood", "PROBLEM", 191, 206], ["symptoms", "PROBLEM", 268, 276], ["an effective symptom management", "TREATMENT", 310, 341], ["skin", "ANATOMY", 117, 121], ["rashes", "OBSERVATION", 122, 128], ["numbness", "OBSERVATION", 130, 138], ["memory loss", "OBSERVATION", 140, 151]]], ["Therefore, in this paper, we investigate the prevalence and potential factors of Chinese PLWHA self-perceived unmet needs and their current HIV-related symptoms.Theoretical frameworkBased on the HIV-related self- and family management theoretical framework (Wang et al., 2016), we revised the model to more closely fit the current study (see Fig. 1).", [["HIV", "ORGANISM", 140, 143], ["HIV", "SPECIES", 140, 143], ["HIV", "SPECIES", 140, 143], ["related symptoms", "PROBLEM", 144, 160], ["the current study", "TEST", 319, 336]]], ["This framework highlights the facilitators of and barriers to the PLWHA, as well as proximal and distal outcomes.", [["proximal", "ANATOMY_MODIFIER", 84, 92], ["distal", "ANATOMY_MODIFIER", 97, 103]]], ["We added potential HIV-related factors (e.g., HIV perceived stigma) as it was affected by unmet symptom management needs.Theoretical frameworkSymptoms and stresses vary in PLWHA.", [["HIV perceived stigma", "DISEASE", 46, 66], ["HIV", "SPECIES", 46, 49], ["HIV", "SPECIES", 19, 22], ["HIV", "SPECIES", 46, 49], ["symptom management", "TREATMENT", 96, 114], ["Theoretical frameworkSymptoms", "PROBLEM", 121, 150], ["stresses", "PROBLEM", 155, 163], ["stresses vary", "OBSERVATION", 155, 168]]], ["For instance, while some individuals have more issues with disclosing their HIV status, others report health access difficulties (Wang, Chen, et al., 2016).", [["HIV", "SPECIES", 76, 79]]], ["In addition, some PLWHA have sought more family and social support while living with HIV (MacCarthy et al., 2018; Wang, Chen, et al., 2016).", [["HIV", "SPECIES", 85, 88]]], ["Particularly, PLWHA have reported higher needs when the symptoms were more severe (Osse, Vernooij-Dassen, Schade, & Grol, 2007).Theoretical frameworkIn the current study, we hypothesized that personal factors (self-management capability and symptom management needs), health status (symptom severity), and HIV specific factors (HIV perceived stigma) will affect proximal outcome (biological outcome and symptom management) and distal outcome (unmet symptom management needs).Study site ::: MethodsThis cross-sectional study was conducted at Shanghai Public Health Clinical Center (SPHCC) in Shanghai, China from April to September 2017.", [["HIV perceived stigma", "DISEASE", 328, 348], ["HIV", "SPECIES", 306, 309], ["HIV", "SPECIES", 328, 331], ["the symptoms", "PROBLEM", 52, 64], ["the current study", "TEST", 152, 169], ["self-management capability", "TREATMENT", 210, 236], ["symptom management", "TREATMENT", 241, 259], ["symptom severity)", "PROBLEM", 283, 300], ["HIV specific factors", "PROBLEM", 306, 326], ["symptom management", "TREATMENT", 403, 421], ["unmet symptom management", "TREATMENT", 443, 467], ["Methods", "TREATMENT", 490, 497], ["This cross-sectional study", "TEST", 497, 523]]], ["SPHCC is an infectious disease hospital focusing on treating all the infectious diseases, including severe acute respiratory syndrome (SARS), HIV/AIDS, hepatitis B and C, and other sexually transmitted diseases.", [["SPHCC", "DISEASE", 0, 5], ["infectious diseases", "DISEASE", 69, 88], ["acute respiratory syndrome", "DISEASE", 107, 133], ["SARS", "DISEASE", 135, 139], ["HIV/AIDS, hepatitis B", "DISEASE", 142, 163], ["sexually transmitted diseases", "DISEASE", 181, 210], ["hepatitis B", "ORGANISM", 152, 163], ["HIV", "SPECIES", 142, 145], ["HIV", "SPECIES", 142, 145], ["severe acute respiratory syndrome", "PROBLEM", 100, 133], ["SARS", "PROBLEM", 135, 139], ["HIV", "PROBLEM", 142, 145], ["AIDS", "PROBLEM", 146, 150], ["hepatitis B and C", "PROBLEM", 152, 169], ["other sexually transmitted diseases", "PROBLEM", 175, 210], ["infectious", "OBSERVATION", 12, 22], ["infectious", "OBSERVATION", 69, 79], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["respiratory syndrome", "OBSERVATION", 113, 133]]], ["Patients with comorbidities and any infectious diseases are treated in the tertiary setting (Chen et al., 2010).", [["infectious diseases", "DISEASE", 36, 55], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["comorbidities", "PROBLEM", 14, 27], ["any infectious diseases", "PROBLEM", 32, 55], ["infectious", "OBSERVATION_MODIFIER", 36, 46]]], ["As such, SPHCC is one of the preeminent infectious disease hospitals in Southern China.", [["SPHCC", "DISEASE", 9, 14], ["infectious disease", "DISEASE", 40, 58], ["infectious", "OBSERVATION", 40, 50]]], ["All study procedures were reviewed and approved by the institutional review board of the School of Nursing, Fudan University.Sample ::: MethodsStudy participants were recruited from the outpatient or inpatient wards with confirmed HIV diagnosis.", [["participants", "SPECIES", 149, 161], ["HIV", "SPECIES", 231, 234], ["All study procedures", "TEST", 0, 20]]], ["Eligible participants were required to be: (a) HIV diagnosed, (b) receiving care at SPHCC, (c) able to read and communicate in Chinese/Mandarin and (d) aged over 18.", [["participants", "SPECIES", 9, 21], ["HIV", "SPECIES", 47, 50], ["HIV", "SPECIES", 47, 50]]], ["Patients who were unable to complete the questionnaire, had other chronic diseases (such as heart disease, diabetes, tuberculosis) or severe cognitive impairment were excluded.Measurement ::: MethodsSymptom management was assessed using a self-administered 49-item questionnaire as the outcome measure.", [["heart", "ANATOMY", 92, 97], ["chronic diseases", "DISEASE", 66, 82], ["heart disease", "DISEASE", 92, 105], ["diabetes", "DISEASE", 107, 115], ["tuberculosis", "DISEASE", 117, 129], ["cognitive impairment", "DISEASE", 141, 161], ["Patients", "ORGANISM", 0, 8], ["heart", "ORGAN", 92, 97], ["Patients", "SPECIES", 0, 8], ["other chronic diseases", "PROBLEM", 60, 82], ["heart disease", "PROBLEM", 92, 105], ["diabetes", "PROBLEM", 107, 115], ["tuberculosis", "PROBLEM", 117, 129], ["severe cognitive impairment", "PROBLEM", 134, 161], ["MethodsSymptom management", "TREATMENT", 192, 217], ["chronic", "OBSERVATION_MODIFIER", 66, 73], ["diseases", "OBSERVATION", 74, 82], ["heart", "ANATOMY", 92, 97], ["disease", "OBSERVATION", 98, 105], ["tuberculosis", "OBSERVATION", 117, 129], ["severe", "OBSERVATION_MODIFIER", 134, 140], ["cognitive impairment", "OBSERVATION", 141, 161]]], ["Symptoms that were highly related to HIV (e.g., fatigue, fever, rash, diarrhea, and depression) were included in the questionnaire.", [["fatigue", "DISEASE", 48, 55], ["fever", "DISEASE", 57, 62], ["rash", "DISEASE", 64, 68], ["diarrhea", "DISEASE", 70, 78], ["depression", "DISEASE", 84, 94], ["HIV", "ORGANISM", 37, 40], ["HIV", "SPECIES", 37, 40], ["HIV", "SPECIES", 37, 40], ["Symptoms", "PROBLEM", 0, 8], ["HIV (e.g.", "PROBLEM", 37, 46], ["fatigue", "PROBLEM", 48, 55], ["fever", "PROBLEM", 57, 62], ["rash", "PROBLEM", 64, 68], ["diarrhea", "PROBLEM", 70, 78], ["depression", "PROBLEM", 84, 94]]], ["Patients indicate for the previous four weeks what symptoms were present along with the symptom severity.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["symptoms", "PROBLEM", 51, 59], ["the symptom severity", "PROBLEM", 84, 104]]], ["If a symptom was present, then participants rate the degree of the need for symptom management (0 = No demand, 1 = Weak demand, 2 = Moderate demand, 3 = Strong demand).", [["participants", "SPECIES", 31, 43], ["a symptom", "PROBLEM", 3, 12], ["symptom management", "TREATMENT", 76, 94]]], ["Sample questions are: During the last 4 weeks, did you need help from HCPs to relieve your symptom of rash?", [["rash", "DISEASE", 102, 106], ["your symptom", "PROBLEM", 86, 98], ["rash", "PROBLEM", 102, 106]]], ["Patients who responded no to the latter question are identified as having an unmet need for that symptom (score = 1).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["The scores of the total unmet needs for symptom management range from 0 to 49, with higher scores indicating more unmet needs.", [["symptom management", "TREATMENT", 40, 58]]], ["The instrument has been shown to have good expert validity with a content validity index (CVI) of 0.918 and Cronbach's alpha coefficients of the needs and unmet needs domains at 0.968 and 0.954, respectively (Zhu, Hu, Guo, & Williams, 2019).Measurement ::: MethodsSymptom burden was adapted from a pre-established survey and assessed via paper-and-pencil questionnaire (Holzemer et al., 2001; Justice et al., 2001).", [["CVI", "TEST", 90, 93], ["Cronbach's alpha coefficients", "TEST", 108, 137], ["MethodsSymptom burden", "PROBLEM", 257, 278]]], ["The symptom burden questionnaire consisted of 23 somatic symptoms and 26 psychological symptoms.", [["The symptom burden questionnaire", "PROBLEM", 0, 32], ["23 somatic symptoms", "PROBLEM", 46, 65], ["26 psychological symptoms", "PROBLEM", 70, 95]]], ["Patients were asked to rate each of the 49 items (a) the severity of symptoms on a scale from 0 (not at all) to 3 (very severe), and (b) how much the symptom distressed him or her on a scale from 0 (not at all) to 3 (very much) during the preceding 4 weeks.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["symptoms", "PROBLEM", 69, 77], ["the symptom", "PROBLEM", 146, 157]]], ["The total score was obtained by calculating a mean of the responses to all the items.", [["The total score", "TEST", 0, 15]]], ["Higher mean scores indicate more severe symptoms.Measurement ::: MethodsHIV perceived stigma was assessed using the Expanded Everyday Discrimination Scale (Williams et al., 2008), as described in a related paper (Zhu, Hu, Guo, & Williams, 2019).", [["HIV", "SPECIES", 72, 75], ["Higher mean scores", "PROBLEM", 0, 18], ["more severe symptoms", "PROBLEM", 28, 48], ["MethodsHIV perceived stigma", "PROBLEM", 65, 92], ["more", "OBSERVATION_MODIFIER", 28, 32], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["symptoms", "OBSERVATION", 40, 48]]], ["The score range was 10\u201340, with the higher score representing lower perceived stigma.", [["The score range", "TEST", 0, 15], ["lower perceived stigma", "PROBLEM", 62, 84], ["lower", "OBSERVATION_MODIFIER", 62, 67], ["perceived stigma", "OBSERVATION", 68, 84]]], ["The instrument showed good expert validity (CVR = 1.00), and Cronbach's alpha coefficient was 0.91 in the present study.Measurement ::: MethodsSelf-management capacity was assessed by a single item: What do you think of your ability to manage your own health?", [["Cronbach's alpha", "GENE_OR_GENE_PRODUCT", 61, 77], ["The instrument", "TEST", 0, 14], ["CVR", "TEST", 44, 47], ["Cronbach's alpha coefficient", "TEST", 61, 89], ["the present study", "TEST", 102, 119], ["good", "OBSERVATION_MODIFIER", 22, 26]]], ["The answer was rated on a Likert scale ranging from very good (1) to very bad (5).", [["a Likert scale", "TEST", 24, 38]]], ["The higher the score, the lower the self-management capacity.Measurement ::: MethodsDemographic and clinical-related variables included gender, age, marital status, education level, current employment status, time since HIV diagnosis, ART use status, latest CD4+ T-cell count, and latest viral load (see Table 1).Sample size ::: MethodsThe sample size was determined according to the item numbers of the main scale being included in the survey.", [["CD4+ T-cell", "ANATOMY", 258, 269], ["CD4", "PROTEIN", 258, 261], ["HIV", "SPECIES", 220, 223], ["latest CD4", "TEST", 251, 261], ["cell count", "TEST", 265, 275], ["latest viral load", "TEST", 281, 298], ["Methods", "TREATMENT", 329, 336], ["The sample size", "TEST", 336, 351], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["size", "OBSERVATION_MODIFIER", 320, 324], ["size", "OBSERVATION_MODIFIER", 347, 351], ["main", "OBSERVATION_MODIFIER", 404, 408]]], ["It was proposed that the sample size should range from 5 to 10 times the item numbers (Wu, 2010).", [["size", "OBSERVATION_MODIFIER", 32, 36]]], ["Given that the main instrument symptom management for PLWHA applied in the survey contained 49 items, it was estimated that 350 participants would be enough.Data collection ::: MethodsPotential participants were recruited from both the inpatient and outpatient wards at SPHCC.", [["participants", "SPECIES", 128, 140], ["participants", "SPECIES", 194, 206], ["the main instrument symptom management", "TREATMENT", 11, 49], ["PLWHA", "TREATMENT", 54, 59], ["main", "OBSERVATION_MODIFIER", 15, 19]]], ["Study participants were informed of the study to ensure that participation was voluntary.", [["participants", "SPECIES", 6, 18], ["the study", "TEST", 36, 45]]], ["After researchers securing study consent, all participants received a copy of their signed consent form.", [["participants", "SPECIES", 46, 58]]], ["Participants received an electronic pill dispenser and an HIV care pamphlet after they completed the survey as the appreciation.", [["Participants", "SPECIES", 0, 12], ["HIV", "SPECIES", 58, 61], ["an electronic pill dispenser", "TREATMENT", 22, 50]]], ["The study surveys were completed within 20 min on average.Data analysis ::: MethodsData analysis was performed using Statistical Package for Social Sciences (SPSS), version 17.0.", [["The study surveys", "TEST", 0, 17], ["Data analysis", "TEST", 58, 71], ["MethodsData analysis", "TEST", 76, 96]]], ["Means and standard deviations (SDs) were presented for continuous variables (e.g., age, symptom burden, HIV perceived stigma, self-management capability).", [["HIV perceived stigma", "DISEASE", 104, 124], ["HIV", "SPECIES", 104, 107], ["standard deviations (SDs)", "PROBLEM", 10, 35], ["symptom burden", "PROBLEM", 88, 102], ["HIV perceived stigma", "PROBLEM", 104, 124], ["self-management capability", "TREATMENT", 126, 152], ["standard deviations", "OBSERVATION", 10, 29]]], ["Frequency and percentage were presented for categorical variables (e.g., gender, marital status, educational level, and unmet symptom management needs).", [["categorical variables", "TEST", 44, 65], ["educational level", "TEST", 97, 114], ["unmet symptom management", "TREATMENT", 120, 144]]], ["Differences between unmet symptom management needs and demographic variables were analyzed.", [["unmet symptom management", "TREATMENT", 20, 44], ["demographic variables", "TEST", 55, 76]]], ["All assumptions for each statistical test were checked.", [["each statistical test", "TEST", 20, 41]]], ["Since those variables did not meet the assumptions for t-test or ANOVA, nonparametric alternatives (Kruskal-Wallis test, Mann-Whitney test) were used.Data analysis ::: MethodsPearson's correlation coefficient tests were used in the analysis of the correlation between unmet symptom management needs and symptom burden, HIV perceived stigma, and self-management capability.", [["HIV perceived stigma", "DISEASE", 319, 339], ["HIV", "SPECIES", 319, 322], ["t-test", "TEST", 55, 61], ["Kruskal-Wallis test", "TEST", 100, 119], ["Data analysis", "TEST", 150, 163], ["MethodsPearson's correlation coefficient tests", "TEST", 168, 214], ["the analysis", "TEST", 228, 240], ["unmet symptom management", "TREATMENT", 268, 292], ["symptom burden", "PROBLEM", 303, 317], ["HIV perceived stigma", "PROBLEM", 319, 339], ["self-management capability", "TREATMENT", 345, 371]]], ["Multiple regression analysis was used to determine the unmet symptom management needs predicting factors of PLWHA by analyzing the significant independent variables (current employment status, recent viral load, symptom burden, HIV perceived stigma, and self-management capability) with unmet symptom management needs as a dependent variable.", [["HIV perceived stigma", "DISEASE", 228, 248], ["HIV", "SPECIES", 228, 231], ["Multiple regression analysis", "TEST", 0, 28], ["symptom management", "TREATMENT", 61, 79], ["recent viral load", "PROBLEM", 193, 210], ["symptom burden", "PROBLEM", 212, 226], ["HIV perceived stigma", "PROBLEM", 228, 248], ["self-management capability", "TREATMENT", 254, 280], ["unmet symptom management", "TREATMENT", 287, 311], ["a dependent variable", "PROBLEM", 321, 341]]], ["An initial investigation was conducted to ensure the non-violation of the regression assumptions of multicollinearity, normality, linearity, and homoscedasticity.", [["An initial investigation", "TEST", 0, 24], ["multicollinearity", "PROBLEM", 100, 117], ["homoscedasticity", "PROBLEM", 145, 161], ["linearity", "OBSERVATION_MODIFIER", 130, 139]]], ["Recent viral loads were dichotomized into two categories (viral load known vs unknown).", [["Recent viral loads", "PROBLEM", 0, 18], ["viral load", "TEST", 58, 68], ["viral loads", "OBSERVATION", 7, 18]]], ["Statistical significance was set at p \u2264 .05.Characteristics of participants ::: ResultsA total of 450 eligible participants was contacted and 390 were recruited and completed the study.", [["participants", "ORGANISM", 111, 123], ["participants", "SPECIES", 63, 75], ["participants", "SPECIES", 111, 123], ["the study", "TEST", 175, 184]]], ["Data for 367 participants was analyzed, with an acceptance rate and validity rate of 87% and 94%, respectively.", [["participants", "ORGANISM", 13, 25], ["participants", "SPECIES", 13, 25], ["an acceptance rate", "TEST", 45, 63], ["validity rate", "TEST", 68, 81]]], ["Most of the participants were male (91%) and had attended at least middle school or higher (34% middle or high school, 59% college or above).", [["participants", "ORGANISM", 12, 24], ["participants", "SPECIES", 12, 24]]], ["The majority of participants were unemployed (56%), and from the inpatient (54%) ward.", [["participants", "ORGANISM", 16, 28], ["participants", "SPECIES", 16, 28]]], ["A large majority (84%) were currently taking ART.", [["large", "OBSERVATION_MODIFIER", 2, 7], ["majority", "OBSERVATION_MODIFIER", 8, 16]]], ["The mean of diagnosis time was 28 months, with 279 cells/mm3 for the latest CD4 count.", [["cells", "ANATOMY", 51, 56], ["CD4", "ANATOMY", 76, 79], ["cells", "CELL", 51, 56], ["CD4", "GENE_OR_GENE_PRODUCT", 76, 79], ["CD4", "PROTEIN", 76, 79], ["the latest CD4 count", "TEST", 65, 85]]], ["More than one-third (34%) of the participants had their most recent HIV viral load undetectable at less than 500 copies/ml blood (see Table 1).", [["blood", "ANATOMY", 123, 128], ["participants", "ORGANISM", 33, 45], ["HIV", "ORGANISM", 68, 71], ["blood", "ORGANISM_SUBSTANCE", 123, 128], ["participants", "SPECIES", 33, 45], ["HIV", "SPECIES", 68, 71], ["HIV", "SPECIES", 68, 71], ["HIV viral load", "TEST", 68, 82]]], ["In addition, mean score of HIV perceived stigma was 33.38 (SD: 7.29) and self-management capacity was 2.81 (SD: 1.16).Symptom burden ::: ResultsCronbach's alpha coefficient was 0.98 in the present study.", [["HIV perceived stigma", "DISEASE", 27, 47], ["HIV", "ORGANISM", 27, 30], ["ResultsCronbach's alpha", "GENE_OR_GENE_PRODUCT", 137, 160], ["HIV", "SPECIES", 27, 30], ["HIV", "SPECIES", 27, 30], ["mean score", "TEST", 13, 23], ["HIV perceived stigma", "TEST", 27, 47], ["self-management capacity", "TEST", 73, 97], ["ResultsCronbach's alpha coefficient", "TEST", 137, 172], ["the present study", "TEST", 185, 202]]], ["Mean score for symptom burden was 0.29 (SD: 0.40) out of a total possible score of 3.", [["Mean score", "TEST", 0, 10], ["symptom burden", "TEST", 15, 29]]], ["Table 2shows the rank order of individual symptom burden.", [["individual symptom burden", "PROBLEM", 31, 56]]], ["Among the individual symptoms, fatigue had the highest score for symptom severity, followed by insomnia/abnormal dreams, fever, unwanted weight loss, and decreased appetite.", [["fatigue", "DISEASE", 31, 38], ["insomnia", "DISEASE", 95, 103], ["abnormal dreams", "DISEASE", 104, 119], ["fever", "DISEASE", 121, 126], ["weight loss", "DISEASE", 137, 148], ["the individual symptoms", "PROBLEM", 6, 29], ["fatigue", "PROBLEM", 31, 38], ["symptom severity", "PROBLEM", 65, 81], ["insomnia", "PROBLEM", 95, 103], ["abnormal dreams", "PROBLEM", 104, 119], ["fever", "PROBLEM", 121, 126], ["weight loss", "PROBLEM", 137, 148], ["decreased appetite", "PROBLEM", 154, 172]]], ["For symptom distress, fatigue was most distressing, followed by insomnia/abnormal dreams, fever, decreased appetite, and unwanted weight loss.Symptom management needs and unmet needs ::: Results", [["symptom distress", "DISEASE", 4, 20], ["fatigue", "DISEASE", 22, 29], ["insomnia", "DISEASE", 64, 72], ["abnormal dreams", "DISEASE", 73, 88], ["fever", "DISEASE", 90, 95], ["decreased appetite", "DISEASE", 97, 115], ["weight loss", "DISEASE", 130, 141], ["symptom distress", "PROBLEM", 4, 20], ["fatigue", "PROBLEM", 22, 29], ["insomnia", "PROBLEM", 64, 72], ["abnormal dreams", "PROBLEM", 73, 88], ["fever", "PROBLEM", 90, 95], ["decreased appetite", "PROBLEM", 97, 115], ["unwanted weight loss", "PROBLEM", 121, 141], ["Symptom management", "TREATMENT", 142, 160]]]], "PMC7200872": [], "PMC5292373": [], "e5774b8f6e9546a696ec3484d7badfb32bc575f1": [["\"The early effects Of COVID-19 on head and neck oncology and microvascular reconstruction practice: National survey of oral and maxillofacial surgeons enrolled in the head and neck special interest group\"Introduction:\"The early effects Of COVID-19 on head and neck oncology and microvascular reconstruction practice: National survey of oral and maxillofacial surgeons enrolled in the head and neck special interest group\"The global health organization announced COVID-19 as a pandemic, something reflected by the continuous surge in the number of infected patients in the US and worldwide.", [["head", "ANATOMY", 34, 38], ["neck", "ANATOMY", 43, 47], ["microvascular", "ANATOMY", 61, 74], ["oral", "ANATOMY", 119, 123], ["head", "ANATOMY", 167, 171], ["neck", "ANATOMY", 176, 180], ["head", "ANATOMY", 251, 255], ["neck", "ANATOMY", 260, 264], ["microvascular", "ANATOMY", 278, 291], ["oral", "ANATOMY", 336, 340], ["head", "ANATOMY", 384, 388], ["neck", "ANATOMY", 393, 397], ["head", "ORGANISM_SUBDIVISION", 34, 38], ["neck", "ORGAN", 43, 47], ["microvascular", "TISSUE", 61, 74], ["oral", "ORGANISM_SUBDIVISION", 119, 123], ["head", "ORGANISM_SUBDIVISION", 167, 171], ["head", "ORGANISM_SUBDIVISION", 251, 255], ["neck", "ORGAN", 260, 264], ["microvascular", "TISSUE", 278, 291], ["oral", "ORGANISM_SUBDIVISION", 336, 340], ["head", "ORGANISM_SUBDIVISION", 384, 388], ["patients", "ORGANISM", 556, 564], ["patients", "SPECIES", 556, 564], ["COVID", "TEST", 22, 27], ["head and neck oncology", "TREATMENT", 34, 56], ["microvascular reconstruction practice", "TREATMENT", 61, 98], ["oral and maxillofacial surgeons", "TREATMENT", 119, 150], ["COVID", "TEST", 239, 244], ["head and neck oncology", "TREATMENT", 251, 273], ["microvascular reconstruction practice", "TREATMENT", 278, 315], ["oral and maxillofacial surgeons", "TREATMENT", 336, 367], ["a pandemic", "PROBLEM", 474, 484], ["neck", "ANATOMY", 43, 47], ["microvascular", "ANATOMY", 61, 74], ["head", "ANATOMY", 167, 171], ["neck", "ANATOMY", 176, 180], ["neck", "ANATOMY", 260, 264], ["head", "ANATOMY", 384, 388], ["neck", "ANATOMY", 393, 397], ["global", "OBSERVATION_MODIFIER", 425, 431], ["infected", "OBSERVATION", 547, 555]]], ["It is expected that only 20% of the population infected by the virus will need medical services.", [["medical services", "TREATMENT", 79, 95]]], ["When we dissect the COVID-19 infected population further, calculated estimates are that 15% will have a severe illness, and 5% will have a critical illness with a mortality rate ranging between (0.25%-3% [PPE] , and strain to the healthcare system to provide diagnostic and therapeutic services (1) .", [["illness", "DISEASE", 111, 118], ["COVID-19", "CELL", 20, 28], ["the COVID", "TEST", 16, 25], ["a severe illness", "PROBLEM", 102, 118], ["a critical illness", "PROBLEM", 137, 155], ["a mortality rate", "TEST", 161, 177], ["infected", "OBSERVATION_MODIFIER", 29, 37], ["severe", "OBSERVATION_MODIFIER", 104, 110], ["illness", "OBSERVATION", 111, 118]]], ["Oral and maxillofacial surgeons (OMS), otolaryngologists, dentists, ophthalmologists, and anesthesiologists are considered high-risk service lines.", [["Oral", "ANATOMY", 0, 4], ["maxillofacial", "ANATOMY", 9, 22]]], ["This is clear from the rising number of articles, professional communications, and organization recommendations such as the american head and neck society, the american association of oral and maxillofacial surgeons (AAOMS), and the american college of surgeons (ACS) .", [["head", "ANATOMY", 133, 137], ["neck", "ANATOMY", 142, 146], ["oral", "ANATOMY", 184, 188], ["ACS", "DISEASE", 263, 266], ["head", "ORGANISM_SUBDIVISION", 133, 137], ["neck", "ORGAN", 142, 146], ["oral", "ORGANISM_SUBDIVISION", 184, 188], ["maxillofacial", "ORGANISM_SUBDIVISION", 193, 206], ["clear", "OBSERVATION", 8, 13], ["rising", "OBSERVATION_MODIFIER", 23, 29], ["number", "OBSERVATION_MODIFIER", 30, 36], ["neck", "ANATOMY", 142, 146], ["maxillofacial", "ANATOMY", 193, 206]]], ["Working in the head and neck region is considered a high risk for exposure to and contracting the virus.", [["head and neck region", "ANATOMY", 15, 35], ["head", "ORGANISM_SUBDIVISION", 15, 19], ["neck", "ORGAN", 24, 28], ["contracting the virus", "PROBLEM", 82, 103], ["head", "ANATOMY", 15, 19], ["neck", "ANATOMY", 24, 28]]], ["Providers manipulating this unique anatomic region might risk infecting other patients, healthcare providers, and their own families.", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86]]], ["This study will survey oral and maxillofacial surgeons who treat head and neck oncology and perform reconstructive surgery regarding the impact of the COVID-19 pandemic on their surgical practice during mid-March to mid-April 2020.", [["oral", "ANATOMY", 23, 27], ["head", "ANATOMY", 65, 69], ["neck", "ANATOMY", 74, 78], ["oral", "ORGANISM_SUBDIVISION", 23, 27], ["head", "ORGANISM_SUBDIVISION", 65, 69], ["This study", "TEST", 0, 10], ["head and neck oncology", "TREATMENT", 65, 87], ["reconstructive surgery", "TREATMENT", 100, 122], ["the COVID", "TREATMENT", 147, 156], ["mid-April", "TREATMENT", 216, 225], ["neck", "ANATOMY", 74, 78]]], ["We anticipate that the COVID-19\"The early effects Of COVID-19 on head and neck oncology and microvascular reconstruction practice: National survey of oral and maxillofacial surgeons enrolled in the head and neck special interest group\"pandemic will impact the surgical practice of (OMS's) performing head and neck oncology and reconstructive surgery (HNORS).", [["head", "ANATOMY", 65, 69], ["neck", "ANATOMY", 74, 78], ["microvascular", "ANATOMY", 92, 105], ["oral", "ANATOMY", 150, 154], ["head", "ANATOMY", 198, 202], ["neck", "ANATOMY", 207, 211], ["head", "ANATOMY", 300, 304], ["neck", "ANATOMY", 309, 313], ["head", "ORGANISM_SUBDIVISION", 65, 69], ["neck", "ORGAN", 74, 78], ["microvascular", "TISSUE", 92, 105], ["oral", "ORGANISM_SUBDIVISION", 150, 154], ["head", "ORGANISM_SUBDIVISION", 198, 202], ["head", "ORGANISM_SUBDIVISION", 300, 304], ["COVID", "TEST", 53, 58], ["head and neck oncology", "TREATMENT", 65, 87], ["microvascular reconstruction practice", "TREATMENT", 92, 129], ["oral and maxillofacial surgeons", "TREATMENT", 150, 181], ["head and neck oncology", "TREATMENT", 300, 322], ["reconstructive surgery", "TREATMENT", 327, 349], ["neck", "ANATOMY", 74, 78], ["microvascular", "ANATOMY", 92, 105], ["head", "ANATOMY", 198, 202], ["neck", "ANATOMY", 207, 211], ["head", "ANATOMY", 300, 304], ["neck", "ANATOMY", 309, 313]]], ["We also aim to compare current (HNORS) practice patterns, especially the ones that might be impacted by COVID-19 with the current published literature.Materials and Methods:In our institution surveys are exempted from the need to obtain an IRB.", [["COVID", "TEST", 104, 109], ["an IRB", "TREATMENT", 237, 243]]], ["For this cross-sectional study, we designed an anonymous survey for fellowship trained (OMS's) in (HNORS).", [["this cross-sectional study", "TEST", 4, 30]]], ["The participants were contacted electronically via email message forwarded by the authors.Materials and Methods:Confidentiality and protection of personal information of the participants were maintained.", [["participants", "ORGANISM", 174, 186], ["participants", "SPECIES", 4, 16], ["participants", "SPECIES", 174, 186]]], ["The hyperlink contained in the document opened directly to the page of the survey.", [["The hyperlink", "PROBLEM", 0, 13]]], ["Also, a QR-code was directly sent with the email to the survey to allow a smooth response from Smartphones, tablets, PC, and laptops.", [["QR", "PROTEIN", 8, 10], ["Smartphones", "TEST", 95, 106], ["tablets", "TREATMENT", 108, 115], ["PC", "TREATMENT", 117, 119], ["laptops", "TREATMENT", 125, 132]]], ["This platform allowed participants to access and complete the survey without having to create a personal account and without entering any personal information.", [["participants", "SPECIES", 22, 34]]], ["The account on the website was created and is maintained by the investigators, and once the participants choose to take the survey, a link included in the email message directly opens only the survey of interest and allows for immediate access.", [["participants", "SPECIES", 92, 104]]], ["After answering the survey, the participants were asked to click on the \"submit\" box; their responses were saved and uploaded.", [["participants", "ORGANISM", 32, 44], ["participants", "SPECIES", 32, 44]]], ["Participants were contacted twice via email with a two-week time frame between the first and second email communications.Materials and Methods:The survey consisted of a 16-item questionnaire aiming to evaluate the impact of COVID-19 on clinical practice and their usual practice patterns of (HNORS).", [["Participants", "SPECIES", 0, 12], ["COVID", "TEST", 224, 229], ["clinical practice", "TREATMENT", 236, 253]]], ["These questions are listed inGeneral information:Overall the response rate to the survey was 60% response rate (39/64), 72% of our responders worked at an academic institution, 18% marked themselves as hybrid academic / private practice, and only 10% were considered hospital-based surgeons.", [["response rate", "TEST", 97, 110]]], ["43% of the participants of this study had less than five years' experience in managing Head and Neck oncology, 38% had more than five years, but less than ten years, and finally, 20% had more than ten years of experience.General information:The impact of COVID-19 on head and neck oncology and reconstructive surgery:General information:Only 8% of the survey responders were asked to pause head and neck oncology cases;General information:however, 23% were asked to pause free flap reconstruction during the COVID-19 pandemic.General information:Contributing circumstances to this situation included local policies and personal protective equipment; both were tied as the first reason.", [["head", "ANATOMY", 267, 271], ["neck", "ANATOMY", 276, 280], ["head", "ANATOMY", 390, 394], ["neck", "ANATOMY", 399, 403], ["flap", "ANATOMY", 477, 481], ["Head and Neck oncology", "DISEASE", 87, 109], ["COVID-19", "CHEMICAL", 255, 263], ["head", "ORGANISM_SUBDIVISION", 267, 271], ["neck", "ORGAN", 276, 280], ["head", "ORGANISM_SUBDIVISION", 390, 394], ["neck", "ORGANISM_SUBDIVISION", 399, 403], ["flap", "TISSUE", 477, 481], ["participants", "SPECIES", 11, 23], ["this study", "TEST", 27, 37], ["COVID", "TEST", 255, 260], ["head and neck oncology", "TREATMENT", 267, 289], ["reconstructive surgery", "TREATMENT", 294, 316], ["free flap reconstruction", "TREATMENT", 472, 496], ["the COVID", "TEST", 504, 513], ["pandemic", "PROBLEM", 517, 525], ["personal protective equipment", "TREATMENT", 619, 648], ["Neck", "ANATOMY", 96, 100], ["neck", "ANATOMY", 276, 280], ["neck", "ANATOMY", 399, 403]]], ["55% agreed that head and neck and reconstructive surgery should be conducted during a pandemic.", [["head", "ANATOMY", 16, 20], ["neck", "ANATOMY", 25, 29], ["head", "ORGANISM_SUBDIVISION", 16, 20], ["neck", "ORGAN", 25, 29], ["head and neck and reconstructive surgery", "TREATMENT", 16, 56], ["a pandemic", "PROBLEM", 84, 94], ["head", "ANATOMY", 16, 20], ["neck", "ANATOMY", 25, 29]]], ["Finally, 45% thought that two weeks is a reasonable time to delay head and neck oncology cases, while 29% thought these cases should never be delayed.Head and neck reconstruction and head and neck practice patterns:97% of our responders performed head and neck reconstruction, and there was a recognized agreement that microvascular tissue transfer was the favored method of reconstruction.", [["head", "ANATOMY", 66, 70], ["neck", "ANATOMY", 75, 79], ["Head", "ANATOMY", 150, 154], ["neck", "ANATOMY", 159, 163], ["head", "ANATOMY", 183, 187], ["neck", "ANATOMY", 192, 196], ["head", "ANATOMY", 247, 251], ["neck", "ANATOMY", 256, 260], ["microvascular tissue", "ANATOMY", 319, 339], ["head", "ORGANISM_SUBDIVISION", 66, 70], ["neck", "ORGAN", 75, 79], ["neck", "ORGAN", 159, 163], ["head", "ORGANISM_SUBDIVISION", 183, 187], ["neck", "ORGAN", 192, 196], ["head", "ORGANISM_SUBDIVISION", 247, 251], ["neck", "ORGAN", 256, 260], ["microvascular tissue", "TISSUE", 319, 339], ["Head and neck reconstruction", "TEST", 150, 178], ["head and neck practice patterns", "TEST", 183, 214], ["our responders", "TEST", 222, 236], ["head and neck reconstruction", "TEST", 247, 275], ["microvascular tissue", "PROBLEM", 319, 339], ["reconstruction", "TREATMENT", 375, 389], ["neck", "ANATOMY", 75, 79], ["neck", "ANATOMY", 159, 163], ["head", "ANATOMY", 183, 187], ["neck", "ANATOMY", 192, 196], ["neck", "ANATOMY", 256, 260], ["microvascular tissue", "ANATOMY", 319, 339]]], ["92% kept their patients in an ICU environment, while only 8% transferred them to a specialized stepdown unit.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23]]], ["In the ICU setting, 51% kept the patient on a ventilator were 47% extubated these patients at the end of the procedure.", [["patient", "ORGANISM", 33, 40], ["patients", "ORGANISM", 82, 90], ["patient", "SPECIES", 33, 40], ["patients", "SPECIES", 82, 90], ["a ventilator", "TREATMENT", 44, 56], ["the procedure", "TREATMENT", 105, 118]]], ["Tracheostomy is performed at an average of 64% of free flap cases among the survey respondents.", [["flap", "ANATOMY", 55, 59], ["flap", "PATHOLOGICAL_FORMATION", 55, 59], ["Tracheostomy", "TREATMENT", 0, 12], ["free flap cases", "TREATMENT", 50, 65], ["free flap", "OBSERVATION", 50, 59]]], ["29% of respondents perform a tracheostomy in >90% of free flap cases, while 24% perform a tracheostomy in limited cases (<30% of the time).Discussion:The purpose of this study was to determine the impact of the COVID-19 pandemic on OMS's performing head and neck oncologic and reconstructive surgery.", [["flap", "ANATOMY", 58, 62], ["head", "ANATOMY", 249, 253], ["neck", "ANATOMY", 258, 262], ["OMS", "DISEASE", 232, 235], ["head", "ORGANISM_SUBDIVISION", 249, 253], ["neck", "ORGAN", 258, 262], ["a tracheostomy", "TREATMENT", 27, 41], ["free flap cases", "TREATMENT", 53, 68], ["a tracheostomy", "TREATMENT", 88, 102], ["this study", "TEST", 165, 175], ["the COVID", "TEST", 207, 216], ["head and neck oncologic", "TREATMENT", 249, 272], ["reconstructive surgery", "TREATMENT", 277, 299], ["tracheostomy", "OBSERVATION", 29, 41], ["tracheostomy", "OBSERVATION", 90, 102], ["head", "ANATOMY", 249, 253], ["neck", "ANATOMY", 258, 262]]], ["We anticipated that the Fortunately, only 8% of our responders were asked to delay head and neck cancer treatment, however, this unprecedented situation made surgeons face many ethical dilemmas, first \"Is delaying head and neck cancer treatment \" acceptable during the COVID-19 pandemic, the second ethical dilemma \" if your institution/hospital allowed head and neck cancer cases to be performed but did not allow microvascular reconstructive surgery should we still perform ablative procedures without a proper reconstruction.", [["head and neck cancer", "ANATOMY", 83, 103], ["head", "ANATOMY", 214, 218], ["neck cancer", "ANATOMY", 223, 234], ["head and neck cancer", "ANATOMY", 354, 374], ["microvascular", "ANATOMY", 415, 428], ["head and neck cancer", "DISEASE", 83, 103], ["head and neck cancer", "DISEASE", 214, 234], ["cancer", "DISEASE", 368, 374], ["head and neck cancer", "CANCER", 83, 103], ["head and neck cancer", "CANCER", 214, 234], ["head and neck cancer", "CANCER", 354, 374], ["microvascular", "TISSUE", 415, 428], ["delay head and neck cancer treatment", "PROBLEM", 77, 113], ["head and neck cancer treatment", "PROBLEM", 214, 244], ["head and neck cancer", "PROBLEM", 354, 374], ["microvascular reconstructive surgery", "TREATMENT", 415, 451], ["ablative procedures", "TREATMENT", 476, 495], ["a proper reconstruction", "TREATMENT", 504, 527], ["neck", "ANATOMY", 92, 96], ["cancer", "OBSERVATION", 97, 103], ["neck", "ANATOMY", 223, 227], ["cancer", "OBSERVATION", 228, 234], ["head", "ANATOMY", 354, 358], ["neck", "ANATOMY", 363, 367], ["cancer", "OBSERVATION", 368, 374]]], ["This situation becomes more complicated when pre-COVID these patients were informed that microvascular reconstruction is the ideal reconstruction modality as it allows complex reconstruction of more than one subunit, can withstand the adverse impact from radiation therapy, can offer immediate dental implant placement, and allow these patients to start adjuvant therapy within the recommended time frame of 6-8 weeks post oncologic ablation.", [["microvascular", "ANATOMY", 89, 102], ["patients", "ORGANISM", 61, 69], ["microvascular", "TISSUE", 89, 102], ["patients", "ORGANISM", 336, 344], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 336, 344], ["microvascular reconstruction", "TREATMENT", 89, 117], ["the ideal reconstruction modality", "TREATMENT", 121, 154], ["complex reconstruction", "TREATMENT", 168, 190], ["radiation therapy", "TREATMENT", 255, 272], ["immediate dental implant placement", "TREATMENT", 284, 318], ["adjuvant therapy", "TREATMENT", 354, 370], ["oncologic ablation", "TREATMENT", 423, 441], ["microvascular", "ANATOMY", 89, 102], ["radiation therapy", "OBSERVATION", 255, 272]]], ["Ultimately the final decision rests with the patient who is under psychological distress from a cancer diagnosis while preparing to start a journey toward cure of their head and neck cancer.Discussion:Compare Free flaps to other reconstructive flaps:Discussion:The superiority of free microvascular tissue transfer (FMTT) to pedicled regional flaps and local flaps has been debated in the literature but is considered the gold standard for reconstructing head and neck defects arising from complex oncologic ablative procedures.", [["cancer", "ANATOMY", 96, 102], ["head and neck cancer", "ANATOMY", 169, 189], ["microvascular tissue", "ANATOMY", 285, 305], ["flaps", "ANATOMY", 343, 348], ["head", "ANATOMY", 455, 459], ["neck", "ANATOMY", 464, 468], ["cancer", "DISEASE", 96, 102], ["head and neck cancer", "DISEASE", 169, 189], ["head and neck defects", "DISEASE", 455, 476], ["patient", "ORGANISM", 45, 52], ["cancer", "CANCER", 96, 102], ["head and neck cancer", "CANCER", 169, 189], ["microvascular tissue", "TISSUE", 285, 305], ["head", "ORGANISM_SUBDIVISION", 455, 459], ["neck", "ORGAN", 464, 468], ["patient", "SPECIES", 45, 52], ["psychological distress", "PROBLEM", 66, 88], ["their head and neck cancer", "PROBLEM", 163, 189], ["Free flaps", "TREATMENT", 209, 219], ["other reconstructive flaps", "TREATMENT", 223, 249], ["free microvascular tissue transfer (FMTT)", "TREATMENT", 280, 321], ["pedicled regional flaps", "TREATMENT", 325, 348], ["local flaps", "TREATMENT", 353, 364], ["reconstructing head and neck defects", "PROBLEM", 440, 476], ["complex oncologic ablative procedures", "TREATMENT", 490, 527], ["cancer", "OBSERVATION", 96, 102], ["head", "ANATOMY", 169, 173], ["neck", "ANATOMY", 178, 182], ["cancer", "OBSERVATION", 183, 189], ["microvascular tissue", "ANATOMY", 285, 305], ["pedicled", "ANATOMY_MODIFIER", 325, 333], ["regional flaps", "ANATOMY", 334, 348], ["local flaps", "OBSERVATION", 353, 364], ["head", "ANATOMY", 455, 459], ["neck", "ANATOMY", 464, 468], ["defects", "OBSERVATION", 469, 476]]], ["(2) (3) (4) (5) .", [["(2) (3) (4", "SIMPLE_CHEMICAL", 0, 10]]], ["Abouyrad et al.Discussion:conducted a literature review of free tissue transfer management and outcomes and concluded that FMTT remains highly successful despite the lack of consensus regarding the care of patients receiving FMTT.", [["tissue", "ANATOMY", 64, 70], ["FMTT", "CHEMICAL", 225, 229], ["tissue", "TISSUE", 64, 70], ["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 206, 214], ["free tissue transfer management", "TREATMENT", 59, 90], ["FMTT", "TREATMENT", 225, 229]]], ["(2) There are many reasons FMTT is considered the gold standard for head and neck reconstruction; first, these defects arising from head and neck ablation are complex, and they tend to involve multiple anatomic subunits, have proximity to vital structures, and the ultimate goal is to restore pre-ablative form and function.", [["head", "ANATOMY", 68, 72], ["neck", "ANATOMY", 77, 81], ["head", "ANATOMY", 132, 136], ["neck", "ANATOMY", 141, 145], ["head", "ORGANISM_SUBDIVISION", 68, 72], ["neck", "ORGAN", 77, 81], ["head", "ORGANISM_SUBDIVISION", 132, 136], ["neck", "ORGAN", 141, 145], ["head and neck reconstruction", "TREATMENT", 68, 96], ["these defects", "PROBLEM", 105, 118], ["head and neck ablation", "TREATMENT", 132, 154], ["neck", "ANATOMY", 77, 81], ["defects", "OBSERVATION", 111, 118], ["head", "ANATOMY", 132, 136], ["neck", "ANATOMY", 141, 145], ["ablation", "OBSERVATION", 146, 154]]], ["Success rates of FMTT vary in the literature, reaching 95% -97% irrespective of the setting of FMTT being performed at, such as academic institutions or a community hospital.", [["FMTT", "TREATMENT", 95, 99]]], ["(6) (7) (8) The selection process of the ideal reconstructive option for head and neck ablative defects depends on multiple variables, including available local resources.", [["head", "ANATOMY", 73, 77], ["neck", "ANATOMY", 82, 86], ["head", "ORGANISM_SUBDIVISION", 73, 77], ["neck", "ORGAN", 82, 86], ["the ideal reconstructive option", "TREATMENT", 37, 68], ["head and neck ablative defects", "PROBLEM", 73, 103], ["neck", "ANATOMY", 82, 86], ["ablative", "OBSERVATION", 87, 95]]], ["Gabrysz-Forget et al in a systematic review, found no statistical significance in terms of hospital length of stay between free flap and pedicled flap groups (9) ; however, the results were variable when FMTT was explicitly compared to the submental island or supraclavicular flaps.", [["flap", "ANATOMY", 128, 132], ["flap", "ANATOMY", 146, 150], ["submental island", "ANATOMY", 240, 256], ["supraclavicular flaps", "ANATOMY", 260, 281], ["flap", "TISSUE", 128, 132], ["submental island", "MULTI-TISSUE_STRUCTURE", 240, 256], ["supraclavicular flaps", "MULTI-TISSUE_STRUCTURE", 260, 281], ["free flap and pedicled flap groups", "TREATMENT", 123, 157], ["supraclavicular flaps", "TREATMENT", 260, 281], ["pedicled flap", "ANATOMY", 137, 150], ["submental", "ANATOMY", 240, 249], ["island", "ANATOMY_MODIFIER", 250, 256], ["supraclavicular", "ANATOMY", 260, 275], ["flaps", "OBSERVATION", 276, 281]]], ["In this comparison, FMTT length of stay was longer.Discussion:Comparing FMTT to pectorals myocutanous flaps [PMCF], FMTT tended to have a shorter length of stay.", [["pectorals myocutanous flaps", "ANATOMY", 80, 107], ["pectorals myocutanous flaps", "TREATMENT", 80, 107]]], ["Complications reported with PMCF ranged between 16%-63% while complications arising from FMTT is between 14%-30% (9).", [["FMTT", "DISEASE", 89, 93], ["PMCF", "TEST", 28, 32]]], ["It is essential to mention that there are many published descriptions of PMCF as a \"Workhorse\" or \"The flap the stood the test of time.\" (10) (11) (12) (13) However, it is essential not to confuse these terms with \"Gold standard\" that is often tagged to FMTT when it comes to head and neck oncologic reconstruction (14) .", [["head", "ANATOMY", 276, 280], ["neck", "ANATOMY", 285, 289], ["PMCF", "DISEASE", 73, 77], ["PMCF", "CANCER", 73, 77], ["head", "ORGANISM_SUBDIVISION", 276, 280], ["neck", "ORGAN", 285, 289], ["The flap", "TREATMENT", 99, 107], ["head and neck oncologic reconstruction", "TREATMENT", 276, 314], ["neck", "ANATOMY", 285, 289]]], ["Tackling head and neck cancer reconstruction with a one size fits all approach is rarely optimal, and a pandemic should not be an excuse to apply old or outdated concepts.", [["head and neck cancer", "ANATOMY", 9, 29], ["head and neck cancer", "DISEASE", 9, 29], ["head and neck cancer", "CANCER", 9, 29], ["Tackling head and neck cancer reconstruction", "PROBLEM", 0, 44], ["neck", "ANATOMY", 18, 22], ["cancer", "OBSERVATION", 23, 29]]], ["(3) This was well reflected in our survey, as all respondents selected FMTT as their preferred method of reconstruction Figure 1 .Discussion:FMTT allows predictable reconstruction of large and complex head and neck defects and tends to tolerate the adverse effects of radiation therapy.", [["head", "ANATOMY", 201, 205], ["neck", "ANATOMY", 210, 214], ["head and neck defects", "DISEASE", 201, 222], ["head", "ORGANISM_SUBDIVISION", 201, 205], ["neck", "ORGAN", 210, 214], ["predictable reconstruction", "TREATMENT", 153, 179], ["large and complex head and neck defects", "PROBLEM", 183, 222], ["radiation therapy", "TREATMENT", 268, 285], ["large", "OBSERVATION_MODIFIER", 183, 188], ["head", "ANATOMY", 201, 205], ["neck", "ANATOMY", 210, 214], ["defects", "OBSERVATION", 215, 222]]], ["Besides, FMTT has a lower incidence of post-operative infection, dehiscence, and partial or complete flap necrosis (15) .", [["flap", "ANATOMY", 101, 105], ["FMTT", "CHEMICAL", 9, 13], ["infection", "DISEASE", 54, 63], ["dehiscence", "DISEASE", 65, 75], ["necrosis", "DISEASE", 106, 114], ["post-operative infection", "PROBLEM", 39, 63], ["dehiscence", "PROBLEM", 65, 75], ["partial or complete flap necrosis", "PROBLEM", 81, 114], ["lower incidence", "OBSERVATION_MODIFIER", 20, 35], ["post-operative", "OBSERVATION_MODIFIER", 39, 53], ["infection", "OBSERVATION", 54, 63], ["dehiscence", "OBSERVATION", 65, 75], ["partial", "OBSERVATION_MODIFIER", 81, 88], ["complete", "OBSERVATION_MODIFIER", 92, 100], ["flap", "OBSERVATION_MODIFIER", 101, 105], ["necrosis", "OBSERVATION", 106, 114]]], ["In some ablative defects such as near-total mandibular composite defects, through and through buccal defects, or defects involving the temporomandibular joint local flap such as pedicled flap reconstruction cannot offer a comparable result while laying a solid foundation for dental rehabilitation with dental implants. or ventilator related lung injury.", [["mandibular", "ANATOMY", 44, 54], ["buccal", "ANATOMY", 94, 100], ["temporomandibular", "ANATOMY", 135, 152], ["flap", "ANATOMY", 165, 169], ["flap", "ANATOMY", 187, 191], ["lung", "ANATOMY", 342, 346], ["buccal defects", "DISEASE", 94, 108], ["lung injury", "DISEASE", 342, 353], ["buccal", "ORGAN", 94, 100], ["temporomandibular joint", "MULTI-TISSUE_STRUCTURE", 135, 158], ["lung", "ORGAN", 342, 346], ["some ablative defects", "PROBLEM", 3, 24], ["near-total mandibular composite defects", "PROBLEM", 33, 72], ["buccal defects", "PROBLEM", 94, 108], ["defects involving the temporomandibular joint local flap", "PROBLEM", 113, 169], ["pedicled flap reconstruction", "TREATMENT", 178, 206], ["a solid foundation", "TREATMENT", 253, 271], ["dental rehabilitation", "TREATMENT", 276, 297], ["dental implants", "TREATMENT", 303, 318], ["ventilator related lung injury", "PROBLEM", 323, 353], ["some", "OBSERVATION_MODIFIER", 3, 7], ["ablative defects", "OBSERVATION", 8, 24], ["total", "OBSERVATION_MODIFIER", 38, 43], ["mandibular", "ANATOMY", 44, 54], ["composite defects", "OBSERVATION", 55, 72], ["buccal", "ANATOMY_MODIFIER", 94, 100], ["defects", "OBSERVATION", 101, 108], ["defects", "OBSERVATION", 113, 120], ["temporomandibular joint", "ANATOMY", 135, 158], ["local flap", "OBSERVATION", 159, 169], ["pedicled flap", "OBSERVATION", 178, 191], ["dental implants", "OBSERVATION", 303, 318], ["lung", "ANATOMY", 342, 346], ["injury", "OBSERVATION", 347, 353]]], ["This risk persists even if a surgical airway is performed.", [["airway", "ANATOMY", 38, 44], ["airway", "MULTI-TISSUE_STRUCTURE", 38, 44], ["a surgical airway", "TEST", 27, 44], ["airway", "ANATOMY", 38, 44]]], ["(18) (19) (20) .Discussion:Many theories offer explanations for the positive correlation between operative time and surgical infections.", [["infections", "DISEASE", 125, 135], ["surgical infections", "PROBLEM", 116, 135], ["infections", "OBSERVATION", 125, 135]]], ["Amplified exposure to airborne pathogens, elongated trauma resulting from prolonged surgical manipulation, and finally increased foot traffic in the operating room by the surgical team and axillary staff.", [["foot", "ANATOMY", 129, 133], ["trauma", "DISEASE", 52, 58], ["airborne pathogens", "PROBLEM", 22, 40], ["elongated trauma", "PROBLEM", 42, 58], ["prolonged surgical manipulation", "TREATMENT", 74, 105], ["airborne pathogens", "OBSERVATION", 22, 40], ["elongated", "OBSERVATION_MODIFIER", 42, 51], ["trauma", "OBSERVATION", 52, 58], ["surgical manipulation", "OBSERVATION", 84, 105], ["foot", "ANATOMY", 129, 133], ["axillary", "ANATOMY", 189, 197]]], ["Regarding COVID-19 specifically, we know that the virus targets mainly the lower respiratory tract, something that hypothetically might be amplified if a patient is infected with the virus after prolonged operating time.", [["lower respiratory tract", "ANATOMY", 75, 98], ["lower", "ORGANISM_SUBDIVISION", 75, 80], ["respiratory tract", "ORGANISM_SUBDIVISION", 81, 98], ["patient", "ORGANISM", 154, 161], ["COVID-19", "DNA", 10, 18], ["patient", "SPECIES", 154, 161], ["COVID", "TEST", 10, 15], ["the virus targets mainly the lower respiratory tract", "PROBLEM", 46, 98], ["the virus", "PROBLEM", 179, 188], ["lower", "ANATOMY_MODIFIER", 75, 80], ["respiratory tract", "ANATOMY", 81, 98]]], ["Many centers realized the adverse effects of prolonged operative times in head and neck cancer and reconstructive surgery.", [["head and neck cancer", "ANATOMY", 74, 94], ["head and neck cancer", "DISEASE", 74, 94], ["head and neck cancer", "CANCER", 74, 94], ["head and neck cancer", "PROBLEM", 74, 94], ["reconstructive surgery", "TREATMENT", 99, 121], ["head", "ANATOMY", 74, 78], ["neck", "ANATOMY", 83, 87], ["cancer", "OBSERVATION", 88, 94], ["reconstructive surgery", "OBSERVATION", 99, 121]]], ["These centers adopted various approaches to reduce that time.", [["various approaches", "TREATMENT", 22, 40]]], ["They adapted a two-team approach to reduce operative time but now needs to be weighed against the shortage of PPE and exposure risk to an increased number of surgeons and assistants participating in high-risk procedures.", [["high-risk procedures", "TREATMENT", 199, 219]]], ["82% of respondents performed reconstruction surgery with a two-team approach.Discussion:One strategy to reduce operative time is computer-assisted surgery/planning.", [["reconstruction surgery", "TREATMENT", 29, 51], ["a two-team approach", "TREATMENT", 57, 76], ["computer-assisted surgery", "TREATMENT", 129, 154]]], ["Surgical planning of the osseous ablative resection margins, osseous donor site cutting guides, and 3D printing modeling with the option of custom made plates (21, 22) .Tracheostomy:Head and neck ablative or reconstructive procedures can be associated with a higher risk of upper airway obstruction.", [["osseous", "ANATOMY", 25, 32], ["neck", "ANATOMY", 191, 195], ["airway", "ANATOMY", 280, 286], ["airway obstruction", "DISEASE", 280, 298], ["neck", "ORGAN", 191, 195], ["upper airway", "ORGANISM_SUBDIVISION", 274, 286], ["the osseous ablative resection margins", "TREATMENT", 21, 59], ["osseous donor site cutting guides", "TREATMENT", 61, 94], ["custom made plates", "TREATMENT", 140, 158], ["Tracheostomy", "TREATMENT", 169, 181], ["Head and neck ablative", "TREATMENT", 182, 204], ["reconstructive procedures", "TREATMENT", 208, 233], ["upper airway obstruction", "PROBLEM", 274, 298], ["osseous", "ANATOMY", 25, 32], ["ablative", "OBSERVATION_MODIFIER", 33, 41], ["resection", "OBSERVATION_MODIFIER", 42, 51], ["margins", "OBSERVATION_MODIFIER", 52, 59], ["osseous", "ANATOMY", 61, 68], ["Head", "ANATOMY", 182, 186], ["neck", "ANATOMY", 191, 195], ["ablative", "OBSERVATION", 196, 204], ["upper", "ANATOMY_MODIFIER", 274, 279], ["airway", "ANATOMY", 280, 286], ["obstruction", "OBSERVATION", 287, 298]]], ["Therefore, many surgeons elect to perform a tracheostomy to eliminate this risk.", [["a tracheostomy", "TREATMENT", 42, 56]]], ["Obstruction of the airway may be associated with an oversized, bulky reconstruction or specific anatomical sites, including the mandible, floor of mouth, and tongue.Tracheostomy:Additionally, bilateral neck dissection has an increased risk of airway obstruction.", [["airway", "ANATOMY", 19, 25], ["sites", "ANATOMY", 107, 112], ["mandible", "ANATOMY", 128, 136], ["floor", "ANATOMY", 138, 143], ["mouth", "ANATOMY", 147, 152], ["tongue", "ANATOMY", 158, 164], ["neck", "ANATOMY", 202, 206], ["airway", "ANATOMY", 243, 249], ["Obstruction of the airway", "DISEASE", 0, 25], ["airway obstruction", "DISEASE", 243, 261], ["airway", "MULTI-TISSUE_STRUCTURE", 19, 25], ["mandible", "ORGAN", 128, 136], ["mouth", "ORGANISM_SUBDIVISION", 147, 152], ["tongue", "ORGAN", 158, 164], ["neck", "ORGAN", 202, 206], ["airway obstruction", "PATHOLOGICAL_FORMATION", 243, 261], ["Obstruction of the airway", "PROBLEM", 0, 25], ["an oversized, bulky reconstruction", "TREATMENT", 49, 83], ["specific anatomical sites", "PROBLEM", 87, 112], ["the mandible, floor of mouth, and tongue", "PROBLEM", 124, 164], ["Tracheostomy", "TREATMENT", 165, 177], ["bilateral neck dissection", "PROBLEM", 192, 217], ["airway obstruction", "PROBLEM", 243, 261], ["airway", "ANATOMY", 19, 25], ["may be associated with", "UNCERTAINTY", 26, 48], ["oversized", "OBSERVATION_MODIFIER", 52, 61], ["bulky", "OBSERVATION_MODIFIER", 63, 68], ["reconstruction", "OBSERVATION", 69, 83], ["anatomical sites", "OBSERVATION", 96, 112], ["mandible", "ANATOMY", 128, 136], ["floor", "ANATOMY", 138, 143], ["mouth", "ANATOMY", 147, 152], ["tongue", "ANATOMY", 158, 164], ["bilateral", "ANATOMY_MODIFIER", 192, 201], ["neck", "ANATOMY", 202, 206], ["dissection", "OBSERVATION", 207, 217], ["increased", "OBSERVATION_MODIFIER", 225, 234], ["airway", "ANATOMY", 243, 249], ["obstruction", "OBSERVATION", 250, 261]]], ["Tracheostomy has been found to increase the cost of care and lengthen the operative time by 30-45 min.Tracheostomy:Specific to head and neck surgery, airway protection with continued intubation rather than tracheostomy has demonstrated its safety in many studies.", [["head", "ANATOMY", 127, 131], ["neck", "ANATOMY", 136, 140], ["airway", "ANATOMY", 150, 156], ["head", "ORGANISM_SUBDIVISION", 127, 131], ["neck", "ORGAN", 136, 140], ["airway", "MULTI-TISSUE_STRUCTURE", 150, 156], ["Tracheostomy", "TREATMENT", 0, 12], ["Tracheostomy", "TREATMENT", 102, 114], ["head and neck surgery", "TREATMENT", 127, 148], ["airway protection", "TREATMENT", 150, 167], ["continued intubation", "TREATMENT", 173, 193], ["tracheostomy", "TREATMENT", 206, 218], ["many studies", "TEST", 250, 262], ["increase", "OBSERVATION_MODIFIER", 31, 39], ["neck", "ANATOMY", 136, 140], ["surgery", "OBSERVATION", 141, 148], ["airway", "ANATOMY", 150, 156]]], ["This is in addition to other advantages, including reduced lower respiratory tract infections, faster return to speech, and oral intake.", [["lower respiratory tract", "ANATOMY", 59, 82], ["oral", "ANATOMY", 124, 128], ["respiratory tract infections", "DISEASE", 65, 93], ["lower", "ORGANISM_SUBDIVISION", 59, 64], ["respiratory tract", "ORGANISM_SUBDIVISION", 65, 82], ["oral", "ORGANISM_SUBDIVISION", 124, 128], ["reduced lower respiratory tract infections", "PROBLEM", 51, 93], ["reduced", "OBSERVATION_MODIFIER", 51, 58], ["lower", "ANATOMY_MODIFIER", 59, 64], ["respiratory tract", "ANATOMY", 65, 82], ["infections", "OBSERVATION", 83, 93]]], ["Another advantage of this practice is the improved cost effectiveness by decreasing (24) , american dental association (ADA), american head and neck society [AHNS] (25) (30, 31) slightly lower than our survey (90%) Figure 3 .", [["head", "ANATOMY", 135, 139], ["neck", "ANATOMY", 144, 148], ["head", "ORGANISM_SUBDIVISION", 135, 139], ["neck", "ORGAN", 144, 148], ["head", "ANATOMY", 135, 139], ["neck", "ANATOMY", 144, 148]]], ["An ICU stay is proposed to provide many advantages, high nurse: patient ratios ranging from 1: (32) .", [["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71], ["patient ratios", "TEST", 64, 78]]], ["What makes a shortage of ventilators different from other medical supplies is that ventilators might be necessary during a limited window in which the patient's life might be saved.", [["patient", "ORGANISM", 151, 158], ["patient", "SPECIES", 151, 158], ["a shortage of ventilators", "TREATMENT", 11, 36], ["ventilators", "TREATMENT", 83, 94]]], ["The ventilation situation is also affected by local as well as healthcare guidelines.", [["ventilation situation", "OBSERVATION", 4, 25]]], ["A good example; New York, developed guidelines with the concept of \"Saving Most Lives\" defined by the likelihood of this patient surviving this acute medical distress a set of guidelines designed in 2015 (33) .", [["patient", "ORGANISM", 121, 128], ["patient", "SPECIES", 121, 128], ["this acute medical distress", "PROBLEM", 139, 166]]], ["Level I evidence from a prospective, double arm, 1:1 randomized controlled trial of head neck flap patients randomized to ICU vs. specialized ward /step down unit has been collected.Tracheostomy:Flap monitoring protocols were shared among the two groups.", [["head neck flap", "ANATOMY", 84, 98], ["Flap", "ANATOMY", 195, 199], ["head neck", "MULTI-TISSUE_STRUCTURE", 84, 93], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["double arm", "TREATMENT", 37, 47], ["head neck flap", "TREATMENT", 84, 98], ["specialized ward /step down unit", "TREATMENT", 130, 162], ["Tracheostomy", "TREATMENT", 182, 194], ["Flap monitoring protocols", "TREATMENT", 195, 220], ["head", "ANATOMY", 84, 88], ["neck flap", "ANATOMY", 89, 98], ["Flap", "ANATOMY", 195, 199]]], ["In this cited study, the authors did not find any significant differences between the two groups regarding medical comorbidities, prior radiation therapy treatment or chemotherapy, ischemia time, blood loss, transfusion, or postoperative antibiotics use.", [["blood", "ANATOMY", 196, 201], ["ischemia", "DISEASE", 181, 189], ["blood loss", "DISEASE", 196, 206], ["blood", "ORGANISM_SUBSTANCE", 196, 201], ["this cited study", "TEST", 3, 19], ["medical comorbidities", "PROBLEM", 107, 128], ["prior radiation therapy treatment", "TREATMENT", 130, 163], ["chemotherapy", "TREATMENT", 167, 179], ["ischemia", "PROBLEM", 181, 189], ["blood loss", "PROBLEM", 196, 206], ["transfusion", "TREATMENT", 208, 219], ["postoperative antibiotics", "TREATMENT", 224, 249]]], ["It should be noted that in this cited study patients who were assigned to the stepdown unit/specialized ward group that needed postoperatively to be transferred to the ICU for impending flap failure, medical disease like sepsis, delirium, or following a second surgery was still statistical analyzed as a stepdown/specialized unit (34) .", [["flap", "ANATOMY", 186, 190], ["flap failure", "DISEASE", 186, 198], ["sepsis", "DISEASE", 221, 227], ["delirium", "DISEASE", 229, 237], ["patients", "ORGANISM", 44, 52], ["flap", "TISSUE", 186, 190], ["patients", "SPECIES", 44, 52], ["impending flap failure", "PROBLEM", 176, 198], ["medical disease", "PROBLEM", 200, 215], ["sepsis", "PROBLEM", 221, 227], ["delirium", "PROBLEM", 229, 237], ["a second surgery", "TREATMENT", 252, 268], ["flap", "ANATOMY", 186, 190], ["failure", "OBSERVATION", 191, 198], ["sepsis", "OBSERVATION", 221, 227]]], ["These findings support other retrospective studies that compared ICU postoperative stay to the stepdown unit and were integrated into many clinical care pathways but frequently demonstrate similar or better endpoints in the step-down unit group (30, 35) .Cancer stage:Mortality rates from head and neck squamous cell carcinoma (HNSCC) are > 50%, accounting for 375,000 mortalities.", [["Cancer", "ANATOMY", 255, 261], ["head and neck squamous cell carcinoma", "ANATOMY", 289, 326], ["HNSCC", "ANATOMY", 328, 333], ["Cancer", "DISEASE", 255, 261], ["head and neck squamous cell carcinoma", "DISEASE", 289, 326], ["HNSCC", "DISEASE", 328, 333], ["Cancer", "CANCER", 255, 261], ["head and neck squamous cell carcinoma", "CANCER", 289, 326], ["HNSCC", "CANCER", 328, 333], ["other retrospective studies", "TEST", 23, 50], ["Cancer stage", "PROBLEM", 255, 267], ["Mortality rates", "TEST", 268, 283], ["head and neck squamous cell carcinoma", "PROBLEM", 289, 326], ["head", "ANATOMY", 289, 293], ["neck", "ANATOMY", 298, 302], ["squamous cell carcinoma", "OBSERVATION", 303, 326]]], ["The american joint committee on cancer (AJCC) indicated that tumor stage is the most critical prognostic factor for HNSCC in which we use the T, N, M staging system to come up with the clinical and pathological definitive stage (36) .", [["cancer", "ANATOMY", 32, 38], ["AJCC", "ANATOMY", 40, 44], ["tumor", "ANATOMY", 61, 66], ["HNSCC", "ANATOMY", 116, 121], ["cancer", "DISEASE", 32, 38], ["AJCC", "DISEASE", 40, 44], ["tumor", "DISEASE", 61, 66], ["HNSCC", "DISEASE", 116, 121], ["cancer", "CANCER", 32, 38], ["AJCC", "CANCER", 40, 44], ["tumor", "CANCER", 61, 66], ["HNSCC", "CANCER", 116, 121], ["cancer", "PROBLEM", 32, 38], ["tumor stage", "PROBLEM", 61, 72], ["HNSCC", "PROBLEM", 116, 121], ["staging system", "TEST", 150, 164], ["joint", "ANATOMY", 13, 18], ["cancer", "OBSERVATION", 32, 38], ["tumor", "OBSERVATION", 61, 66]]], ["Although this opinion is shared by the majority of head and neck surgeons, it does not take into account the wide variability of head and neck cancers like location/subsite, cancer related risk factors and overall patient prognosis.", [["head and neck", "ANATOMY", 51, 64], ["head and neck cancers", "ANATOMY", 129, 150], ["cancer", "ANATOMY", 174, 180], ["head and neck cancers", "DISEASE", 129, 150], ["cancer", "DISEASE", 174, 180], ["head and neck", "CANCER", 51, 64], ["head and neck cancers", "CANCER", 129, 150], ["cancer", "CANCER", 174, 180], ["patient", "ORGANISM", 214, 221], ["patient", "SPECIES", 214, 221], ["head and neck cancers", "PROBLEM", 129, 150], ["cancer related risk factors", "PROBLEM", 174, 201], ["neck", "ANATOMY", 60, 64], ["head", "ANATOMY", 129, 133], ["neck", "ANATOMY", 138, 142], ["cancers", "OBSERVATION", 143, 150]]], ["Extrapolating from oropharyngeal cancer data and despite this paper small sample size of 13 patients.", [["oropharyngeal cancer", "ANATOMY", 19, 39], ["oropharyngeal cancer", "DISEASE", 19, 39], ["oropharyngeal cancer", "CANCER", 19, 39], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["oropharyngeal cancer data", "TEST", 19, 44], ["oropharyngeal", "ANATOMY", 19, 32], ["cancer", "OBSERVATION", 33, 39], ["small", "OBSERVATION_MODIFIER", 68, 73], ["size", "OBSERVATION_MODIFIER", 81, 85]]], ["Waaijer el al. observed that with a median scanning interval of 35 days, there was an increase in the radiographic tumor volume around 22 cm 3 (37) .", [["tumor", "ANATOMY", 115, 120], ["tumor", "DISEASE", 115, 120], ["tumor", "CANCER", 115, 120], ["the radiographic tumor volume", "TEST", 98, 127], ["increase", "OBSERVATION_MODIFIER", 86, 94], ["radiographic", "OBSERVATION_MODIFIER", 102, 114], ["tumor", "OBSERVATION", 115, 120], ["volume", "OBSERVATION_MODIFIER", 121, 127], ["22 cm", "OBSERVATION_MODIFIER", 135, 140]]], ["A similar oral cavity cancer specific study with a more generous sample size of 38 patients showed a 62% increase in the primary tumor volume and a median increase of 46% of lymph node metastasis.Cancer stage:The time intervals were classified into three-time intervals.", [["oral cavity cancer", "ANATOMY", 10, 28], ["primary tumor", "ANATOMY", 121, 134], ["lymph node", "ANATOMY", 174, 184], ["Cancer", "ANATOMY", 196, 202], ["oral cavity cancer", "DISEASE", 10, 28], ["tumor", "DISEASE", 129, 134], ["Cancer", "DISEASE", 196, 202], ["oral cavity cancer", "CANCER", 10, 28], ["patients", "ORGANISM", 83, 91], ["tumor", "CANCER", 129, 134], ["lymph node", "MULTI-TISSUE_STRUCTURE", 174, 184], ["Cancer", "CANCER", 196, 202], ["patients", "SPECIES", 83, 91], ["A similar oral cavity cancer", "PROBLEM", 0, 28], ["specific study", "TEST", 29, 43], ["a 62% increase in the primary tumor volume", "PROBLEM", 99, 141], ["lymph node metastasis", "PROBLEM", 174, 195], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["oral cavity", "ANATOMY", 10, 21], ["cancer", "OBSERVATION", 22, 28], ["62%", "OBSERVATION_MODIFIER", 101, 104], ["increase", "OBSERVATION_MODIFIER", 105, 113], ["primary", "OBSERVATION_MODIFIER", 121, 128], ["tumor", "OBSERVATION", 129, 134], ["volume", "OBSERVATION_MODIFIER", 135, 141], ["median", "OBSERVATION_MODIFIER", 148, 154], ["increase", "OBSERVATION_MODIFIER", 155, 163], ["46%", "OBSERVATION_MODIFIER", 167, 170], ["lymph node metastasis", "OBSERVATION", 174, 195]]], ["A less than two week period correlated with 33% tumor volume increase, 2-4 weeks' time period a 68% significant increase in tumor volume and finally more than four weeks a 70% increase in tumor volume (38) .", [["tumor", "ANATOMY", 48, 53], ["tumor", "ANATOMY", 124, 129], ["tumor", "ANATOMY", 188, 193], ["tumor", "DISEASE", 48, 53], ["tumor", "DISEASE", 124, 129], ["tumor", "DISEASE", 188, 193], ["tumor", "CANCER", 48, 53], ["tumor", "CANCER", 124, 129], ["tumor", "CANCER", 188, 193], ["33% tumor volume increase", "PROBLEM", 44, 69], ["a 68% significant increase in tumor volume", "PROBLEM", 94, 136], ["tumor volume", "TEST", 188, 200], ["tumor volume", "OBSERVATION", 48, 60], ["increase", "OBSERVATION_MODIFIER", 61, 69], ["significant", "OBSERVATION_MODIFIER", 100, 111], ["increase", "OBSERVATION_MODIFIER", 112, 120], ["tumor volume", "OBSERVATION", 124, 136], ["increase", "OBSERVATION_MODIFIER", 176, 184], ["tumor volume", "OBSERVATION", 188, 200]]], ["It is estimated that 17% of HNSCC patients will progress in stage between the diagnostic workup and treatment. in Hemoglobin (Hgb), which happens postoperatively attributed to hemodilution augmented with postoperative anticoagulation protocols of the surgeon's choice.", [["HNSCC", "ANATOMY", 28, 33], ["HNSCC", "DISEASE", 28, 33], ["hemodilution", "DISEASE", 176, 188], ["HNSCC", "CANCER", 28, 33], ["patients", "ORGANISM", 34, 42], ["Hemoglobin", "GENE_OR_GENE_PRODUCT", 114, 124], ["Hgb", "GENE_OR_GENE_PRODUCT", 126, 129], ["Hemoglobin", "PROTEIN", 114, 124], ["Hgb", "PROTEIN", 126, 129], ["patients", "SPECIES", 34, 42], ["the diagnostic workup", "TEST", 74, 95], ["treatment", "TREATMENT", 100, 109], ["Hemoglobin", "TEST", 114, 124], ["Hgb", "TEST", 126, 129], ["hemodilution", "TREATMENT", 176, 188], ["postoperative anticoagulation protocols", "TREATMENT", 204, 243], ["Hemoglobin", "OBSERVATION_MODIFIER", 114, 124], ["hemodilution", "OBSERVATION", 176, 188]]], ["What complicates the surgeon's decision to transfuse is that anemia is linked with delayed recovery, poor wound healing, and overall fatigue that might interfere with post-surgical mobilization (18, 42) .", [["wound", "ANATOMY", 106, 111], ["anemia", "DISEASE", 61, 67], ["fatigue", "DISEASE", 133, 140], ["wound", "PATHOLOGICAL_FORMATION", 106, 111], ["anemia", "PROBLEM", 61, 67], ["poor wound healing", "PROBLEM", 101, 119], ["overall fatigue", "PROBLEM", 125, 140], ["anemia", "OBSERVATION", 61, 67], ["poor", "OBSERVATION_MODIFIER", 101, 105], ["wound", "OBSERVATION_MODIFIER", 106, 111], ["healing", "OBSERVATION_MODIFIER", 112, 119]]], ["Preferred method of reconstruction Factors that might impact head and neck oncology and reconstruction Postoperative ICU admission of free microvascular tissue transfer patients", [["head", "ANATOMY", 61, 65], ["neck", "ANATOMY", 70, 74], ["microvascular tissue", "ANATOMY", 139, 159], ["head", "ORGANISM_SUBDIVISION", 61, 65], ["neck", "ORGAN", 70, 74], ["microvascular tissue", "TISSUE", 139, 159], ["patients", "ORGANISM", 169, 177], ["patients", "SPECIES", 169, 177], ["reconstruction", "TREATMENT", 20, 34], ["reconstruction", "TREATMENT", 88, 102], ["neck", "ANATOMY", 70, 74], ["microvascular tissue", "ANATOMY", 139, 159]]]], "b327b0ddd9de68b016056f55e5498fa904f573a3": [["Introduction And BackgroundThe coronavirus disease (COVID-19) pandemic continues to sweep across the globe, with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infecting over five million people and killing over a quarter million worldwide to date.", [["coronavirus disease", "DISEASE", 31, 50], ["acute respiratory syndrome coronavirus", "DISEASE", 124, 162], ["coronavirus", "ORGANISM", 31, 42], ["COVID-19", "ORGANISM", 52, 60], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 117, 164], ["SARS-CoV-2", "ORGANISM", 166, 176], ["people", "ORGANISM", 206, 212], ["people", "SPECIES", 206, 212], ["severe acute respiratory syndrome coronavirus", "SPECIES", 117, 162], ["SARS-CoV-2", "SPECIES", 166, 176], ["The coronavirus disease", "PROBLEM", 27, 50], ["COVID", "TEST", 52, 57], ["pandemic", "PROBLEM", 62, 70], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 113, 162], ["coronavirus disease", "OBSERVATION", 31, 50], ["globe", "ANATOMY", 101, 106], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["acute", "OBSERVATION_MODIFIER", 124, 129], ["respiratory syndrome", "OBSERVATION", 130, 150]]], ["A pall of uncertainty and fear has descended upon the world, and the SARS-CoV-2 virus has brought changes to all aspects of life.", [["SARS", "DISEASE", 69, 73], ["SARS-CoV-2 virus", "ORGANISM", 69, 85], ["SARS-CoV-2 virus", "SPECIES", 69, 85], ["the SARS-CoV-2 virus", "PROBLEM", 65, 85], ["pall", "OBSERVATION_MODIFIER", 2, 6]]], ["According to the World Health Organization (WHO), SARS-CoV-2 is transmitted through the spread of virus-containing droplets (i.e., <2-m distance) and/or contaminated surfaces [1] .Introduction And BackgroundThe WHO announced that COVID-19 could become an endemic disease, although they warned that it is difficult to predict its course.", [["SARS", "DISEASE", 50, 54], ["COVID-19", "CHEMICAL", 230, 238], ["SARS-CoV-2", "ORGANISM", 50, 60], ["SARS-CoV", "SPECIES", 50, 58], ["SARS-CoV-2", "PROBLEM", 50, 60], ["COVID", "TEST", 230, 235], ["an endemic disease", "PROBLEM", 252, 270], ["endemic", "OBSERVATION_MODIFIER", 255, 262], ["disease", "OBSERVATION", 263, 270]]], ["To control the devastation caused by the infection, the world is responding with an amalgamation of strategies: social distancing, lockdowns (complete, partial, only in areas of high incidence), testing (voluntary and compulsory, focusing on risk groups), and a plethora of other prophylactic measures [1] .", [["infection", "DISEASE", 41, 50], ["the devastation", "PROBLEM", 11, 26], ["the infection", "PROBLEM", 37, 50], ["other prophylactic measures", "TREATMENT", 274, 301], ["infection", "OBSERVATION", 41, 50]]], ["The biggest challenge lies in identifying and isolating asymptomatic carriers and preventing exponential community transmission [2] .", [["biggest", "OBSERVATION_MODIFIER", 4, 11]]], ["Systemic disease states such as diabetes mellitus, hypertension, and cardiac and pulmonary diseases increase disease susceptibility and mortality [3] .Introduction And BackgroundThe results from previous studies suggest that deleterious habits such as cigarette smoking and vaping could increase the susceptibility to COVID-19 [4] .", [["cardiac", "ANATOMY", 69, 76], ["pulmonary", "ANATOMY", 81, 90], ["diabetes mellitus", "DISEASE", 32, 49], ["hypertension", "DISEASE", 51, 63], ["cardiac and pulmonary diseases", "DISEASE", 69, 99], ["smoking", "CHEMICAL", 262, 269], ["vaping", "CHEMICAL", 274, 280], ["COVID-19", "CHEMICAL", 318, 326], ["cardiac", "ORGAN", 69, 76], ["pulmonary", "ORGAN", 81, 90], ["Systemic disease states", "PROBLEM", 0, 23], ["diabetes mellitus", "PROBLEM", 32, 49], ["hypertension", "PROBLEM", 51, 63], ["cardiac and pulmonary diseases increase disease susceptibility", "PROBLEM", 69, 131], ["previous studies", "TEST", 195, 211], ["deleterious habits", "PROBLEM", 225, 243], ["COVID", "TEST", 318, 323], ["disease", "OBSERVATION", 9, 16], ["hypertension", "OBSERVATION", 51, 63], ["cardiac", "ANATOMY", 69, 76], ["pulmonary", "ANATOMY", 81, 90], ["diseases", "OBSERVATION", 91, 99]]], ["There has not been much research on the increased risk of contracting COVID-19 for smokeless tobacco (SLT) users, although the use of these products is widely prevalent in South Asia and the Western Pacific region.", [["COVID-19", "CHEMICAL", 70, 78], ["SLT", "CHEMICAL", 102, 105], ["COVID-19", "CHEMICAL", 70, 78], ["tobacco", "ORGANISM", 93, 100], ["tobacco", "SPECIES", 93, 100], ["these products", "TREATMENT", 134, 148], ["increased", "OBSERVATION_MODIFIER", 40, 49]]], ["In this review, we explore the possibility of increased susceptibility and infectivity of SLT habitu\u00e9s to COVID-19.ReviewSLT is a broad group of unburned tobacco products that are used orally (chewed and spat out) or inhaled nasally.", [["tobacco", "ORGANISM", 154, 161], ["tobacco", "SPECIES", 154, 161], ["increased susceptibility", "PROBLEM", 46, 70], ["COVID", "TEST", 106, 111], ["unburned tobacco products", "TREATMENT", 145, 170], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["susceptibility", "OBSERVATION", 56, 70], ["tobacco products", "OBSERVATION", 154, 170]]], ["Many Asian and Western Pacific countries use an array of SLT products such as snus, tobacco tooth powders, snuff, gutkha, khaini, tobacco powder, mawa, jarda, mishri, and tobacco paste [5] [6] [7] .", [["tooth", "ANATOMY", 92, 97], ["snuff, gutkha, khaini, tobacco powder, mawa, jarda, mishri", "CHEMICAL", 107, 165], ["tobacco", "ORGANISM", 84, 91], ["tooth", "ORGANISM_SUBDIVISION", 92, 97], ["snuff", "ORGANISM_SUBDIVISION", 107, 112], ["tobacco", "ORGANISM", 130, 137], ["mawa", "SIMPLE_CHEMICAL", 146, 150], ["jarda", "SIMPLE_CHEMICAL", 152, 157], ["mishri", "SIMPLE_CHEMICAL", 159, 165], ["tobacco", "ORGANISM", 171, 178], ["[5] [6] [7]", "SIMPLE_CHEMICAL", 185, 196], ["tobacco", "SPECIES", 84, 91], ["tobacco", "SPECIES", 130, 137], ["tobacco", "SPECIES", 171, 178], ["tobacco", "SPECIES", 84, 91], ["tobacco", "SPECIES", 130, 137], ["tobacco", "SPECIES", 171, 178], ["SLT products", "TREATMENT", 57, 69]]], ["Currently, the South Asian region accounts for 90% of the global consumption of SLT, with a majority in Bangladesh (25%), India (22%), and Myanmar (21%) [8] .ReviewSLT is a stimulant that causes an increase in heart rate, blood pressure, and epinephrine levels.", [["heart", "ANATOMY", 210, 215], ["blood", "ANATOMY", 222, 227], ["epinephrine", "CHEMICAL", 242, 253], ["epinephrine", "CHEMICAL", 242, 253], ["heart", "ORGAN", 210, 215], ["blood", "ORGANISM_SUBSTANCE", 222, 227], ["epinephrine", "SIMPLE_CHEMICAL", 242, 253], ["India", "TEST", 122, 127], ["Myanmar", "TEST", 139, 146], ["heart rate", "TEST", 210, 220], ["blood pressure", "TEST", 222, 236], ["epinephrine levels", "TEST", 242, 260], ["global", "OBSERVATION_MODIFIER", 58, 64], ["consumption", "OBSERVATION_MODIFIER", 65, 76], ["SLT", "OBSERVATION_MODIFIER", 80, 83], ["increase", "OBSERVATION_MODIFIER", 198, 206], ["heart", "ANATOMY", 210, 215]]], ["There is a strong and proven association between the use of SLT and death due to cardiovascular disease, cerebrovascular disease, and cancer [9] .", [["cardiovascular", "ANATOMY", 81, 95], ["cerebrovascular", "ANATOMY", 105, 120], ["cancer", "ANATOMY", 134, 140], ["SLT", "CHEMICAL", 60, 63], ["death", "DISEASE", 68, 73], ["cardiovascular disease", "DISEASE", 81, 103], ["cerebrovascular disease", "DISEASE", 105, 128], ["cancer", "DISEASE", 134, 140], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 105, 120], ["cancer", "CANCER", 134, 140], ["SLT", "TREATMENT", 60, 63], ["death", "PROBLEM", 68, 73], ["cardiovascular disease", "PROBLEM", 81, 103], ["cerebrovascular disease", "PROBLEM", 105, 128], ["cancer", "PROBLEM", 134, 140], ["strong", "OBSERVATION_MODIFIER", 11, 17], ["cardiovascular", "ANATOMY", 81, 95], ["disease", "OBSERVATION", 96, 103], ["cerebrovascular", "ANATOMY", 105, 120], ["disease", "OBSERVATION", 121, 128], ["cancer", "OBSERVATION", 134, 140]]], ["The increased cellular tropism in oral mucosa and altered immune response among SLT habitu\u00e9s can increase an individual's susceptibility to COVID-19 infection.", [["cellular", "ANATOMY", 14, 22], ["oral mucosa", "ANATOMY", 34, 45], ["infection", "DISEASE", 149, 158], ["cellular", "CELL", 14, 22], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 34, 45], ["COVID-19", "GENE_OR_GENE_PRODUCT", 140, 148], ["COVID-19", "SPECIES", 140, 148], ["The increased cellular tropism in oral mucosa", "PROBLEM", 0, 45], ["altered immune response", "PROBLEM", 50, 73], ["SLT habitu\u00e9s", "PROBLEM", 80, 92], ["an individual's susceptibility", "PROBLEM", 106, 136], ["COVID", "TEST", 140, 145], ["19 infection", "PROBLEM", 146, 158], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["cellular tropism", "OBSERVATION", 14, 30], ["oral mucosa", "ANATOMY", 34, 45], ["altered", "OBSERVATION_MODIFIER", 50, 57], ["immune response", "OBSERVATION", 58, 73], ["infection", "OBSERVATION", 149, 158]]], ["This, compounded by the act of public spitting, frequent hand-to-mouth contact, and sharing of apparatus among SLT habitu\u00e9s, could potentially aid in increasing disease transmission.Smokeless tobacco habitu\u00e9s: increased cellular tropism in the oral mucosa (tongue) for COVID-19The recognition of viral host cell receptors and their interaction with the host cell is crucial in studying viral tissue tropism and pathogenesis.", [["hand", "ANATOMY", 57, 61], ["cellular", "ANATOMY", 220, 228], ["oral mucosa", "ANATOMY", 244, 255], ["tongue", "ANATOMY", 257, 263], ["cell", "ANATOMY", 307, 311], ["cell", "ANATOMY", 358, 362], ["tissue", "ANATOMY", 392, 398], ["tobacco", "ORGANISM", 192, 199], ["cellular", "CELL", 220, 228], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 244, 255], ["tongue", "ORGAN", 257, 263], ["host cell", "CELL", 302, 311], ["host cell", "CELL", 353, 362], ["tissue", "TISSUE", 392, 398], ["viral host cell receptors", "PROTEIN", 296, 321], ["tobacco", "SPECIES", 192, 199], ["Smokeless tobacco habitu\u00e9s", "SPECIES", 182, 208], ["public spitting", "PROBLEM", 31, 46], ["increasing disease transmission", "PROBLEM", 150, 181], ["increased cellular tropism", "PROBLEM", 210, 236], ["COVID", "TEST", 269, 274], ["viral host cell receptors", "PROBLEM", 296, 321], ["viral tissue tropism", "PROBLEM", 386, 406], ["pathogenesis", "PROBLEM", 411, 423], ["increasing", "OBSERVATION_MODIFIER", 150, 160], ["disease", "OBSERVATION", 161, 168], ["increased", "OBSERVATION_MODIFIER", 210, 219], ["cellular tropism", "OBSERVATION", 220, 236], ["oral mucosa", "ANATOMY", 244, 255], ["tongue", "ANATOMY", 257, 263], ["viral host cell receptors", "OBSERVATION", 296, 321], ["host cell", "OBSERVATION", 353, 362], ["viral tissue tropism", "OBSERVATION", 386, 406]]], ["An individual's susceptibility to viral infections is attributed to the presence of a host cell surface attachment site (receptor) and a conducive intracellular environment to favor virus replication and release [10] .Smokeless tobacco habitu\u00e9s: increased cellular tropism in the oral mucosa (tongue) for COVID-19Coronaviruses belong to the family of Coronaviridae and contain a large, single, plus-stranded ribonucleic acid (RNA) genome.", [["cell surface", "ANATOMY", 91, 103], ["intracellular", "ANATOMY", 147, 160], ["cellular", "ANATOMY", 256, 264], ["oral mucosa", "ANATOMY", 280, 291], ["tongue", "ANATOMY", 293, 299], ["viral infections", "DISEASE", 34, 50], ["ribonucleic acid", "CHEMICAL", 408, 424], ["cell", "CELL", 91, 95], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 147, 160], ["tobacco", "ORGANISM", 228, 235], ["cellular", "CELL", 256, 264], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 280, 291], ["tongue", "ORGAN", 293, 299], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 351, 364], ["host cell surface attachment site", "PROTEIN", 86, 119], ["plus-stranded ribonucleic acid (RNA) genome", "DNA", 394, 437], ["tobacco", "SPECIES", 228, 235], ["Smokeless tobacco habitu\u00e9s", "SPECIES", 218, 244], ["viral infections", "PROBLEM", 34, 50], ["a host cell surface attachment site", "TREATMENT", 84, 119], ["a conducive intracellular environment", "TREATMENT", 135, 172], ["virus replication", "TREATMENT", 182, 199], ["increased cellular tropism", "PROBLEM", 246, 272], ["Coronaviridae", "TREATMENT", 351, 364], ["stranded ribonucleic acid (RNA) genome", "TREATMENT", 399, 437], ["viral infections", "OBSERVATION", 34, 50], ["host cell", "OBSERVATION", 86, 95], ["surface", "OBSERVATION_MODIFIER", 96, 103], ["increased", "OBSERVATION_MODIFIER", 246, 255], ["cellular tropism", "OBSERVATION", 256, 272], ["oral mucosa", "ANATOMY", 280, 291], ["tongue", "ANATOMY", 293, 299], ["large", "OBSERVATION_MODIFIER", 379, 384]]], ["There is a spike protein (S glycoprotein) on the surface of SARS-CoV-2 that binds to angiotensin-converting enzyme 2 (ACE2) receptors on the host cell membrane and facilitates viral entry into target cells.", [["surface", "ANATOMY", 49, 56], ["cell membrane", "ANATOMY", 146, 159], ["cells", "ANATOMY", 200, 205], ["angiotensin", "CHEMICAL", 85, 96], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 26, 40], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 60, 70], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 85, 116], ["ACE2", "GENE_OR_GENE_PRODUCT", 118, 122], ["cell membrane", "CELLULAR_COMPONENT", 146, 159], ["cells", "CELL", 200, 205], ["spike protein", "PROTEIN", 11, 24], ["S glycoprotein", "PROTEIN", 26, 40], ["angiotensin-converting enzyme 2 (ACE2) receptors", "PROTEIN", 85, 133], ["target cells", "CELL_TYPE", 193, 205], ["SARS-CoV", "SPECIES", 60, 68], ["a spike protein (S glycoprotein)", "PROBLEM", 9, 41], ["SARS", "PROBLEM", 60, 64], ["CoV", "TEST", 65, 68], ["angiotensin", "TEST", 85, 96], ["converting enzyme", "TEST", 97, 114], ["the host cell membrane", "TREATMENT", 137, 159], ["host cell membrane", "OBSERVATION", 141, 159], ["target cells", "OBSERVATION", 193, 205]]], ["The S glycoprotein is primed by host membrane proteases (i.e., proprotein convertase) and then cleaved (at the S1/S2 cleavage site) by the host-derived enzyme furin into two subunits, S1 and S2.", [["membrane", "ANATOMY", 37, 45], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 4, 18], ["S2", "GENE_OR_GENE_PRODUCT", 114, 116], ["furin", "GENE_OR_GENE_PRODUCT", 159, 164], ["S2", "GENE_OR_GENE_PRODUCT", 191, 193], ["S glycoprotein", "PROTEIN", 4, 18], ["host membrane proteases", "PROTEIN", 32, 55], ["proprotein convertase", "PROTEIN", 63, 84], ["S1", "PROTEIN", 111, 113], ["S2 cleavage site", "PROTEIN", 114, 130], ["host-derived enzyme", "PROTEIN", 139, 158], ["furin", "PROTEIN", 159, 164], ["S1", "PROTEIN", 184, 186], ["S2", "PROTEIN", 191, 193], ["The S glycoprotein", "TREATMENT", 0, 18], ["host membrane proteases", "TREATMENT", 32, 55], ["proprotein convertase", "TREATMENT", 63, 84], ["S2", "ANATOMY", 191, 193]]], ["The S2 subunit facilitates viral and host membrane fusion through the heptad repeats HR1 and HR2 [11] [12] [13] [14] .Smokeless tobacco habitu\u00e9s: increased cellular tropism in the oral mucosa (tongue) for COVID-19Studies have shown that the ACE2 receptor is expressed in the oral epithelial cells of the tongue, buccal mucosa, gingiva, minor salivary gland ducts, T and B lymphocytes, and fibroblasts of the oral sub-mucosa.", [["membrane", "ANATOMY", 42, 50], ["cellular", "ANATOMY", 156, 164], ["oral mucosa", "ANATOMY", 180, 191], ["tongue", "ANATOMY", 193, 199], ["oral epithelial cells", "ANATOMY", 275, 296], ["tongue", "ANATOMY", 304, 310], ["buccal mucosa", "ANATOMY", 312, 325], ["gingiva", "ANATOMY", 327, 334], ["salivary gland ducts", "ANATOMY", 342, 362], ["T", "ANATOMY", 364, 365], ["B lymphocytes", "ANATOMY", 370, 383], ["fibroblasts", "ANATOMY", 389, 400], ["oral sub-mucosa", "ANATOMY", 408, 423], ["S2", "GENE_OR_GENE_PRODUCT", 4, 6], ["host membrane", "CELLULAR_COMPONENT", 37, 50], ["tobacco", "ORGANISM", 128, 135], ["cellular", "CELL", 156, 164], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 180, 191], ["tongue", "ORGAN", 193, 199], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 241, 254], ["oral epithelial cells", "CELL", 275, 296], ["tongue", "ORGAN", 304, 310], ["buccal mucosa", "MULTI-TISSUE_STRUCTURE", 312, 325], ["gingiva", "MULTI-TISSUE_STRUCTURE", 327, 334], ["salivary gland ducts", "MULTI-TISSUE_STRUCTURE", 342, 362], ["T", "CELL", 364, 365], ["B lymphocytes", "CELL", 370, 383], ["fibroblasts", "CELL", 389, 400], ["oral", "ORGANISM_SUBDIVISION", 408, 412], ["sub-mucosa", "MULTI-TISSUE_STRUCTURE", 413, 423], ["S2 subunit", "PROTEIN", 4, 14], ["heptad repeats", "PROTEIN", 70, 84], ["HR1", "PROTEIN", 85, 88], ["ACE2 receptor", "PROTEIN", 241, 254], ["oral epithelial cells", "CELL_TYPE", 275, 296], ["T and B lymphocytes", "CELL_TYPE", 364, 383], ["fibroblasts", "CELL_TYPE", 389, 400], ["tobacco", "SPECIES", 128, 135], ["Smokeless tobacco habitu\u00e9s", "SPECIES", 118, 144], ["viral and host membrane fusion", "TREATMENT", 27, 57], ["the heptad repeats HR1", "TEST", 66, 88], ["HR2", "TEST", 93, 96], ["increased cellular tropism", "PROBLEM", 146, 172], ["COVID-19Studies", "TEST", 205, 220], ["the ACE2 receptor", "TEST", 237, 254], ["viral", "OBSERVATION", 27, 32], ["increased", "OBSERVATION_MODIFIER", 146, 155], ["cellular tropism", "OBSERVATION", 156, 172], ["oral mucosa", "ANATOMY", 180, 191], ["tongue", "ANATOMY", 193, 199], ["oral", "ANATOMY", 275, 279], ["epithelial cells", "OBSERVATION", 280, 296], ["tongue", "ANATOMY", 304, 310], ["buccal mucosa", "ANATOMY", 312, 325], ["gingiva", "ANATOMY", 327, 334], ["minor", "ANATOMY_MODIFIER", 336, 341], ["salivary gland", "ANATOMY", 342, 356], ["ducts", "ANATOMY", 357, 362], ["lymphocytes", "ANATOMY", 372, 383], ["fibroblasts", "OBSERVATION", 389, 400], ["oral sub", "ANATOMY_MODIFIER", 408, 416], ["mucosa", "ANATOMY", 417, 423]]], ["This suggests that SARS-CoV-2 exhibits tropism for the oral cavity [15] .", [["oral cavity", "ANATOMY", 55, 66], ["SARS", "DISEASE", 19, 23], ["SARS-CoV-2", "ORGANISM", 19, 29], ["oral", "ORGANISM_SUBDIVISION", 55, 59], ["SARS-CoV", "SPECIES", 19, 27], ["SARS", "TEST", 19, 23], ["CoV", "TEST", 24, 27], ["SARS", "OBSERVATION", 19, 23], ["oral cavity", "ANATOMY", 55, 66]]], ["SARS-CoV-2-positive individuals exhibit oral symptoms such as amblygeustia and dry mouth, which could be explained by the dysfunction of the ACE2 receptors in virally infected oral tissue [2] .Smokeless tobacco habitu\u00e9s: increased cellular tropism in the oral mucosa (tongue) for COVID-19Several inherent factors could result in increased infectivity of the oral cavity by SARS-CoV-2 [12] .", [["oral", "ANATOMY", 40, 44], ["mouth", "ANATOMY", 83, 88], ["oral tissue", "ANATOMY", 176, 187], ["cellular", "ANATOMY", 231, 239], ["oral mucosa", "ANATOMY", 255, 266], ["tongue", "ANATOMY", 268, 274], ["oral cavity", "ANATOMY", 358, 369], ["amblygeustia", "DISEASE", 62, 74], ["dry mouth", "DISEASE", 79, 88], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["individuals", "ORGANISM", 20, 31], ["oral", "ORGANISM_SUBDIVISION", 40, 44], ["mouth", "ORGANISM_SUBDIVISION", 83, 88], ["ACE2", "GENE_OR_GENE_PRODUCT", 141, 145], ["oral tissue", "TISSUE", 176, 187], ["tobacco", "ORGANISM", 203, 210], ["cellular", "CELL", 231, 239], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 255, 266], ["tongue", "ORGAN", 268, 274], ["oral cavity", "ORGAN", 358, 369], ["ACE2 receptors", "PROTEIN", 141, 155], ["tobacco", "SPECIES", 203, 210], ["Smokeless tobacco habitu\u00e9s", "SPECIES", 193, 219], ["SARS-CoV", "SPECIES", 373, 381], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["positive individuals", "PROBLEM", 11, 31], ["oral symptoms", "PROBLEM", 40, 53], ["amblygeustia", "PROBLEM", 62, 74], ["dry mouth", "PROBLEM", 79, 88], ["the dysfunction of the ACE2 receptors", "PROBLEM", 118, 155], ["virally infected oral tissue", "PROBLEM", 159, 187], ["increased cellular tropism", "PROBLEM", 221, 247], ["COVID", "TREATMENT", 280, 285], ["19Several inherent factors", "PROBLEM", 286, 312], ["increased infectivity of the oral cavity", "PROBLEM", 329, 369], ["increased", "OBSERVATION_MODIFIER", 221, 230], ["cellular tropism", "OBSERVATION", 231, 247], ["oral mucosa", "ANATOMY", 255, 266], ["tongue", "ANATOMY", 268, 274], ["increased", "OBSERVATION_MODIFIER", 329, 338], ["infectivity", "OBSERVATION", 339, 350], ["oral cavity", "ANATOMY", 358, 369]]], ["Immunostaining studies have revealed a high expression of the furin enzyme in the human tongue [13, 14] .", [["tongue", "ANATOMY", 88, 94], ["furin", "GENE_OR_GENE_PRODUCT", 62, 67], ["human", "ORGANISM", 82, 87], ["tongue", "ORGAN", 88, 94], ["furin enzyme", "PROTEIN", 62, 74], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 82, 87], ["Immunostaining studies", "TEST", 0, 22], ["the furin enzyme", "TEST", 58, 74], ["high expression", "OBSERVATION_MODIFIER", 39, 54], ["human tongue", "ANATOMY", 82, 94]]], ["The presence of a furin-like cleavage site in the viral spike protein enhances the invasiveness of the virus to the host cell [12] .", [["cell", "ANATOMY", 121, 125], ["furin", "GENE_OR_GENE_PRODUCT", 18, 23], ["host cell", "CELL", 116, 125], ["furin", "PROTEIN", 18, 23], ["viral spike protein", "PROTEIN", 50, 69], ["a furin-like cleavage site", "PROBLEM", 16, 42], ["the viral spike protein", "PROBLEM", 46, 69], ["viral spike", "OBSERVATION", 50, 61], ["host cell", "OBSERVATION", 116, 125]]], ["The nicotine-induced increased expression of the ACE2 receptor in the oral mucosa would favor viral tropism [16] .", [["oral mucosa", "ANATOMY", 70, 81], ["nicotine", "CHEMICAL", 4, 12], ["nicotine", "CHEMICAL", 4, 12], ["nicotine", "SIMPLE_CHEMICAL", 4, 12], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 49, 62], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 70, 81], ["ACE2 receptor", "PROTEIN", 49, 62], ["The nicotine", "TREATMENT", 0, 12], ["the ACE2 receptor", "TREATMENT", 45, 62], ["viral tropism", "PROBLEM", 94, 107], ["oral mucosa", "ANATOMY", 70, 81]]], ["Thus, SLT induces higher expression of ACE2 receptors, and, combined with the presence of furin in the oral mucosa, there would be an increased susceptibility of SLT habitu\u00e9s to COVID-19 ( Figure 1 ) [11] [12] [13] [14] [15] [16] [17] [18] [19] .FIGURE 1: Pathogenesis: increased cellular tropism for COVID-19 in the oral mucosa and tongue of smokeless tobacco habitu\u00e9sThe known action of the enzyme furin and the nicotine-induced increased expression of the ACE2 receptor result in COVID-19 viral tropism to the oral mucosal tissues in smokeless tobacco habitu\u00e9s [11] [12] [13] [14] [15] [16] [17] [18] [19] .FIGURE 1: Pathogenesis: increased cellular tropism for COVID-19 in the oral mucosa and tongue of smokeless tobacco habitu\u00e9sTMPRSS2, transmembrane protease serine 2; ACE2, angiotensin-converting enzyme 2; ER, endoplasmic reticulum; COVID-19, coronavirus diseaseFIGURE 1: Pathogenesis: increased cellular tropism for COVID-19 in the oral mucosa and tongue of smokeless tobacco habitu\u00e9sSmokeless tobacco habitu\u00e9s: comorbidity due to an altered 2020immune responseIt has been shown that frequent and prolonged use of various forms of SLT causes immunosuppression by affecting the adaptive (helper T cells, CD4+CD25+ regulatory T cells, CD8+ T cells, B cells, and memory T/B lymphocytes) and innate (dendritic cells, macrophages, and natural killer cells) immune mechanisms.", [["oral mucosa", "ANATOMY", 103, 114], ["cellular", "ANATOMY", 280, 288], ["oral mucosa", "ANATOMY", 317, 328], ["tongue", "ANATOMY", 333, 339], ["oral mucosal tissues", "ANATOMY", 513, 533], ["cellular", "ANATOMY", 644, 652], ["oral mucosa", "ANATOMY", 681, 692], ["tongue", "ANATOMY", 697, 703], ["endoplasmic reticulum", "ANATOMY", 818, 839], ["cellular", "ANATOMY", 904, 912], ["oral mucosa", "ANATOMY", 941, 952], ["tongue", "ANATOMY", 957, 963], ["helper T cells", "ANATOMY", 1196, 1210], ["CD4+CD25+ regulatory T cells", "ANATOMY", 1212, 1240], ["CD8+ T cells", "ANATOMY", 1242, 1254], ["B cells", "ANATOMY", 1256, 1263], ["memory T/B lymphocytes", "ANATOMY", 1269, 1291], ["dendritic cells", "ANATOMY", 1305, 1320], ["macrophages", "ANATOMY", 1322, 1333], ["natural killer cells", "ANATOMY", 1339, 1359], ["SLT", "CHEMICAL", 6, 9], ["COVID-19", "CHEMICAL", 178, 186], ["COVID-19", "CHEMICAL", 301, 309], ["nicotine", "CHEMICAL", 414, 422], ["COVID-19", "CHEMICAL", 665, 673], ["angiotensin", "CHEMICAL", 781, 792], ["COVID-19", "CHEMICAL", 925, 933], ["SLT", "CHEMICAL", 1140, 1143], ["COVID-19", "CHEMICAL", 178, 186], ["COVID-19", "CHEMICAL", 301, 309], ["nicotine", "CHEMICAL", 414, 422], ["COVID-19", "CHEMICAL", 665, 673], ["serine", "CHEMICAL", 765, 771], ["COVID-19", "CHEMICAL", 925, 933], ["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["furin", "GENE_OR_GENE_PRODUCT", 90, 95], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 103, 114], ["Figure 1 ) [11] [12] [13] [14] [15] [16] [17] [18] [19]", "SIMPLE_CHEMICAL", 189, 244], ["cellular", "CELL", 280, 288], ["COVID-19", "GENE_OR_GENE_PRODUCT", 301, 309], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 317, 328], ["tongue", "ORGAN", 333, 339], ["tobacco", "ORGANISM", 353, 360], ["furin", "GENE_OR_GENE_PRODUCT", 400, 405], ["nicotine", "SIMPLE_CHEMICAL", 414, 422], ["ACE2", "GENE_OR_GENE_PRODUCT", 459, 463], ["COVID-19", "GENE_OR_GENE_PRODUCT", 483, 491], ["oral mucosal tissues", "TISSUE", 513, 533], ["tobacco", "ORGANISM", 547, 554], ["[11] [12] [13] [14] [15] [16] [17] [18] [19]", "SIMPLE_CHEMICAL", 564, 608], ["cellular", "CELL", 644, 652], ["COVID-19", "GENE_OR_GENE_PRODUCT", 665, 673], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 681, 692], ["tongue", "ORGAN", 697, 703], ["tobacco", "ORGANISM", 717, 724], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 733, 740], ["transmembrane protease serine 2", "GENE_OR_GENE_PRODUCT", 742, 773], ["ACE2", "GENE_OR_GENE_PRODUCT", 775, 779], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 781, 812], ["ER", "GENE_OR_GENE_PRODUCT", 814, 816], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 818, 839], ["COVID-19", "GENE_OR_GENE_PRODUCT", 841, 849], ["cellular", "CELL", 904, 912], ["COVID-19", "GENE_OR_GENE_PRODUCT", 925, 933], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 941, 952], ["tongue", "ORGAN", 957, 963], ["tobacco", "ORGANISM", 977, 984], ["tobacco", "ORGANISM", 1003, 1010], ["helper T cells", "CELL", 1196, 1210], ["CD4", "GENE_OR_GENE_PRODUCT", 1212, 1215], ["CD25", "GENE_OR_GENE_PRODUCT", 1216, 1220], ["CD8", "GENE_OR_GENE_PRODUCT", 1242, 1245], ["B cells", "CELL", 1256, 1263], ["B lymphocytes", "CELL", 1278, 1291], ["dendritic cells", "CELL", 1305, 1320], ["macrophages", "CELL", 1322, 1333], ["natural killer cells", "CELL", 1339, 1359], ["SLT", "PROTEIN", 6, 9], ["ACE2 receptors", "PROTEIN", 39, 53], ["furin", "PROTEIN", 90, 95], ["COVID", "PROTEIN", 301, 306], ["ACE2 receptor", "PROTEIN", 459, 472], ["COVID", "PROTEIN", 665, 670], ["TMPRSS2", "PROTEIN", 733, 740], ["transmembrane protease serine 2; ACE2, angiotensin-converting enzyme 2", "PROTEIN", 742, 812], ["ER", "PROTEIN", 814, 816], ["COVID-19", "PROTEIN", 925, 933], ["helper T cells", "CELL_TYPE", 1196, 1210], ["CD4", "PROTEIN", 1212, 1215], ["CD25", "PROTEIN", 1216, 1220], ["regulatory T cells", "CELL_TYPE", 1222, 1240], ["CD8+ T cells", "CELL_TYPE", 1242, 1254], ["B cells", "CELL_TYPE", 1256, 1263], ["memory T/B lymphocytes", "CELL_TYPE", 1269, 1291], ["dendritic cells", "CELL_TYPE", 1305, 1320], ["macrophages", "CELL_TYPE", 1322, 1333], ["natural killer cells", "CELL_TYPE", 1339, 1359], ["tobacco", "SPECIES", 353, 360], ["tobacco", "SPECIES", 717, 724], ["tobacco", "SPECIES", 977, 984], ["tobacco", "SPECIES", 1003, 1010], ["smokeless tobacco habitu\u00e9s", "SPECIES", 343, 369], ["tobacco", "SPECIES", 547, 554], ["smokeless tobacco habitu\u00e9s", "SPECIES", 707, 733], ["smokeless tobacco habitu\u00e9s", "SPECIES", 967, 993], ["tobacco", "SPECIES", 1003, 1010], ["ACE2 receptors", "PROBLEM", 39, 53], ["furin in the oral mucosa", "PROBLEM", 90, 114], ["an increased susceptibility of SLT habitu\u00e9s", "PROBLEM", 131, 174], ["COVID", "TEST", 178, 183], ["increased cellular tropism", "PROBLEM", 270, 296], ["COVID", "TEST", 301, 306], ["the enzyme furin", "PROBLEM", 389, 405], ["the nicotine", "TREATMENT", 410, 422], ["the ACE2 receptor", "TEST", 455, 472], ["COVID", "TEST", 483, 488], ["viral tropism", "PROBLEM", 492, 505], ["increased cellular tropism", "PROBLEM", 634, 660], ["COVID", "TEST", 665, 670], ["TMPRSS2", "TEST", 733, 740], ["transmembrane protease serine", "TEST", 742, 771], ["ACE2", "TEST", 775, 779], ["angiotensin", "TEST", 781, 792], ["enzyme", "TEST", 804, 810], ["COVID", "TEST", 841, 846], ["increased cellular tropism", "PROBLEM", 894, 920], ["COVID", "TEST", 925, 930], ["an altered 2020immune response", "PROBLEM", 1040, 1070], ["SLT", "TREATMENT", 1140, 1143], ["immunosuppression", "TREATMENT", 1151, 1168], ["CD4", "TEST", 1212, 1215], ["CD25", "TEST", 1216, 1220], ["regulatory T cells", "TEST", 1222, 1240], ["CD8", "TEST", 1242, 1245], ["T cells", "PROBLEM", 1247, 1254], ["B cells", "TEST", 1256, 1263], ["memory T/B lymphocytes", "TEST", 1269, 1291], ["innate (dendritic cells", "TREATMENT", 1297, 1320], ["macrophages", "PROBLEM", 1322, 1333], ["natural killer cells", "TREATMENT", 1339, 1359], ["oral mucosa", "ANATOMY", 103, 114], ["increased", "OBSERVATION_MODIFIER", 134, 143], ["increased", "OBSERVATION_MODIFIER", 270, 279], ["cellular tropism", "OBSERVATION", 280, 296], ["oral mucosa", "ANATOMY", 317, 328], ["tongue", "ANATOMY", 333, 339], ["viral tropism", "OBSERVATION", 492, 505], ["mucosal tissues", "ANATOMY", 518, 533], ["increased", "OBSERVATION_MODIFIER", 634, 643], ["cellular tropism", "OBSERVATION", 644, 660], ["oral mucosa", "ANATOMY", 681, 692], ["tongue", "ANATOMY", 697, 703], ["endoplasmic reticulum", "ANATOMY", 818, 839], ["cellular tropism", "OBSERVATION", 904, 920], ["oral mucosa", "ANATOMY", 941, 952], ["tongue", "ANATOMY", 957, 963], ["frequent", "OBSERVATION_MODIFIER", 1093, 1101], ["dendritic cells", "OBSERVATION", 1305, 1320], ["natural killer cells", "OBSERVATION", 1339, 1359]]], ["Chronic inflammation of oral mucosa caused by SLT results in a release of prostaglandins and cytokines such as interleukin-6, interferon-\u03b1, tumor necrosis factor, and transforming growth factor \u03b2 at the site of irritation, which could potentiate a pro-inflammatory cytokine response as well as cause immune system dysfunction [20] [21] [22] .immune responseWhen virally infected immune cells disrupt the cellular and humoral immune response, this subjects SLT habitu\u00e9s to cardiovascular, respiratory, and autoimmune diseases, as well as allergies, cancers, and transplant rejection [22] .", [["oral mucosa", "ANATOMY", 24, 35], ["immune system", "ANATOMY", 300, 313], ["immune cells", "ANATOMY", 379, 391], ["cellular", "ANATOMY", 404, 412], ["cardiovascular", "ANATOMY", 472, 486], ["respiratory", "ANATOMY", 488, 499], ["cancers", "ANATOMY", 548, 555], ["inflammation", "DISEASE", 8, 20], ["prostaglandins", "CHEMICAL", 74, 88], ["tumor necrosis", "DISEASE", 140, 154], ["cardiovascular, respiratory, and autoimmune diseases", "DISEASE", 472, 524], ["allergies", "DISEASE", 537, 546], ["cancers", "DISEASE", 548, 555], ["prostaglandins", "CHEMICAL", 74, 88], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 24, 35], ["prostaglandins", "SIMPLE_CHEMICAL", 74, 88], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 111, 124], ["interferon-\u03b1", "GENE_OR_GENE_PRODUCT", 126, 138], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 140, 161], ["transforming growth factor \u03b2", "GENE_OR_GENE_PRODUCT", 167, 195], ["[20] [21] [22] .immune", "SIMPLE_CHEMICAL", 326, 348], ["immune cells", "CELL", 379, 391], ["cellular", "CELL", 404, 412], ["cardiovascular", "ANATOMICAL_SYSTEM", 472, 486], ["cancers", "CANCER", 548, 555], ["cytokines", "PROTEIN", 93, 102], ["interleukin-6", "PROTEIN", 111, 124], ["interferon-\u03b1", "PROTEIN", 126, 138], ["tumor necrosis factor", "PROTEIN", 140, 161], ["transforming growth factor \u03b2", "PROTEIN", 167, 195], ["cytokine", "PROTEIN", 265, 273], ["virally infected immune cells", "CELL_TYPE", 362, 391], ["Chronic inflammation of oral mucosa", "PROBLEM", 0, 35], ["a release of prostaglandins", "TREATMENT", 61, 88], ["cytokines", "TREATMENT", 93, 102], ["interleukin", "TEST", 111, 122], ["interferon", "TREATMENT", 126, 136], ["tumor necrosis factor", "PROBLEM", 140, 161], ["transforming growth factor", "PROBLEM", 167, 193], ["irritation", "PROBLEM", 211, 221], ["a pro-inflammatory cytokine response", "PROBLEM", 246, 282], ["immune system dysfunction", "PROBLEM", 300, 325], [".immune responseWhen virally infected immune cells", "PROBLEM", 341, 391], ["autoimmune diseases", "PROBLEM", 505, 524], ["allergies", "PROBLEM", 537, 546], ["cancers", "PROBLEM", 548, 555], ["transplant rejection", "PROBLEM", 561, 581], ["inflammation", "OBSERVATION", 8, 20], ["oral mucosa", "ANATOMY", 24, 35], ["tumor", "OBSERVATION_MODIFIER", 140, 145], ["necrosis", "OBSERVATION", 146, 154], ["irritation", "OBSERVATION", 211, 221], ["immune cells", "OBSERVATION", 379, 391], ["humoral immune response", "OBSERVATION", 417, 440], ["cardiovascular", "ANATOMY", 472, 486], ["respiratory", "ANATOMY", 488, 499], ["autoimmune diseases", "OBSERVATION", 505, 524], ["cancers", "OBSERVATION", 548, 555]]], ["It has also been shown that the group of COVID-19 patients with the worst outcomes had at least one of these comorbid conditions [3] .immune responseThis dysfunctional immune response in SLT habitu\u00e9s against SARS-CoV-2 results in increased viral dissemination and cellular destruction via cytokine storm.", [["cellular", "ANATOMY", 264, 272], ["SARS", "DISEASE", 208, 212], ["patients", "ORGANISM", 50, 58], ["SLT habitu\u00e9s", "ORGANISM", 187, 199], ["SARS-CoV-2", "ORGANISM", 208, 218], ["cellular", "CELL", 264, 272], ["cytokine", "PROTEIN", 289, 297], ["patients", "SPECIES", 50, 58], ["SARS-CoV", "SPECIES", 208, 216], ["these comorbid conditions", "PROBLEM", 103, 128], ["This dysfunctional immune response", "PROBLEM", 149, 183], ["SLT habitu\u00e9s", "TEST", 187, 199], ["SARS", "PROBLEM", 208, 212], ["CoV", "TEST", 213, 216], ["increased viral dissemination", "PROBLEM", 230, 259], ["cellular destruction via cytokine storm", "PROBLEM", 264, 303], ["immune response", "OBSERVATION", 168, 183], ["increased", "OBSERVATION_MODIFIER", 230, 239], ["viral dissemination", "OBSERVATION", 240, 259], ["cellular destruction", "OBSERVATION", 264, 284], ["cytokine storm", "OBSERVATION", 289, 303]]], ["This likely increases the chances that an SLT habitu\u00e9 would contract COVID-19 ( Figure 2 ) [20] [21] [22] .Smokeless tobacco habitu\u00e9s: spitting in public and COVID-19 outbreakSLT chewing and spitting in public is a widespread, acceptable custom in many countries of South Asia [7] .", [["COVID-19", "CHEMICAL", 69, 77], ["COVID-19", "CHEMICAL", 69, 77], ["tobacco", "ORGANISM", 117, 124], ["tobacco", "SPECIES", 117, 124], ["Smokeless tobacco habitu\u00e9s", "SPECIES", 107, 133], ["an SLT habitu\u00e9", "TEST", 39, 53], ["COVID", "TEST", 69, 74], ["spitting", "PROBLEM", 135, 143]]], ["The habit of spitting in public places unleashes a stream of saliva droplets directly in the path of commuters, pedestrians, and any nearby people [23] .Smokeless tobacco habitu\u00e9s: spitting in public and COVID-19 outbreakPhysiologically, saliva is a biomixture of crevicular fluid, desquamated oral epithelial cells, and microorganisms, and may contain blood, respiratory secretions, gastric acid from reflux, and food debris, all of which may be infectious [24] .", [["crevicular fluid", "ANATOMY", 264, 280], ["oral epithelial cells", "ANATOMY", 294, 315], ["blood", "ANATOMY", 353, 358], ["respiratory secretions", "ANATOMY", 360, 382], ["gastric", "ANATOMY", 384, 391], ["reflux", "DISEASE", 402, 408], ["saliva", "ORGANISM_SUBSTANCE", 61, 67], ["tobacco", "ORGANISM", 163, 170], ["saliva", "ORGANISM_SUBSTANCE", 238, 244], ["crevicular fluid", "ORGANISM_SUBSTANCE", 264, 280], ["oral epithelial cells", "CELL", 294, 315], ["blood", "ORGANISM_SUBSTANCE", 353, 358], ["gastric acid", "SIMPLE_CHEMICAL", 384, 396], ["desquamated oral epithelial cells", "CELL_TYPE", 282, 315], ["people", "SPECIES", 140, 146], ["tobacco", "SPECIES", 163, 170], ["Smokeless tobacco habitu\u00e9s", "SPECIES", 153, 179], ["spitting", "PROBLEM", 13, 21], ["saliva droplets", "TREATMENT", 61, 76], ["spitting", "PROBLEM", 181, 189], ["COVID", "TEST", 204, 209], ["crevicular fluid", "TEST", 264, 280], ["desquamated oral epithelial cells", "PROBLEM", 282, 315], ["microorganisms", "PROBLEM", 321, 335], ["blood, respiratory secretions", "PROBLEM", 353, 382], ["gastric acid from reflux", "PROBLEM", 384, 408], ["food debris", "PROBLEM", 414, 425], ["infectious", "PROBLEM", 447, 457], ["habit", "OBSERVATION_MODIFIER", 4, 9], ["crevicular", "ANATOMY", 264, 274], ["epithelial cells", "OBSERVATION", 299, 315], ["respiratory", "ANATOMY", 360, 371], ["secretions", "OBSERVATION", 372, 382], ["gastric", "ANATOMY", 384, 391], ["acid", "OBSERVATION_MODIFIER", 392, 396], ["reflux", "OBSERVATION", 402, 408], ["food debris", "OBSERVATION", 414, 425], ["may be", "UNCERTAINTY", 440, 446], ["infectious", "OBSERVATION", 447, 457]]], ["Infected saliva generated during spitting can increase transmission of various respiratory infections through droplets spread to the mouth, nose, or eyes of individuals who are in close proximity [17] .Smokeless tobacco habitu\u00e9s: spitting in public and COVID-19 outbreakIt has been validated that saliva is a viable sample source for SARS-CoV-2 detection when compared to nasopharyngeal or oropharyngeal swabs [25, 26] .", [["respiratory", "ANATOMY", 79, 90], ["mouth", "ANATOMY", 133, 138], ["nose", "ANATOMY", 140, 144], ["eyes", "ANATOMY", 149, 153], ["nasopharyngeal", "ANATOMY", 372, 386], ["oropharyngeal swabs", "ANATOMY", 390, 409], ["respiratory infections", "DISEASE", 79, 101], ["saliva", "ORGANISM_SUBSTANCE", 9, 15], ["mouth", "ORGANISM_SUBDIVISION", 133, 138], ["nose", "ORGANISM_SUBDIVISION", 140, 144], ["eyes", "ORGAN", 149, 153], ["tobacco", "ORGANISM", 212, 219], ["saliva", "ORGANISM_SUBSTANCE", 297, 303], ["CoV-2", "ORGANISM", 339, 344], ["nasopharyngeal", "CANCER", 372, 386], ["oropharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 390, 409], ["tobacco", "SPECIES", 212, 219], ["Smokeless tobacco habitu\u00e9s", "SPECIES", 202, 228], ["SARS-CoV", "SPECIES", 334, 342], ["Infected saliva", "PROBLEM", 0, 15], ["spitting", "PROBLEM", 33, 41], ["various respiratory infections", "PROBLEM", 71, 101], ["spitting", "PROBLEM", 230, 238], ["SARS", "PROBLEM", 334, 338], ["nasopharyngeal or oropharyngeal swabs", "TEST", 372, 409], ["various", "OBSERVATION_MODIFIER", 71, 78], ["respiratory infections", "OBSERVATION", 79, 101], ["mouth", "ANATOMY", 133, 138], ["nose", "ANATOMY", 140, 144], ["eyes", "ANATOMY", 149, 153], ["nasopharyngeal", "ANATOMY", 372, 386], ["oropharyngeal", "ANATOMY", 390, 403]]], ["Positive results were obtained from salivary samples collected from COVID-19 patients who were analyzed using reverse transcriptase-polymerase chain reaction, which is considered the gold standard for detecting viruses in respiratory secretions and blood [26] .", [["salivary samples", "ANATOMY", 36, 52], ["respiratory secretions", "ANATOMY", 222, 244], ["blood", "ANATOMY", 249, 254], ["salivary samples", "ORGANISM_SUBSTANCE", 36, 52], ["patients", "ORGANISM", 77, 85], ["secretions", "ORGANISM_SUBSTANCE", 234, 244], ["blood", "ORGANISM_SUBSTANCE", 249, 254], ["reverse transcriptase", "PROTEIN", 110, 131], ["patients", "SPECIES", 77, 85], ["salivary samples", "TEST", 36, 52], ["reverse transcriptase-polymerase chain reaction", "TREATMENT", 110, 157], ["viruses in respiratory secretions", "PROBLEM", 211, 244], ["blood", "TEST", 249, 254], ["respiratory secretions", "OBSERVATION", 222, 244]]], ["It has been proved that saliva can harbor the virus in an active replicative state [2, 25] .Smokeless tobacco habitu\u00e9s: spitting in public and COVID-19 outbreakInterestingly, individuals in whom pharyngeal and bronchoalveolar swabs proved to be negative showed positive salivary results on the same day [27] .", [["pharyngeal", "ANATOMY", 195, 205], ["bronchoalveolar swabs", "ANATOMY", 210, 231], ["salivary", "ANATOMY", 270, 278], ["saliva", "ORGANISM_SUBSTANCE", 24, 30], ["tobacco", "ORGANISM", 102, 109], ["pharyngeal", "ORGAN", 195, 205], ["bronchoalveolar swabs", "ORGANISM_SUBSTANCE", 210, 231], ["salivary", "ORGAN", 270, 278], ["tobacco", "SPECIES", 102, 109], ["Smokeless tobacco habitu\u00e9s", "SPECIES", 92, 118], ["the virus", "PROBLEM", 42, 51], ["spitting", "PROBLEM", 120, 128], ["bronchoalveolar swabs", "TEST", 210, 231], ["positive salivary results", "PROBLEM", 261, 286], ["active", "OBSERVATION_MODIFIER", 58, 64], ["pharyngeal", "ANATOMY", 195, 205], ["bronchoalveolar", "ANATOMY", 210, 225]]], ["During hospitalization, the median viral load of the early saliva specimens among infected patients was 3.3 \u00d7 106 copies/mL (range: 9.9 \u00d7 102 to 1.2 \u00d7 108 copies/mL).", [["saliva specimens", "ANATOMY", 59, 75], ["saliva specimens", "ORGANISM_SUBSTANCE", 59, 75], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["the median viral load", "TEST", 24, 45], ["the early saliva specimens", "TEST", 49, 75]]], ["Saliva specimens collected thereafter showed reduced salivary SARS-CoV-2 RNA levels after hospitalization [28] .", [["Saliva specimens", "ANATOMY", 0, 16], ["salivary", "ANATOMY", 53, 61], ["Saliva specimens", "ORGANISM_SUBSTANCE", 0, 16], ["CoV-2", "GENE_OR_GENE_PRODUCT", 67, 72], ["Saliva specimens", "TEST", 0, 16], ["reduced salivary SARS", "PROBLEM", 45, 66], ["CoV", "TEST", 67, 70]]], ["Another striking feature noted was that patients who had otherwise tested negative through nasal swab and had cleared from all clinical symptoms still tested SARS-CoV-2 RNA-positive, suggesting that low levels of SARS-CoV-2 RNA could be excreted in saliva even after clinical recovery [29] .Smokeless tobacco habitu\u00e9s: spitting in public and COVID-19 outbreakSLT chewing increases salivary secretion, which is followed by a very strong desire to spit [7, 23] .", [["nasal swab", "ANATOMY", 91, 101], ["salivary", "ANATOMY", 381, 389], ["SARS", "DISEASE", 158, 162], ["SARS", "DISEASE", 213, 217], ["patients", "ORGANISM", 40, 48], ["nasal swab", "ORGANISM_SUBSTANCE", 91, 101], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 158, 168], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 213, 223], ["saliva", "ORGANISM_SUBSTANCE", 249, 255], ["tobacco", "ORGANISM", 301, 308], ["salivary", "ORGAN", 381, 389], ["SARS-CoV-2 RNA", "RNA", 213, 227], ["patients", "SPECIES", 40, 48], ["tobacco", "SPECIES", 301, 308], ["SARS-CoV", "SPECIES", 213, 221], ["Smokeless tobacco habitu\u00e9s", "SPECIES", 291, 317], ["nasal swab", "TEST", 91, 101], ["all clinical symptoms", "PROBLEM", 123, 144], ["SARS", "TEST", 158, 162], ["CoV", "TEST", 163, 166], ["RNA", "TEST", 169, 172], ["low levels of SARS", "PROBLEM", 199, 217], ["CoV-2 RNA", "PROBLEM", 218, 227], ["increases salivary secretion", "PROBLEM", 371, 399], ["low levels", "OBSERVATION_MODIFIER", 199, 209]]], ["Saliva droplets generated by spitting are formed as particles in a mixture of moisture with droplet nuclei of microorganisms.", [["Saliva droplets", "ANATOMY", 0, 15], ["nuclei", "ANATOMY", 100, 106], ["Saliva", "ORGANISM_SUBSTANCE", 0, 6], ["Saliva droplets", "TREATMENT", 0, 15]]], ["It has been observed that saliva can form into an aerosol along the air flow and become a medium for virus transmission [30, 31] .Smokeless tobacco habitu\u00e9s: spitting in public and COVID-19 outbreakThe size of the saliva droplets determines the risk of viral transmission to host cells.", [["saliva droplets", "ANATOMY", 214, 229], ["cells", "ANATOMY", 280, 285], ["saliva", "ORGANISM_SUBSTANCE", 26, 32], ["tobacco", "ORGANISM", 140, 147], ["saliva", "ORGANISM_SUBSTANCE", 214, 220], ["host cells", "CELL", 275, 285], ["host cells", "CELL_TYPE", 275, 285], ["tobacco", "SPECIES", 140, 147], ["Smokeless tobacco habitu\u00e9s", "SPECIES", 130, 156], ["an aerosol", "TREATMENT", 47, 57], ["spitting", "PROBLEM", 158, 166], ["the saliva droplets", "TREATMENT", 210, 229], ["viral transmission to host cells", "PROBLEM", 253, 285], ["air flow", "OBSERVATION", 68, 76], ["size", "OBSERVATION_MODIFIER", 202, 206], ["saliva droplets", "OBSERVATION", 214, 229], ["viral", "OBSERVATION", 253, 258], ["host cells", "OBSERVATION", 275, 285]]], ["Large droplets (diameter > 60 \u03bcm) tend to settle in the air quickly, and, therefore, the spread is limited to individuals nearest to the aerosol source.", [["droplets", "ANATOMY", 6, 14], ["Large droplets", "PROBLEM", 0, 14], ["diameter", "TEST", 16, 24], ["droplets", "OBSERVATION", 6, 14], ["diameter", "OBSERVATION_MODIFIER", 16, 24], ["air", "OBSERVATION", 56, 59]]], ["Most communicable respiratory infections are transmitted through large droplets within a short distance or by contacting contaminated surfaces.", [["respiratory", "ANATOMY", 18, 29], ["respiratory infections", "DISEASE", 18, 40], ["Most communicable respiratory infections", "PROBLEM", 0, 40], ["large droplets", "PROBLEM", 65, 79], ["respiratory infections", "OBSERVATION", 18, 40], ["large", "OBSERVATION_MODIFIER", 65, 70], ["droplets", "OBSERVATION", 71, 79]]], ["Small droplets are likely to evaporate into droplet nuclei (diameter < 10 \u03bcm) in the environment and may be transmitted over short distances (<1 m).", [["droplet nuclei", "ANATOMY", 44, 58], ["Small droplets", "PROBLEM", 0, 14], ["droplets", "OBSERVATION", 6, 14], ["likely to", "UNCERTAINTY", 19, 28], ["droplet nuclei", "OBSERVATION", 44, 58], ["may be", "UNCERTAINTY", 101, 107]]], ["Long-distance aerosol transmission is also determined by the length of time that the saliva droplets reside in the air (physical decay), the period during which pathogens remain viable in saliva droplets (biological decay), and the rate of acquisition of these infective droplets [30, 31] .Smokeless tobacco habitu\u00e9s: spitting in public and COVID-19 outbreakIn India, SLT consumption is a habit more commonly observed in socioeconomically deprived and less literate Indian men [32] .", [["saliva droplets", "ANATOMY", 85, 100], ["SLT", "CHEMICAL", 368, 371], ["saliva", "ORGANISM_SUBSTANCE", 188, 194], ["tobacco", "ORGANISM", 300, 307], ["men", "ORGANISM", 473, 476], ["tobacco", "SPECIES", 300, 307], ["men", "SPECIES", 473, 476], ["Smokeless tobacco habitu\u00e9s", "SPECIES", 290, 316], ["Long-distance aerosol transmission", "TREATMENT", 0, 34], ["the saliva droplets", "TREATMENT", 81, 100], ["these infective droplets", "TREATMENT", 255, 279], ["spitting", "PROBLEM", 318, 326], ["air", "ANATOMY", 115, 118]]], ["However, in a few states of India, the SLT consumption in women is very high and is comparable to that of the male population [8] .", [["women", "ORGANISM", 58, 63], ["women", "SPECIES", 58, 63], ["the SLT consumption", "TEST", 35, 54]]], ["SLT users often deface public places in many Indian cities by spitting, a practice prevalent in tiny congested low socio-economic dwellings and urban slums.", [["tiny congested low socio-economic dwellings", "PROBLEM", 96, 139], ["tiny", "OBSERVATION_MODIFIER", 96, 100], ["congested", "OBSERVATION_MODIFIER", 101, 110], ["low", "OBSERVATION_MODIFIER", 111, 114]]], ["The remainder of the community is subsequently at increased risk of contracting a range of communicable diseases.", [["communicable diseases", "DISEASE", 91, 112], ["communicable diseases", "PROBLEM", 91, 112], ["remainder", "OBSERVATION_MODIFIER", 4, 13]]], ["India is particularly vulnerable because it bears the burden of the second largest population in the world, at approximately 420 persons/km 2 [33] .", [["largest", "OBSERVATION_MODIFIER", 75, 82], ["population", "OBSERVATION_MODIFIER", 83, 93]]], ["At present, Asia's largest slum (Dharavi in Mumbai) has become an area with very high infection rates for COVID-19, where SLT consumption is a popular part of daily life [34] .", [["infection", "DISEASE", 86, 95], ["very high infection rates", "PROBLEM", 76, 101], ["COVID", "TEST", 106, 111], ["largest", "OBSERVATION_MODIFIER", 19, 26], ["very", "OBSERVATION_MODIFIER", 76, 80], ["high", "OBSERVATION_MODIFIER", 81, 85], ["infection", "OBSERVATION", 86, 95]]], ["Moreover, SLT habitu\u00e9s gather in large numbers at retail tobacco outlets, where social distancing is not practiced.Smokeless tobacco habitu\u00e9s: spitting in public and COVID-19 outbreakVery recently, the Government of India passed an order under the Disaster Management Act that prohibits the sales of SLT products and bans spitting in public places.", [["tobacco", "ORGANISM", 57, 64], ["tobacco", "ORGANISM", 125, 132], ["tobacco", "SPECIES", 125, 132], ["Smokeless tobacco habitu\u00e9s", "SPECIES", 115, 141], ["spitting", "PROBLEM", 143, 151], ["the Disaster Management", "TREATMENT", 244, 267], ["SLT products", "TREATMENT", 300, 312], ["large", "OBSERVATION_MODIFIER", 33, 38]]], ["However, the order was then amended, and, under Section 51 (b), the sale of SLT products is once again permitted, but the prohibition of spitting in public places was maintained [7] .Smokeless tobacco habitu\u00e9s: transmission of COVID-19 by hand-to-mouth contactFrequent hand-to-mouth contact is one of the major avenues for transmission of viral infections such as COVID-19.", [["hand", "ANATOMY", 239, 243], ["hand", "ANATOMY", 269, 273], ["mouth", "ANATOMY", 277, 282], ["COVID-19", "CHEMICAL", 227, 235], ["viral infections", "DISEASE", 339, 355], ["COVID-19", "CHEMICAL", 227, 235], ["tobacco", "ORGANISM", 193, 200], ["mouth", "ORGANISM_SUBDIVISION", 247, 252], ["tobacco", "SPECIES", 193, 200], ["Smokeless tobacco habitu\u00e9s", "SPECIES", 183, 209], ["SLT products", "TREATMENT", 76, 88], ["spitting", "PROBLEM", 137, 145], ["viral infections", "PROBLEM", 339, 355], ["COVID", "TEST", 364, 369], ["mouth", "ANATOMY", 247, 252], ["viral infections", "OBSERVATION", 339, 355]]], ["The actual act of SLT chewing involves placing these products inside the oral cavity using fingers several times during the day [7, 35] .", [["oral cavity", "ANATOMY", 73, 84], ["oral cavity", "ORGANISM_SUBDIVISION", 73, 84], ["fingers", "ORGANISM_SUBDIVISION", 91, 98], ["SLT chewing", "TREATMENT", 18, 29], ["these products", "TREATMENT", 47, 61], ["oral cavity", "ANATOMY", 73, 84]]], ["Thus, SLT habitu\u00e9s may be more vulnerable to COVID-19 due to the possibility of transmission from frequent hand-to-mouth contact.RecommendationsBecause SLT products are often produced by numerous methods in small cottage industries and sold in unregulated markets, effective regulation is difficult.", [["hand", "ANATOMY", 107, 111], ["mouth", "ANATOMY", 115, 120], ["COVID-19", "CHEMICAL", 45, 53], ["hand", "ORGANISM_SUBDIVISION", 107, 111], ["mouth", "ORGANISM_SUBDIVISION", 115, 120], ["SLT habitu\u00e9s", "TEST", 6, 18], ["COVID", "TEST", 45, 50], ["SLT products", "TREATMENT", 152, 164], ["mouth", "ANATOMY", 115, 120], ["small", "OBSERVATION_MODIFIER", 207, 212]]], ["Eradicating the use of SLT in Asia and other parts of the world would be beneficial to human health by preventing the development of chronic disease as well as the dissemination of communicable diseases.RecommendationsA uniform, incremental taxation regime, the prohibition of public spitting, bans on illegal SLT export between countries, standardized and validated testing of the content of SLT products, implementation of large and clear pictorial warnings on packaging, and forbidding sales to minors should be strictly enforced to flatten the curve of the growing SLT menace [38] .RecommendationsTobacco cessation should be accelerated using evidence-based cessation and prevention strategies such as varenicline, nicotine replacement therapies, and behavioral interventions, which may help SLT users to quit [9] .", [["SLT", "CHEMICAL", 23, 26], ["chronic disease", "DISEASE", 133, 148], ["communicable diseases", "DISEASE", 181, 202], ["varenicline", "CHEMICAL", 706, 717], ["nicotine", "CHEMICAL", 719, 727], ["varenicline", "CHEMICAL", 706, 717], ["nicotine", "CHEMICAL", 719, 727], ["human", "ORGANISM", 87, 92], ["Tobacco", "ORGANISM", 601, 608], ["varenicline", "SIMPLE_CHEMICAL", 706, 717], ["nicotine", "SIMPLE_CHEMICAL", 719, 727], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["SLT in Asia", "TREATMENT", 23, 34], ["chronic disease", "PROBLEM", 133, 148], ["communicable diseases", "PROBLEM", 181, 202], ["incremental taxation regime", "TREATMENT", 229, 256], ["public spitting", "PROBLEM", 277, 292], ["SLT products", "TREATMENT", 393, 405], ["packaging", "TREATMENT", 463, 472], ["Tobacco cessation", "TREATMENT", 601, 618], ["prevention strategies", "TREATMENT", 676, 697], ["varenicline", "TREATMENT", 706, 717], ["nicotine replacement therapies", "TREATMENT", 719, 749], ["behavioral interventions", "TREATMENT", 755, 779], ["chronic", "OBSERVATION_MODIFIER", 133, 140], ["disease", "OBSERVATION", 141, 148], ["large", "OBSERVATION_MODIFIER", 425, 430]]], ["There should be increased public awareness through increased social media usage during this pandemic to effectively wean habitu\u00e9s away from their usual triggers to consume tobacco.", [["tobacco", "ORGANISM", 172, 179], ["tobacco", "SPECIES", 172, 179], ["increased public awareness", "PROBLEM", 16, 42], ["increased", "OBSERVATION_MODIFIER", 16, 25]]], ["In countries such as India, it is a public health challenge to teach SLT habitu\u00e9s to frequently wash their hands with soap and water or alcohol-based hand sanitizer (approved by the Centers for Disease Control and Prevention) to ensure optimal hand hygiene and reduce the risk of community transmission of COVID-19 [1] .RecommendationsOnce a novel vaccine is found to be safe and effective against COVID-19, it would be justifiable to prioritize assistance for young SLT users who are in the preparation or action transtheoretical stage [39] of quitting.", [["hand", "ANATOMY", 150, 154], ["hand", "ANATOMY", 244, 248], ["alcohol", "CHEMICAL", 136, 143], ["alcohol", "CHEMICAL", 136, 143], ["COVID-19", "CHEMICAL", 306, 314], ["alcohol", "SIMPLE_CHEMICAL", 136, 143], ["hand", "ORGANISM_SUBDIVISION", 150, 154], ["hand", "ORGANISM_SUBDIVISION", 244, 248], ["hand sanitizer", "TREATMENT", 150, 164], ["Disease Control", "TREATMENT", 194, 209], ["COVID", "TEST", 306, 311], ["a novel vaccine", "TREATMENT", 340, 355]]], ["This could act as an incentive to accelerate the quitting process and arrest the spread of COVID-19 infection.", [["COVID-19", "CHEMICAL", 91, 99], ["infection", "DISEASE", 100, 109], ["COVID-19", "CELL", 91, 99], ["COVID-19", "SPECIES", 91, 99], ["COVID-19 infection", "PROBLEM", 91, 109], ["infection", "OBSERVATION", 100, 109]]], ["It is imperative to prioritize research aimed at exploring the potential association of SLT use with COVID-19 to develop evidence-based policy options.ConclusionsThis review reveals that SLT addiction is likely to worsen the progression and prognosis of COVID-19 infection by nicotine-induced increased expression of the ACE2 receptor and action of the furin enzyme in the oral cavity.", [["oral cavity", "ANATOMY", 373, 384], ["COVID-19", "CHEMICAL", 254, 262], ["infection", "DISEASE", 263, 272], ["nicotine", "CHEMICAL", 276, 284], ["nicotine", "CHEMICAL", 276, 284], ["COVID-19", "CELL", 254, 262], ["nicotine", "SIMPLE_CHEMICAL", 276, 284], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 321, 334], ["furin", "GENE_OR_GENE_PRODUCT", 353, 358], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 373, 384], ["ACE2 receptor", "PROTEIN", 321, 334], ["furin enzyme", "PROTEIN", 353, 365], ["COVID", "TREATMENT", 101, 106], ["SLT addiction", "PROBLEM", 187, 200], ["COVID", "TEST", 254, 259], ["19 infection", "PROBLEM", 260, 272], ["nicotine", "TREATMENT", 276, 284], ["the ACE2 receptor", "TREATMENT", 317, 334], ["the furin enzyme", "TEST", 349, 365], ["likely to", "UNCERTAINTY", 204, 213], ["progression", "OBSERVATION_MODIFIER", 225, 236], ["oral cavity", "ANATOMY", 373, 384]]], ["Furthermore, the use of SLT also increases the transmission of infection by users who engage in public spitting, frequent hand-to-mouth contact, and sharing of tobacco apparatus.", [["hand", "ANATOMY", 122, 126], ["infection", "DISEASE", 63, 72], ["tobacco", "ORGANISM", 160, 167], ["tobacco", "SPECIES", 160, 167], ["SLT", "TREATMENT", 24, 27], ["infection", "PROBLEM", 63, 72], ["public spitting", "PROBLEM", 96, 111], ["infection", "OBSERVATION", 63, 72]]], ["Hence, we cannot overlook the fact that cessation of SLT product usage by habitu\u00e9s can contribute to reducing the risk of infection and spread of COVID-19.", [["infection", "DISEASE", 122, 131], ["COVID-19", "CHEMICAL", 146, 154], ["SLT product usage", "TREATMENT", 53, 70], ["infection", "PROBLEM", 122, 131], ["COVID", "TEST", 146, 151], ["infection", "OBSERVATION", 122, 131]]], ["At the outset, the trajectory of COVID-19 worldwide is in the hands of citizens and those who can initiate and propagate a change in regional and global tobacco control policies.", [["tobacco", "ORGANISM", 153, 160], ["tobacco", "SPECIES", 153, 160], ["COVID", "TEST", 33, 38]]]], "PMC7404215": []}